<PAGE> 1
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
<TABLE>
<S> <C>
[X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission
Only (as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
</TABLE>
INTEGRATED SURGICAL SYSTEMS, INC.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:1
------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
------------------------------------------------------------------------
(5) Total fee paid:
------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
------------------------------------------------------------------------
(3) Filing Party:
------------------------------------------------------------------------
(4) Date Filed:
------------------------------------------------------------------------
<PAGE> 2
INTEGRATED SURGICAL SYSTEMS, INC.
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON AUGUST 18, 1999
To the Stockholders of Integrated Surgical Systems, Inc.:
Notice is hereby given that a Special Meeting of Stockholders of Integrated
Surgical Systems, Inc., a Delaware corporation (the "Company"), will be held on
August 18, 1999, at the Company's executive offices, 1850 Research Park Drive,
Davis, California 95616-4884, at the hour of 9:00 A.M., for the following
purposes:
1. To approve the issue and sale to ILTAG International Licensing Holding
S.A.L., Bernd Herrmann and Urs Wettstein of an aggregate of 2,922,396
shares of common stock and warrants to purchase an additional number of
shares of common stock, at an exercise price of $1.02656 per share,
that if exercised would give them 40% of the fully diluted common
stock, for a total purchase price of $4 million pursuant to a Stock and
Warrant Purchase Agreement dated as of July , 1999.
2. To transact such other business as may properly come before the Special
Meeting or any adjournments thereof.
Only stockholders of record at the close of business on June 28, 1999 are
entitled to notice of and to vote at the Special Meeting or any adjournments
thereof.
A list of stockholders entitled to vote at the Special Meeting will be open
to examination by any stockholder for any purpose germane to the meeting, at the
executive offices of the Company, 1850 Research Park Drive, California
95616-4884, for a period of ten days prior to the Special Meeting. Such list
also shall be available during the Special Meeting.
By Order of the Board of Directors
MARK W. WINN
Secretary
Davis, California
July , 1999
IMPORTANT:
WHETHER OR NOT YOU PLAN TO ATTEND THE SPECIAL MEETING, PLEASE PROMPTLY
COMPLETE, SIGN AND DATE THE ENCLOSED PROXY, WHICH IS SOLICITED BY THE BOARD OF
DIRECTORS OF THE COMPANY, AND RETURN IT TO THE COMPANY. THE PROXY MAY BE REVOKED
AT ANY TIME BEFORE IT IS VOTED, AND STOCKHOLDERS EXECUTING PROXIES MAY ATTEND
THE MEETING AND VOTE IN PERSON SHOULD THEY SO DESIRE.
<PAGE> 3
INTEGRATED SURGICAL SYSTEMS, INC.
1850 RESEARCH PARK DRIVE
DAVIS, CALIFORNIA 95616-4884
(530) 792-2600
------------------------
PROXY STATEMENT
------------------------
This Proxy Statement is being furnished to holders of shares of common
stock, par value $.01 per share (the "Common Stock"), of Integrated Surgical
Systems, Inc., a Delaware corporation (the "Company"), in connection with the
solicitation of proxies by the Board of Directors of the Company (the "Board of
Directors" or the "Board") for use at a Special Meeting of Stockholders (the
"Special Meeting") to be held at 9:00 a.m., on Wednesday, August 18, 1999 at the
Company's executive offices, 1850 Research Park Drive, Davis, California
95616-4884.
The Company requires additional financing to fund its operations and
research and development activities until it generates sufficient cash flow from
sales of its semi-autonomous surgical robotic systems. The principal market for
the Company's ROBODOC(R) Surgical Assistant System has been Europe, with most
sales in Germany and Austria. Although the ROBODOC system has been favorably
received in Germany and Austria, the Company's ability to achieve greater market
penetration in these countries and throughout Europe has been impaired by its
lack of a European identity, limited financial, marketing and sales resources,
and potential competition from a German manufacturer that has entered the market
with a device similar to the ROBODOC system.
The Company has secured a commitment for additional equity financing from a
group of foreign investors with business relationships in Europe and has
negotiated a distribution agreement with a distributor based in Germany for the
distribution of its products in Europe, the Middle East and Africa. The Company
believes that through these relationships it will improve its ability to expand
the customer base for the ROBODOC system throughout Europe.
On July , 1999 the Company entered into a Stock and Warrant Purchase
Agreement (the "Purchase Agreement") with ILTAG International Licensing Holding
S.A.L. ("ILTAG"), Bernd Herrmann and Urs Wettstein (collectively, the
"Purchasers") for the issue and sale (the "Sale") of an aggregate of 2,922,396
shares of Common Stock (the "Shares") and three-year warrants (the "Warrants")
to purchase an additional number of shares of Common Stock that if exercised
would give the Purchasers the right to purchase 40% of the fully diluted Common
Stock (the "Warrants Shares"). The exercise price of the Warrants is $1.02656
per share. The total purchase price for the Shares and Warrants is $4 million.
Based upon the assumptions set forth under the caption "Dilution," the Company
estimates that the Purchasers will receive Warrants to purchase 9,641,000 shares
of Common Stock. If 9,641,000 Warrants are exercised, the Company will receive
an additional $9,897,065. The form of Purchase Agreement is annexed as Appendix
I to this Proxy Statement and the form of Warrant appears as Exhibit B to
Appendix I.
ILTAG is a Lebanese company owned by The Dogmoch Group of Companies
("Dogmoch"). ILTAG invests in health care and information technology companies.
Dogmoch provides consulting and support services to over 20 German companies
doing business in countries throughout the Middle East. Dogmoch owns an equity
interest in a private orthopedic clinic in Marbella, Spain organized by the
Company in 1998. The Company was introduced to Dogmoch by Dr. A. Bauer, the head
of and an equity investor in the Marbella clinic. The principal stockholder of
Dogmoch is M.Y. Dogmoch. Bernd Herrmann and Urs Wettstein are private European
investors.
CHANGE IN CONTROL
Following the Sale, the Purchasers will own approximately 26% of the shares
of Common Stock outstanding on June 28, 1999, and together with the Warrants,
approximately 40% of the Common Stock on a fully diluted basis. ILTAG will
purchase 1,461,198 shares and one-half of the total number of Warrants for $2
<PAGE> 4
million. Messrs. Herrmann and Wettstein will each purchase 730,599 shares and
one-quarter of the total number of Warrants for $1 million. If the Sale is
approved by the Stockholders, Messrs. Herrmann, Wettstein and Falah Al-Khadi,
the Vice Chairman of Dogmoch, will become three of the five members of the Board
of Directors. Since the Purchasers will have control of the Board and effective
voting control of the Company following the Sale, the Sale will result in a
change in control of the Company.
The Board of Directors by this Proxy Statement and the enclosed proxy card
is soliciting proxies from holders of its Common Stock (the "Stockholders") to
approve the proposed Sale at the Special Meeting. The Company is submitting the
proposed Sale to Stockholders for approval in accordance with the rules of the
Nasdaq Stock Market, Inc. since the Sale involves a change in control and the
issuance of 20% or more of the outstanding Common Stock.
Only stockholders of record as of the close of business on June 28, 1999
will be entitled to vote at the Special Meeting or any adjournments thereof. The
total number of shares of Common Stock outstanding as of June 28, 1999, was
8,509,113 shares. The Common Stock is the only outstanding class of securities
of the Company entitled to vote. Each share of Common Stock has one vote.
The affirmative vote by the majority of the votes present at the Special
Meeting and entitled to vote is required to approve the Sale. All proxies will
be counted for determining the presence of a quorum. In the absence of specific
instructions, all proxies duly executed and received by the Company will be
voted FOR the Sale. Shares represented by proxies which are marked "abstain"
will only be counted for the purpose of determining the presence of a quorum. In
addition, where brokers are prohibited from exercising discretionary authority
for beneficial owners who have not provided voting instructions (commonly
referred to as "broker non-votes"), those shares will not be included in the
vote totals.
A proxy may be revoked at any time before being voted by sending a new
proxy bearing a later date or a revocation notice to the Company at the above
address, attn: Secretary, or by notifying the Secretary of the Company at the
Special Meeting. The Company will pay all costs of this solicitation. The
Company will request banks and brokers to solicit their customers who
beneficially own shares listed of record in names of nominees, and will
reimburse those banks and brokers for the reasonable out-of-pocket expenses of
such solicitations. The Company will solicit proxies by mail. Officers and other
employees of the Company also may solicit proxies by telephone, telegram or in
person, but no additional compensation will be paid to such individuals. This
Proxy Statement is being mailed on or about July , 1999.
REASONS FOR THE SALE
The Company experienced net losses of approximately $10.3 million and
approximately $4.5 million during 1998 and 1997, respectively, and a net loss of
approximately $2.3 million for the three months ended March 31, 1999. Since
1998, the Company has incurred significant expenses in building a sales and
marketing organization and field support staff in Europe. It also has incurred
substantial research and development costs to develop its DigiMatch pinless
registration system and expand the number of implants compatible with the
ROBODOC System. Because of the continuing operating losses and limited working
capital, the Company has relied on equity financings to fund its operations and
research and development programs. Since September 1998, the Company has
received aggregate net proceeds of approximately $6,829,000 from the sale of
preferred stock convertible into common stock at an approximately 15% discount
to the prevailing market price, including $2,582,500 from convertible preferred
stock financings completed in June 1999. The Company continues to require
additional financing.
The proposed Sale would provide the Company with an immediate cash infusion
of approximately $3,900,000, after transaction costs. The Company will receive
additional proceeds if the Warrants are exercised. The proceeds from the Sale
will be used as working capital in the Company's business.
DISCUSSIONS LEADING TO THE SALE
In March 1999, Manfred Schmitt, an equity investor in the Marbella
orthopedic clinic organized by the Company in 1998, advised the Company that a
group of foreign investors was interested in acquiring a 40%
2
<PAGE> 5
fully diluted equity interest in the Company for $4 million. Mr. Schmitt noted
that the Company's difficulties in penetrating the European market was due to
its identity as a U.S. company without a significant presence in Europe. The
foreign investors indicated that the proposed equity investment was subject to
the Company establishing a European identity, including European management and
a significant European presence, to signify its long-term commitment to the
European market.
The Company entered into a letter of intent on May 25, 1999 with ILTAG for
an equity investment in the Company by several foreign investors. The letter of
intent contemplated the sale of a 40% fully-diluted equity interest in the
Company. The investment would consist of shares of Common Stock and three-year
warrants to purchase additional shares of Common Stock. The number of shares of
Common Stock to be purchased was to be determined by dividing $4 million by the
average closing price of the Common Stock on The Nasdaq SmallCap Market during
the ten trading days preceding May 24, 1999. The purchase price per share as so
determined was $1.36874. The exercise price of the Warrants was to be 75% of the
per share purchase price for the Shares, or consequently, $1.02656 per share.
The closing sale price of the Common Stock on The Nasdaq SmallCap Market was
$1.125 on May 24, 1999, the day before the Company issued a press release
announcing that it had entered into a letter of intent for the proposed Sale.
The investors also would have the right to designate three of the five members
of the Board. In addition, the letter of intent contemplated that the Company
would enter into a distribution agreement granting the distributor exclusive
distribution rights to the Company's products in Europe, the Middle East and
Africa through 2000.
The terms of the Sale, including the purchase price for the Shares and the
exercise price of the Warrants were negotiated between representatives of the
Purchasers and Drs. Kapoor and Trivedi on behalf of the Company, taking into
account various factors, including the Company's financial condition and
prospects, the availability of alternate sources of financing, the size of the
equity investment by the Purchasers, and the range of market prices of the
Common Stock.
The Board of Directors approved the terms of the letter of intent on May
24, 1999. At the May 24 Board meeting, the Board considered discussions with
others approached by the Company concerning an investment in the Company. The
Company had not received any substantive proposals or definitive offers from
these or any other sources, and the Board did not believe that any of these
other sources was prepared to move quickly at that time toward negotiation and
consummation of an alternative transaction.
On June 28, 1999, the Board approved the issue and sale of the Shares and
Warrants to the Purchasers and the form of Purchase Agreement. The Board of
Directors believes that the equity investment represented by the Shares and
Warrants is in the best interests of the Company in that it will improve the
Company's capital position and provide the Company with an immediate cash
infusion that will allow the Company to continue operations at existing levels,
and provide an opportunity for future capital infusion as the Warrants are
exercised. A primary consideration of the Board was that the financial condition
of the Company required a significant equity infusion. No alternative source of
financing was prepared to commit to provide the Company with the capital it
needed. Without the equity infusion by the Purchasers, the Company will have to
consider financial alternatives available to it, including reducing or
curtailing the level of operations and its research and development activities.
The Board views as favorable the fact that, following the Sale, current
stockholders will be able to participate in any future growth and profitability
of the Company and in its efforts to realize long-term value, notwithstanding
the Purchasers' ability to exercise a controlling influence over the Company.
The Board also considered the fact that full disclosure of the Sale would be
made to stockholders, and the consummation of the Sale would be subject to the
approval of the stockholders.
COMPOSITION OF THE BOARD OF DIRECTORS FOLLOWING THE SALE
The Board of Directors consists of six members. The Directors of the
Company are James C. McGroddy (Chairman), John N. Kapoor, Paul A. H. Pankow,
Gerald D. Knudson and Patrick G. Hays, all of whom were elected at the Company's
Annual Meeting of Stockholders on April 27, 1999. There is one vacancy on the
Board.
If the Sale is approved by Stockholders and the other conditions to closing
are satisfied, Dr. McGroddy and Messrs. Pankow, Knudson and Hays will resign
from the Board immediately prior to the closing of the
3
<PAGE> 6
Sale, and they will be replaced by Messrs. Al-Khadi, Herrmann and Wettstein.
Following the Sale, the Board will consist of five members. Dr. John N. Kapoor
will continue to serve as a Director and Dr. Ramesh C. Trivedi will be appointed
to fill the remaining vacancy on the Board. Messrs. Al-Khadi, Herrmann and
Wettstein, as well as Dr. Trivedi, have consented to be named in this Proxy
Statement and to serve as Directors if the Sale is approved by Stockholders.
Information with respect Messrs. Al-Khadi, Herrmann and Wettstein, as well
as Dr. Trivedi, is set forth below.
<TABLE>
<CAPTION>
NAME AGE PRINCIPAL OCCUPATION AND RELATED INFORMATION
- ---- --- --------------------------------------------
<S> <C> <C>
Falah Al-Khadi....................... 50 Vice Chairman of the Dogmoch Group of Companies since
1994; owner and Managing Director of Business Advising
Bureau in Abu Dhabi from 1981 to 1993.
Bernd Herrmann....................... 32 Private investor since 1997; Asset Manager, Commerzbank
AG, Frankfurt/Main, Germany from 1995 to 1997 and
Deutsche Bank AG, Mannheim and Kaiserslautern, Germany
from 1986 to 1995.
Urs Wettstein........................ 44 Private investor; independent tax and accounting
consultant in Zurich, Switzerland since 1983; Financial
and Tax Consultant, Coopers and Lybrand, Zurich,
Switzerland from 1977 to 1982.
Ramesh C. Trivedi.................... 59 Chief Executive Officer of the Company since November
1995; Director of the Company from November 1995 through
April 1999; consultant to the Company from February 1995
until November 1995; Principal of California Biomedical
Consultants (an international consulting firm) since
1987; President and Chief Executive Officer of DigiRad
Corporation (a medical imaging company) from 1985 to
1986.
</TABLE>
THE PURCHASE AGREEMENT
The following is brief summary of the Purchase Agreement. It does not
purport to be complete and is qualified in its entirety by reference to the
Purchase Agreement, a copy of which is attached as Appendix I to this Proxy
Statement.
The Purchase Agreement provides for the purchase by the Purchasers from the
Company of an aggregate of 2,922,396 shares of Common Stock and warrants to
purchase an additional number of shares of Common Stock that if exercised would
give the Purchasers 40% of the fully diluted Common Stock for a total purchase
price of $4,000,000. The Purchase Agreement also provides, as a condition of
closing, that Messrs. Herrmann, Wettstein and Al-Khadi become members of a
reconstituted Board of Directors consisting of five members. The consummation of
the Sale is subject to approval of Stockholders, the consent of IBM, which owns
warrants to purchase 2,274,066 shares of Common Stock, and the holders of the
Company's Series B Convertible Preferred Stock. The consummation of the Sale
also is subject to the execution and delivery of the distribution agreement. The
terms of the distribution agreement are summarized below.
WARRANTS
The following description of the Warrants does not purport to be complete
and is qualified in its entirety by reference to the Warrants, the form of which
is annexed as Exhibit B to Appendix I to this Proxy Statement.
The Warrants entitle the holders to purchase that number of shares of
Common Stock that if exercised, together with the Shares, would give them 40% of
the fully diluted Common Stock. Warrants may be exercised at any time or from
time to time for a period of three years from the date of the closing of the
issue and sale of the Shares and Warrants to the Purchasers. The exercise price
of the Warrant is $1.02656 per
4
<PAGE> 7
share. The exercise price and number and kind of shares of Common Stock or other
securities purchasable upon exercise of the Warrants are subject to adjustment
upon the occurrence of certain events, including the subdivision, combination,
or reclassification of outstanding shares of Common Stock. No fractional shares
will be issued upon exercise; however, the Company will pay a cash adjustment
for any fractional shares based on the exercise price of the Warrants. The
Warrants do not confer upon the holder any voting or preemptive rights, or any
other rights of a stockholder of the Company.
REGISTRATION RIGHTS
The following description of the registration rights granted to the
Purchasers does not purport to be complete and is qualified in its entirety by
reference to the Registration and Stockholder Rights Agreement, the form of
which is annexed as Exhibit C to Appendix I to this Proxy Statement.
Holders of not less than the lesser of (x) 25% of the Shares and Warrant
Shares (including for this purpose, holders of the Warrants), and (y) Shares and
Warrant Shares (together, the "Registrable Securities") having an anticipated
aggregate offering price (net of underwriting discounts and commissions) of at
least $2,000,000 will have the right to request the filing of registration
statements under the Securities Act for the sale of their Shares and/or Warrant
Shares. The number of registration statements that the Company must file on a
registration form other than Form S-3 is limited to two registrations. In
addition, holders of the Registrable Securities will have the right (with
certain limited exceptions) to include their Shares and/or Warrant Shares in any
registration statement filed by the Company on its own behalf or on behalf of
other stockholders, subject to cross indemnification in the event of liability
under the Securities Act. Any such registration statement would be filed at the
Company's expense, except that underwriters' commissions, brokerage fees,
transfer taxes and attorneys' or accountants' fees and expenses incurred by the
holders requesting registration of their Shares and/or Warrant Shares would be
paid by such holders.
DISTRIBUTION AGREEMENT
The Company is negotiating a distribution agreement with a German company
controlled by Manfred Schmitt, that would give the distributor the exclusive
right to distribute its products in Europe, the Middle East and Africa through
2003. The distributor would be obligated to purchase a minimum of 24 ROBODOC
Systems (less the number previously sold by the Company) in 1999 and 32 ROBODOC
Systems in 2000. The distributor would be required to pay the Company advance
payments of $400,000 per month through 2000, offset by the purchase price of
products purchased. However, the distributor will have no minimum purchase or
advance payment obligation after 2000, even though it will retain exclusive
rights to distribute the Company's products in Europe, the Middle East and
Africa through 2003. The distributor's only obligation to the Company after 2000
is to pay for products that it purchases. The distributor's liability to the
Company under the distribution agreement is limited to $1 million, exclusive of
the minimum purchase obligation. The Company has the right to purchase the
assets of the distributor relating to the distribution of the Company's products
at their book value upon not less than 30 days prior written notice at any time
during 2001. It is anticipated that the Company's European sales and marketing
personnel, as well as its European field support staff, will join the
distributor.
The distribution agreement will eliminate marketing, sales and
administrative expenses associated with the Company's European activities and
provide the Company with a more predictable source of revenues based upon the
minimum purchase commitments of the distributor. Although the Purchasers and Mr.
Schmitt have participated in business ventures, neither the distributor nor Mr.
Schmitt is affiliated with, or has any financial interest in, any of the
Purchasers.
CAPITALIZATION
The following table sets forth (i) the capitalization of the Company as of
March 31, 1999, (ii) the pro forma capitalization as of that date, after giving
effect to the issuance and sale of 750 shares of Series C Convertible Preferred
Stock, 2,000 shares of Series D Convertible Preferred Stock and an aggregate of
3,927 shares of Common Stock in connection with those convertible preferred
stock financings, the conversion of
5
<PAGE> 8
3,080 shares of Series A Convertible Preferred Stock and 120 shares of Series B
Convertible Preferred Stock into an aggregate of 2,718,958 shares of Common
Stock and the exercise of options to purchase an aggregate of 26,954 shares of
Common Stock, all of which occurred during the period from April 1 through June
30, 1999, and (iii) the pro forma capitalization, as further adjusted for the
proposed issuance and sale of the Shares and Warrants.
<TABLE>
<CAPTION>
PRO FORMA,
AS
ACTUAL PRO FORMA(5) ADJUSTED(6)
------------ ------------ ------------
<S> <C> <C> <C>
Stockholders' Equity:
Convertible preferred stock, $.01 par value;
1,000,000 shares authorized.
Series A, 3,520 shares authorized; 3,180 issued
and outstanding at March 31, 1999, 100 pro
forma and pro forma, as adjusted(1)......... $ 32 $ 1 $ 1
Series B, 1,000 shares authorized; 1,000 issued
and outstanding at March 31, 1999, 880 pro
forma and pro forma, as adjusted(1)......... 10 9 9
Series C, 750 shares authorized; none issued
and outstanding at March 31, 1999; 750
issued and outstanding pro forma and pro
forma, as adjusted(1)(2).................... 8 8
Series D, 2,000 shares authorized; none issued
and outstanding at March 31, 1999; 2,000
issued and outstanding pro forma and pro
forma, as adjusted(1)(3).................... 20 20
Common stock, $.01 par value, 15,000,000 shares
authorized(4); 5,827,116 shares issued and
outstanding; 8,576,955 issued and outstanding
pro forma and 11,499,351 issued and outstanding
pro forma, as adjusted......................... 58,271 85,770 114,994
Additional paid-in capital....................... 43,479,375 46,521,562 50,392,338
Deferred stock compensation...................... (70,353) (70,353) (70,353)
Preferred stock discount......................... (171,569) (656,863) (656,863)
Accumulated other comprehensive loss............. (110,229) (110,229) (110,229)
Accumulated deficit.............................. (36,773,711) (36,773,711) (36,773,711)
------------ ------------ ------------
$ 6,411,826 $ 8,996,214 $ 12,896,214
============ ============ ============
</TABLE>
- ---------------
(1) Each series of convertible preferred stock has a stated value of $1,000 per
share and is convertible into Common Stock at a conversion price equal to
85% of the lowest sale price of the Common Stock on the Nasdaq SmallCap
Market over the five trading days preceding the date of conversion. The
number of shares of Common Stock that may be acquired upon conversion is
determined by dividing the stated value of the number of shares of preferred
stock to be converted by the conversion price. There is no minimum
conversion price, but the maximum conversion prices are as follows: Series
A -- $3.66; Series B -- $2.60; Series C -- $2.11; and Series D -- $3.35.
(2) Shares of Series C Convertible Preferred Stock were sold on June 10, 1999
resulting in net proceeds of $697,500.
(3) Shares of Series D Convertible Preferred Stock were sold on June 30, 1999
resulting in net proceeds of $1,885,000.
(4) The number of authorized shares of Common Stock was increased to 50,000,000
on April 27, 1999.
(5) Includes net proceeds of $2,582,500 from the sale of convertible preferred
stock, plus $1,887 from the exercise of stock options.
6
<PAGE> 9
(6) Gives effect to the issuance and sale of 2,922,396 shares of Common Stock
and the Warrants under the Purchase Agreement, resulting in net proceeds of
$3,900,000.
EFFECT ON BOOK VALUE PER SHARE
Set forth below is information concerning the Company's net tangible book
value, net tangible book value per share of Common Stock, net tangible book
value per fully-diluted share of Common Stock and Common and fully-diluted
Common Stock outstanding (i) at March 31, 1999, (ii) pro forma at March 31,
1999, after giving effect to equity transactions consummated by the Company
through June 30, 1999, (iii) pro forma as adjusted for the proposed sale of
2,922,396 shares of Common Stock and the Warrants for net proceeds of $3,900,000
and (iv) pro forma as adjusted for the exercise of the Warrants.
<TABLE>
<CAPTION>
PRO FORMA
ADJUSTED FOR PRO FORMA
SALE OF ADJUSTED FOR
STOCK AND EXERCISE OF
ACTUAL PRO FORMA WARRANTS WARRANTS
---------- ------------ ------------ ------------
<S> <C> <C> <C> <C>
Net tangible book value of Common
Stock(1)............................. $3,606,608 $6,190,996 $10,090,996 $19,988,061
Net tangible book value per share of
Common Stock......................... $ 0.62 $ 0.72 $ 0.88 $ 0.95
Net tangible book value per share of
fully-diluted Common Stock........... $ 0.23 $ 0.35 $ 0.32 $ 0.64
Shares of Common Stock
outstanding(2)....................... 5,827,116 8,576,955 11,499,351 21,140,351
Fully-diluted Common Stock
outstanding(2),(3)................... 15,857,944 17,446,017 31,407,584 31,407,584
</TABLE>
- ---------------
(1) Excludes intangible assets aggregating $2,805,218 at March 31, 1999.
(2) Pro forma, Pro forma Adjusted for Sale of Stock and Warrants and Pro forma
Adjusted for Exercise of Warrants include assumed conversion prices per
share to calculate the number of shares of Common Stock issuable to
Convertible Preferred Stockholders upon future conversion of their shares.
The number of shares that may be acquired upon conversion of the convertible
preferred stock has been computed using the maximum conversion price for
Series A ($2.23), B ($1.03) and C ($1.03), after giving effect to
antidilution adjustments resulting from the proposed Sale, and an assumed
conversion price of $3.00 per shares for Series D.
(3) Fully-diluted Common Stock assumes the exercise of all outstanding warrants
and conversion of Convertible Preferred Stock. Where applicable,
anti-dilution provisions associated with applicable warrants have been
considered in calculating outstanding warrants.
(4) Assumes that Warrants to purchase 9,641,000 shares of Common Stock are
issued. The actual number of Warrants to be issued to Purchasers at closing
is that number of Warrants which if exercised, together with the Shares,
would give the Purchasers 40% of the fully diluted Common Stock.
DILUTION
Completion of the Sale will substantially reduce the current stockholders'
percentage ownership in the Company and will allow the Purchasers to designate
three of the five members of the Board of Directors. In addition, if the
Purchasers increase their voting percentage above 50% of the outstanding
securities of the Company, they will be able to effect certain transactions,
including mergers, consolidations and sales of substantially all of the assets
of the Company, without the consent of any of the Company's minority
stockholders. Following consummation of the Sale, the Purchasers will also be
able to effect a change in control of the Company or to prevent such a change in
control. Furthermore, if the Purchasers were to sell a substantial portion of
their Common Stock, whether pursuant to Rule 144 under the Securities Act,
registration under the Securities Act or otherwise, such sale could adversely
affect the market price of the Common Stock.
7
<PAGE> 10
The table below indicates certain dilutive effects of the Sale.
<TABLE>
<CAPTION>
NUMBER OF
SHARES PERCENTAGE
---------- ----------
<S> <C> <C>
Shares outstanding at June 30, 1999......................... 8,576,955 27.3%
Shares issuable on conversion of convertible preferred
stock(1).................................................. 2,210,673 7.1%
Shares issuable upon exercise of warrants owned by IBM(2)... 2,274,066 7.2%
Shares issuable upon exercise of other warrants(3).......... 4,457,324 14.2%
Shares issuable upon exercise of employee stock
options(4)................................................ 1,325,170 4.2%
Shares and Warrants to be issued to the Purchasers
Shares.................................................... 2,922,396 9.3%
Warrants(5)............................................... 9,641,000 30.7%
---------- -----
Subtotal............................................... 12,563,396 40.0%
---------- -----
Total....................................................... 31,407,584 100.0%
========== =====
</TABLE>
- ---------------
(1) The number of shares that may be acquired upon conversion of the convertible
preferred stock has been computed using the maximum conversion price for
Series A ($2.23), B ($1.03) and C ($1.03), after giving effect to
antidilution adjustments resulting from the proposed Sale, and an assumed
conversion price of $3.00 per shares for Series D.
(2) The exercise price of these warrants is not subject to adjustment as a
result of the Sale.
(3) These warrants are primarily underwriter and other financing related
warrants. The exercise price and number of shares purchased upon exercise of
these warrants are subject to adjustment as a result of the sale of Shares
and Warrants to the Purchasers.
(4) These are options for shares issuable under stock option plans. The exercise
prices of these options are not subject to adjustment as a result of the
Sale.
(5) Assumes that warrants to purchase 9,641,000 shares of Common Stock are
issued. Under terms of the Purchase Agreement, the Purchasers are to receive
Shares and Warrants equal to approximately 40% of the fully-diluted shares
outstanding.
TAX CONSEQUENCES OF THE COMPANY
The Company has at December 31, 1998 a net operating loss carryover of
approximately $16,200,000 for federal income tax purposes which expires between
2005 and 2013, a net operating loss carryforward of approximately $5,700,000 for
state income tax purposes which expires through 2003, and a net operating loss
carryforward of approximately $1,500,000 for foreign income tax purposes. The
Company has at December 31, 1998 research and development credit carryovers of
approximately $294,000 and $448,000 for federal and state income tax purposes,
respectively.
As a result of stock sales a change of ownership (as defined in Section 382
of the Internal Revenue Code of 1986, as amended) has occurred. As a result of
this change, the Company's federal and state net operating loss carryforwards
generated through December 21, 1995 (approximately $14,300,000 and $2,600,000,
respectively) will be subject to a total annual limitation in the amount of
approximately $400,000.
As a result of the Sale, in combination with prior transfers of stock of
the Company, an additional change of ownership will occur which would further
limit the net operating loss carryforwards available for future utilization.
RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board of Directors recommend that Stockholders approve the Sale. The
Sale provides the Company with an immediate cash infusion of approximately
$3,900,000, after transaction costs, to continue operations at existing levels
and on-going research and development activities. In addition, Messrs. Herrmann,
Wettstein
8
<PAGE> 11
and Al-Khadi, who will become Directors of the Company as a result of the Sale,
are knowledgeable and experienced in doing business in Europe, and in
particular, the German market. Furthermore, the Company expects to benefit from
its relationship with Dogmoch, a diversified company with investments and a
strong presence in Europe and throughout the Middle East. The Company believes
that these relationships, together with the distribution agreement, will
increase sales opportunities for the Company's products in the European market.
If the proposed sale to the Purchasers is not approved by Stockholders, or
the Company is unable to obtain alternative financing on a timely basis, it may
have to reduce or curtail its operations to a level that will not allow it to
pursue its product development objectives or to continue to support its long
term business objectives. There can be no assurance that alternative financing
will be available on terms acceptable to the Company or its stockholders, or
that such financing will be available within a time frame required by the
Company. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and the Company's Financial Statements, which begin on
page F-1 of this Proxy Statement.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis relates to the operations of
Integrated Surgical Systems, Inc. and does not include the operations of IMMI,
except for the results of its operations subsequent to its acquisition by the
Company on September 5, 1997, and should be read in conjunction with the
Company's audited financial statements for the year ended December 31, 1998 and
the unaudited financial statements for the three months ended March 31, 1999,
including the notes thereto, commencing on page F-1 of this Proxy Statement.
RESULTS OF OPERATIONS
Year Ended December 31, 1998 As Compared to Year Ended December 31, 1997
Net Sales. Net Sales for the year ended December 31, 1998 increased by
approximately $1,212,000 or 25% to $6,146,000 compared to $4,934,000 for year
ended December 31, 1997. This increase in net sales is due to the increase in
the sale of ROBODOC Systems. During 1998, nine systems were sold and two were
leased compared to seven sold and one leased year during 1997.
Cost of Sales. Cost of sales for 1998 was $3,413,000 or 56% of net sales
as compared to $2,183,000 or 44% of net sales for the prior year. The higher
cost as a percent of sales for 1998 is due primarily to discounts granted to
several customers who placed orders for multiple systems.
Selling, General and Administrative. Selling, general and administrative
expenses for 1998 were $6,216,000 compared to $3,701,000 for 1997. Selling,
general and administrative expenses increased by $2,515,000 as the Company
staffed its European sales organization with additional sales, administrative,
and training personnel. Additionally, sales expenses increased with the addition
of a sales staff to begin the marketing of the ORTHODOC and NeuroMate in the
United States. Finally, 1998 was the first full year in which the expenses
associated with IMMI were reflected in the consolidated results of the Company.
IMMI was acquired in September of 1997.
Research and Development. Expenses for research and development during
1998 increased by 115% to $6,603,000 from $3,064,000 during 1997. During 1998,
the Company elected to aggressively pursue the development of its DigiMatch
Single Surgery System proprietary pinless registration technology. This
technology eliminates the need for a preliminary surgical procedure to place
pins in the patient's femur prior to the implant surgery and at the time a CT
image is taken of the patient's bone. Historically this was done to effect an
accurate correlation of the patient's CT image to the patient's femur in the THA
surgical procedure. In addition, the Company determined that it was
competitively appropriate to expend more resources on the development implant
base, thus providing its customers with the largest offering of implants from
which to select.
9
<PAGE> 12
During 1998, the Company amortized $839,000 of identified intangible assets
acquired in the IMMI transaction in 1997. This charge was $559,000 higher than
the amount recorded in 1997. Similarly, 1998 was the first full year in which
research and development costs of were recorded in connection with IMMI.
Stock Compensation. During 1998, amounts expensed for stock compensation
decreased to $131,000 from $155,000 during 1997. Amounts decreased since there
were fewer shares of options that vested in 1998. Deferred compensation for the
non-vested portion is being amortized into expense over the vesting period of
the stock options, which generally range from three to four years. As of the end
of 1998, there remains an additional $86,000 subject to being expensed in future
years.
Interest Income and Expense. For 1998, interest income amounted to
$241,000 compared to $215,000 in 1997. The difference is the result of generally
higher average cash balances during the year. During the 1998 year, the Company
also made borrowings against a revolving line of credit, and had other interest
expenses which, in total, generated interest expense in the amount of $124,000.
Foreign Currency Gain (Loss). Gains incurred in connection with foreign
currency transactions amounted to $129,158 in 1998 as a result of exchange rates
that weakened the U.S. Dollar relative to European currencies. In 1997,
transaction losses were approximately $147,000.
Other Income and Expense. Other expense for 1998 amounted to $270,000
compared to other income of $32,000 for the same period in 1997. In June 1998
the Company and six other investors agreed to organize a Dutch company to be
known as Marbella High Care B.V. for the purpose of capitalizing a Spanish
company to be known as Marbella High Care S/A ("MBHC") to develop a surgical and
rehabilitation center in Marbella, Spain. As of December 31, 1998, the Company
owned 22% of the outstanding shares of MBHC and accounts for its investment in
MBHC under the equity method. The Company's investment in MBHC, including loans,
was approximately $563,000 in 1998. For the year ended December 31, 1998, the
Company recorded $317,000 of expense relating to its investment and advances in
MBHC for the period, which has been included in other income (expense).
Preferred Stock Accretion. During 1998, the Company entered into a private
placement agreement whereby the Company's Series A Preferred Stock was placed
with two private investors. The terms of the preferred stock include a
Beneficial Conversion Feature. The value assigned to the Beneficial Conversion
Feature, as determined using the quoted market price of the Company's common
stock on the date the Series A Preferred Stock was sold, amounted to $616,000,
which represents a discount to the value of the Series A Preferred Stock (the
"Discount"). The Discount is being accreted using the straight-line method
through March 9, 1999. Approximately $376,000 of the Discount was accreted in
1998.
Net Loss. The net loss applicable to common stockholders for 1998
increased by 138% from $4,478,000 in 1997 to $10,644,000 in 1998. The increase
in the loss is due primarily to lower gross margins, higher operating expenses,
the write-off of the Company's pro-rata share of losses on its investment in
MBHC, and amounts attributable to the preferred stock accretion in connection
with the private placement in September of 1998.
Three Months Ended March 31, 1999 Compared to Three Months Ended March 31,
1998
Net Sales. Net sales for the three months ended March 31, 1999 (the "1999
Interim Period") were approximately $2,287,000, largely attributable to the sale
of three ROBODOC systems, as compared to the three months ended March 31, 1998
(the "1998 Interim Period") of approximately $1,383,000 which included the sale
of two ROBODOC systems.
Cost of Sales. Cost of sales for the 1999 Interim Period was approximately
$1,105,000 (48% of net sales) as compared to the 1998 Interim Period of
approximately $622,000 (45% of net sales). The higher cost as a percent of sales
in the 1999 Interim Period is a result of lower unit selling prices attributable
to two customers purchasing more than one ROBODOC system.
Selling, General and Administrative. Selling, general and administrative
expenses for the 1999 Interim Period (approximately $1,577,000) increased by
approximately $199,000, or 14% as compared to the 1998
10
<PAGE> 13
Interim Period (approximately $1,378,000). Marketing costs increased
approximately $107,000 with the addition of five employees in sales and
increased participation in medical conferences and potential customer sites.
General and administrative costs increased approximately $92,000 to support
increased growth as well as investor relations.
Research and Development. Research and development expenses for the 1999
Interim Period (approximately $1,630,000) increased by approximately $140,000,
or approximately 9%, as compared to the 1998 Interim Period (approximately
$1,490,000), due to additional engineering staff required to support new
applications of existing products and new product development projects.
Stock Compensation. Stock compensation expense during the 1999 Interim
Period was $15,000, $3,000 lower than the 1998 Interim Period ($18,000). The
Company charged to operations in 1996 deferred stock compensation relating to
stock options granted during 1996 with exercise prices less than the estimated
fair value of the Company's Common Stock, as determined by an independent
valuation analysis, on the date of grant. Deferred compensation for the
non-vested portion is being amortized into expense over the vesting period of
the stock options, which generally range from three to five years. Stock
compensation expense in the 1999 and 1998 Interim Periods represents the
additional vesting which occurred in the first three months of 1999 and 1998.
Interest Income. Interest income for the 1999 Interim Period
(approximately $37,000) decreased by approximately $63,000, or 63%, as compared
to the 1998 Interim Period (approximately $100,000), primarily due to lower
average cash balances during the 1999 Interim Period as a result of the
Company's 1998 operating loss.
Other Income and Expense. Other expense for the 1999 Interim Period was
approximately $288,000 compared to expense of approximately $10,000 in the 1998
Interim Period. The increase in expense ($278,000) is primarily attributable to
an exchange rate loss associated with a weaker Dutch Guilder against the U.S.
dollar in the 1999 Interim Period.
Net Loss. The net loss for the 1999 Interim Period (approximately
$2,306,000) increased by approximately $261,000, or approximately 13%, as
compared to the net loss for the 1998 Interim Period (approximately $2,045,000).
LIQUIDITY AND CAPITAL RESOURCES
Since inception, the Company's expenses have exceeded net sales. Operations
have been funded primarily from the issuance of debt and the sale of equity
securities aggregating approximately $36.6 million. In addition, the Company was
the beneficiary of proceeds from a $3 million key-man life insurance policy in
1993 upon the death of one of its executives.
The Company used cash from operating activities of approximately $4,438,000
and $8,673,000 in 1997 and 1998, respectively. Net cash used for operations in
each of these periods resulted primarily from the net loss. Cash used for
operations in 1997 reflected an increase in accounts receivable and inventories.
Cash used for operations in 1998 reflected an increase in accounts receivable
and inventories, partially offset by an increase in customer deposits. The
Company is eligible to receive reimbursement for 49% of its qualified
expenditures under the terms of a grant from the National Institute for
Standards & Technology. The Company received reimbursements from this program of
approximately $317,000 and $514,000 for 1997 and 1998, respectively.
The Company used cash in investing activities of approximately $924,000 and
$4,259,000 in 1997 and 1998, respectively. The Company's investing activities
have consisted primarily of expenditures for property and equipment that totaled
approximately $377,000 and $1,746,000 in 1997 and 1998, respectively,
investments in sales-type leases of approximately $453,000 in 1997 and payments
of $119,000 in connection with the purchase of IMMI in 1997. In 1998, the
Company also invested $2,024,000 in marketable securities and $563,000 in the
MBHC.
11
<PAGE> 14
Cash provided by financing activities from inception through 1998 is
comprised principally of the net cash proceeds from the sale of a convertible
note in the principal amount of $3,000,000, the sale of convertible preferred
stock and warrants for $14,676,000, the sale of Common Stock and warrants for
approximately $6,137,000 resulting from the Company's initial public offering in
November 1996, approximately $8,440,000 from the Company's European offering of
Common Stock in November 1997, and the sale of convertible preferred stock and
warrants for $3,300,400 in September 1998. As part of the recapitalization of
the Company in December 1995, the entire $3,000,000 principal amount of the
convertible note, together with accrued interest thereon of approximately
$1,224,000, was converted into a warrant to purchase Common Stock. A total of
$11,734,000 and $2,942,000 of preferred stock and warrants to purchase preferred
stock was converted into Common Stock and warrants to purchase Common Stock in
December 1995 and November 1996, respectively. In 1998, the Company also
established a $1.5 million revolving credit facility with a bank. At December
31, 1998, the outstanding amount of debt against the revolving line of credit
was approximately $678,000.
The Company's use of cash in operating activities of approximately $72,000
in the 1999 Interim Period decreased by approximately $1,837,000 as compared to
cash usage due to operating activities in the 1998 Interim Period of
approximately $1,909,000. The reduced operating cash usage in the 1999 Interim
Period was primarily a result of an increase in accounts payable of
approximately $1,596,000, an increase in customer deposits of approximately
$442,000, a reduction in accounts receivable of approximately $206,000 and an
increase in inventories of approximately $707,000.
The Company's use of cash in investing activities of approximately $599,000
in the 1999 Interim Period increased by approximately $372,000 as compared to
1998 Interim Period of approximately $227,000. The investment cash usage in the
1999 Interim Period was primarily due to investments in customer sales-type and
operating leases.
Cash provided by financing activities in the 1999 Interim Period was
approximately $1,636,000 and increased by approximately $1,651,000 as compared
to the financing activities during the 1998 Interim Period. In March 1999 the
Company received aggregate net proceeds of approximately $947,000 from the sale
of convertible preferred stock and warrants (see Note C to the unaudited
consolidated financial statements). In June of 1999, the Company received net
proceeds of approximately $2,582,500 from the sale of convertible preferred
stock and warrants (see Note C to the unaudited consolidated financial
statements).
The Company's available cash resources, together with anticipated cash
flows from operations, may not be sufficient to continue operations without
additional financing. For this reason the Company has sought investment funding
from the investment community under terms that have been satisfactory. If the
proposed Sale to the Purchasers is not approved by Stockholders, or the Company
is unable to obtain alternative financing on a timely basis, it may have to
reduce or curtail its operations to a level that will not allow it to pursue its
product development objectives or to continue to support its long term business
objectives. There can be no assurance that alternative financing will be
available on terms acceptable to the Company or its stockholders, or that such
financing will be available within a time frame required by the Company.
12
<PAGE> 15
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information concerning the
beneficial ownership of the Company's Common Stock at June 28, 1999 by (i) each
stockholder known by the Company to be a beneficial owner of more than five
percent of the outstanding Common Stock, (ii) each director of the Company,
(iii) each executive officer of the Company listed in the Summary Compensation
Table and (iv) all directors and officers as a group.
<TABLE>
<CAPTION>
AMOUNT AND
NATURE OF PERCENTAGE OF
BENEFICIAL COMMON STOCK
NAME OWNERSHIP(1) BENEFICIALLY OWNED(2)
- ---- ------------ ---------------------
<S> <C> <C>
International Business Machines Corporation
Old Orchard Road,
Armonk, N.Y. 10504....................................... 2,274,066(3) 21.20%
EJ Financial Investments V, L.P.
225 East Deer Path Road, Suite 250
Lake Forest, IL 60045.................................... 1,039,792 12.30%
Ramesh C. Trivedi(4)....................................... 367,109(5) 4.18%
John N. Kapoor(6).......................................... 1,039,792(7) 12.30%
James C. McGroddy(8)....................................... 49,843(9) *
Paul A.H. Pankow(10)....................................... 9,401(11) *
Patrick G. Hays(12)........................................ 5,469(13) *
Gerald D. Knudson(14)...................................... 5,469(13) *
Mark Winn(4)............................................... 17,250(15)* 0
All directors and officers as a group (7 persons).......... 1,494,333 16.79%
</TABLE>
- ---------------
* Less than one percent.
(1) Unless otherwise indicated, each person has sole investment and voting
power with respect to the shares indicated, subject to community property
laws, where applicable.
(2) For purposes of computing the percentage of outstanding shares held by each
person or group of persons named above on June 28, 1999, any security which
such person or group of persons has the right to acquire within 60 days
after such date is deemed to be outstanding for the purpose of computing
the percentage ownership for such person or persons, but is not deemed to
be outstanding for the purpose of computing the percentage ownership of any
other person.
(3) Includes warrants to purchase 2,206,479 shares of Common Stock at an
exercise price of $0.01 per share exercisable until December 31, 2005, and
warrants to purchase 67,587 shares of Common Stock at an exercise price of
$0.07 per share exercisable until December 31, 2000, which warrants are
presently exercisable.
(4) Address is c/o the Company, 1850 Research Park, Davis, California
95616-4884.
(5) Includes 7,000 shares owned by Dr. Trivedi and 360,109 shares that he may
acquire upon exercise of stock options exercisable within 60
days -- 316,907 shares at an exercise price of $0.07 per share and 43,202
shares at an exercise price of $3.00 per share. Dr. Trivedi may acquire an
additional 76,798 shares upon exercise of stock options that become
exercisable over the remaining term of the options at an exercise price of
$3.00 per share.
(6) Address is c/o EJ Financial Enterprises, 225 E. Deer Path Road, Suite 250,
Lake Forest, Illinois 60045.
(7) Represents shares of Common Stock owned by EJ Financial Investments V,
L.P., a limited partnership of which Mr. Kapoor is the managing general
partner. Mr. Kapoor disclaims beneficial ownership of such shares.
(8) Address is 200 Business Park Drive, Armonk, New York 10504.
13
<PAGE> 16
(9) Includes 26,000 shares owned by Dr. McGroddy, 1,000 shares beneficially
owned by his daughter, and 22,843 shares that he may acquire upon exercise
of stock options exercisable within 60 days -- 18,406 shares at an exercise
price of $5.00 per share, 937 shares at an exercise price of $5.625 and
3,500 shares at an exercise price of $3.9375. Dr. McGroddy may acquire an
additional 13,083 shares upon exercise of stock options that become
exercisable over the remaining term of the options at exercise prices
ranging from $1.5625 to $5.625.
(10) Address is 7840 East Lake Carlos Drive N.E., Carlos, Minnesota 56319.
(11) Represents shares that Mr. Pankow may acquire upon exercise of stock
options exercisable within 60 days -- 2,704 shares at an exercise price of
$2.07 per share, 937 shares at an exercise price of $5.625 per share, 2,260
shares at an exercise price of $5.00 per share, and 3,500 shares at an
exercise price of $3.9375 per share. Mr. Pankow may acquire an additional
5,469 shares upon exercise of stock options that become exercisable over
the remaining term of the options at exercise prices ranging from $1.5625
to $5.00 per share.
(12) Address is c/o Blue Cross/Blue Shield Association, 225 North Michigan, 9th
Floor, Chicago, Illinois 60601-7680.
(13) Represents shares that he may acquire upon exercise of options exercisable
within 60 days -- 1,969 shares at an exercise price of $5.625 per share and
3,500 shares at an exercise price of $3.9375. He may acquire an additional
5,031 shares issuable upon exercise of stock options that become
exercisable over the remaining term of the options at exercise prices
ranging from $1.5625 of $5.625 per share.
(14) Address is c/o Sterling Diagnostic Imaging, Inc., 10 South Academy Street,
Greenville, South Carolina 29602.
(15) Includes 11,250 shares that Mr. Winn may acquire upon exercise of options
exercisable within 60 days at an exercise price of $3.00. Does not include
33,750 shares that Mr. Winn may acquire upon exercise of options not
exercisable within 60 days at an exercise price of $3.00 per share.
14
<PAGE> 17
GENERAL INFORMATION
INFORMATION ABOUT THE BOARD OF DIRECTORS AND ITS COMMITTEES
The Board of Directors has two standing committees, an Audit Committee and
a Compensation Committee.
The Audit Committee is composed of Dr. Kapoor (Chairman), Mr. Hays and Mr.
Pankow. The duties of the Audit Committee include recommending the engagement of
independent auditors, reviewing and considering actions of management in matters
relating to audit functions, reviewing with independent auditors the scope and
results of its audit engagement, reviewing reports from various regulatory
authorities, reviewing the system of internal controls and procedures of the
Company, and reviewing the effectiveness of procedures intended to prevent
violations of law and regulations. The Audit Committee held one meeting in 1998.
The Company's Compensation Committee is composed of Dr. McGroddy
(Chairman), Dr. Kapoor and Mr. Knudson. The duties of this Committee are to
recommend to the Board remuneration for officers of the Company, to determine
the number and issuance of options pursuant to the Company's stock option plans
and to recommend the establishment of and to monitor a compensation and
incentive program for all executives of the Company. The Compensation Committee
held five meetings in 1998.
The Board of Directors held seven meetings in 1998. All of the Directors
attended at least 75% of the total number of Board meetings and meetings of
committees on which they served during the period they served thereon in 1998.
The Company pays independent Directors $7,500 per annum, plus $500 for each
Board of Directors meeting attended in person and $250 for each Board of
Directors meeting attended by telephone. Members who serve on either the Audit
or Compensation Committees are paid $300 for each meeting attended in person and
$150 for each meeting attended by telephone. Committee chairmen also are paid
$500 per annum. Independent Directors (other than Dr. Kapoor) also receive
annually ten year non-qualified stock options to purchase 3,500 shares of the
Company's Common Stock at an exercise price equal to the fair market value of
the Common Stock on the date of grant.
15
<PAGE> 18
SUMMARY COMPENSATION TABLE
The following table sets forth the compensation awarded to, earned by or
paid to the Company's Chief Executive Officer and each other executive officer
of the Company whose salary and bonus exceeded $100,000 for the year ended
December 31, 1998.
<TABLE>
<CAPTION>
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
------------------------------- ------------
OTHER SECURITIES
ANNUAL UNDERLYING
NAME AND PRINCIPAL POSITION YEAR SALARY COMPENSATION OPTIONS
- --------------------------- ---- -------- ------------ ------------
<S> <C> <C> <C> <C>
Ramesh C. Trivedi................................ 1998 $279,840 $42,501 120,000
Chief Executive Officer and President 1997 $264,000 $50,400 20,000
1996 $264,000 $50,000 316,907
Mark W. Winn..................................... 1998 $118,333 $ -- --
Chief Financial Officer 1997(1) $ 38,333 $ 8,316 45,000
</TABLE>
- ---------------
(1) Mr. Winn commenced employment with the Company on September 2, 1997.
STOCK OPTIONS
The following table contains information concerning the grant of stock
options under the Company's 1998 Stock Option Plan to Dr. Trivedi and Mr. Winn
(collectively, the "Named Executive Officers") during the fiscal year ended
December 31, 1998.
OPTION GRANTS IN LAST FISCAL YEAR
(INDIVIDUAL GRANTS)
<TABLE>
<CAPTION>
PERCENT OF
NUMBER OF TOTAL
SHARES OPTIONS
UNDERLYING GRANTED TO EXERCISE
OPTIONS EMPLOYEES IN PRICE PER EXPIRATION
NAME GRANTED(1) FISCAL YEAR SHARE(2) DATE
- ---- ---------- ------------ --------- ----------
<S> <C> <C> <C> <C>
Ramesh C. Trivedi.............................. 120,000 16.6% $3.00 8/27/08
Mark W. Winn................................... 45,000 6.2% $3.00 8/27/08
</TABLE>
- ---------------
(1) Stock options are granted at the discretion of the Compensation Committee of
the Company's Board of Directors. Stock options have a 10-year term and vest
periodically over a period not to exceed five years.
(2) The Compensation Committee of the Company's Board of Directors may elect to
reduce the exercise price of any option to the current fair market value of
the Common Stock if the value of the Common Stock has declined from the date
of grant.
The following table summarizes for each of the Named Executive Officers the
total number of unexercised options, if any, held at December 31, 1998, and the
aggregate dollar value of in-the-money, unexercised options, held at December
31, 1998. The value of the unexercised, in-the-money options at December 31,
1998, is the difference between their exercise or base price and the value of
the underlying Common Stock on December 31, 1998. The closing sale price of the
Common Stock on The Nasdaq SmallCap Market on December 31, 1998 was $3.125 per
share.
16
<PAGE> 19
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FY END OPTION VALUES
<TABLE>
<CAPTION>
SHARES ACQUIRED NUMBER OF SECURITIES
UPON EXERCISE OF UNDERLYING VALUE OF UNEXERCISED
OPTIONS DURING FISCAL UNEXERCISED OPTIONS IN-THE-MONEY OPTIONS AT
1998 AT DECEMBER 31, 1998 DECEMBER 31, 1998
---------------------- ---------------------------- ----------------------------
VALUE
NAME NUMBER REALIZED EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ---- -------- ---------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Ramesh C. Trivedi...... None None 334,510 102,397 $987,754(1) $12,800(2)
Mark W. Winn........... None None 0 45,000 0(3) $ 5,625(3)
</TABLE>
- ---------------
(1) Represents value of options to purchase 316,907 shares at an exercise price
of $0.07 per share and options to purchase 17,603 shares at an exercise
price of $3.00 per share.
(2) Represents value of options to purchase 102,397 shares at an exercise price
of $3.00 per share.
(3) Represents value of options to purchase 45,000 shares at an exercise price
of $3.00 per share.
REPRICING OF OPTIONS
<TABLE>
<CAPTION>
LENGTH OF
NUMBER OF MARKET ORIGINAL
SECURITIES PRICE OF OPTION TERM
UNDERLYING STOCK AT EXERCISE PRICE OF REMAINING
REPRICE/ OPTIONS TIME OF STOCK AT TIME OF NEW AT DATE OF
REGRANT REPRICED OR REPRICING OR REPRICING OR EXERCISE REPRICING OR
NAME DATE AMENDED AMENDMENT AMENDMENT PRICE AMENDMENT
- ---- -------- ----------- ------------ ----------------- -------- --------------
<S> <C> <C> <C> <C> <C> <C>
Ramesh C. Trivedi...... 8/28/98 120,000 $3.00 40,000 @ $6.13 $3.00 8 yrs. 7 mos.
100,000 @ $4.75 9 yrs. 6 mos.
Mark W. Winn........... 7/28/98 45,000 $3.00 25,000 @ $8.25 $3.00 9 yrs. 10 mos.
20,000 @ $4.875 9 yrs. 8 mos.
</TABLE>
The Compensation Committee of the Board of Directors approved the
replacement of these options to Dr. Trivedi and Mr. Winn, and options to other
employees of the Company, at an exercise price of $3.00 per share, having
concluded that the principal purpose of the Company's stock option program
(i.e., to provide an equity incentive to employees to remain in the employment
of the Company and to work diligently in its best interests) would not be
achieved for those employees holding options exercisable above the market price
of the Common Stock.
INDEPENDENT AUDITORS
Representatives of Ernst & Young LLP, the Company's independent auditors,
are expected to be present at the Special Meeting to respond to appropriate
questions from stockholders and to make a statement if they desire to do so.
Ernst & Young LLP has audited the Company's financial statements since the
fiscal year ended December 31, 1991. They have no financial interest, either
direct or indirect, in the Company.
17
<PAGE> 20
OTHER MATTERS
The Board of Directors is not aware of any business to be presented at the
Special Meeting except the proposed Sale described in this Proxy Statement.
Unless otherwise directed, all shares represented by Board of Directors' proxies
will be voted in favor of the proposed Sale. If any other matters come before
the Special Meeting, the persons named in the accompanying Proxy will vote on
those matters according to their best judgment.
By Order of the Board of Directors
Mark W. Winn, Secretary
Davis, California
July , 1999
18
<PAGE> 21
INTEGRATED SURGICAL SYSTEMS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<S> <C>
AUDITED FINANCIAL STATEMENTS:
Report of Ernst & Young LLP, Independent Auditors........... F-2
Consolidated Balance Sheet at December 31, 1998............. F-3
Consolidated Statements of Operations for the years ended
December 31, 1997 and 1998................................ F-4
Consolidated Statements of Stockholders' Equity for the
years ended December 31, 1997 and 1998.................... F-5
Consolidated Statements of Cash Flows for the years ended
December 31, 1997 and 1998................................ F-6
Notes to Consolidated Financial Statements.................. F-7
UNAUDITED FINANCIAL STATEMENTS:
Consolidated Balance Sheet at March 31, 1999................ F-21
Consolidated Statements of Operations for the three months
ended March 31, 1999 and 1998............................. F-22
Consolidated Statements of Cash Flows for the three months
ended March 31, 1999 and 1998............................. F-23
Notes to Consolidated Financial Statements for the three
months ended March 31, 1999............................... F-24
</TABLE>
F-1
<PAGE> 22
REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
The Board of Directors and Stockholders
Integrated Surgical Systems, Inc.
We have audited the accompanying consolidated balance sheet of Integrated
Surgical Systems, Inc. as of December 31, 1998, and the related consolidated
statements of operations, stockholders' equity, and cash flows for the years
ended December 31, 1997 and 1998. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Integrated
Surgical Systems, Inc. at December 31, 1998, and the consolidated results of its
operations and its cash flows for the years ended December 31, 1997 and 1998 in
conformity with generally accepted accounting principles.
ERNST & YOUNG LLP
Sacramento, California
February 12, 1999
F-2
<PAGE> 23
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED BALANCE SHEET
DECEMBER 31, 1998
<TABLE>
<S> <C>
ASSETS
Current assets:
Cash and cash equivalents................................. $ 223,581
Short-term investments.................................... 2,024,278
Accounts receivable....................................... 1,905,138
Inventory................................................. 3,005,658
Other current assets...................................... 464,421
------------
Total current assets........................................ 7,623,076
Net property and equipment.................................. 1,350,839
Leased equipment, net....................................... 641,411
Long-term net investment in sales-type leases............... 262,334
Intangible assets, net...................................... 3,014,978
Other assets................................................ 272,532
------------
$ 13,165,170
============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.......................................... $ 1,475,754
Value added taxes payable................................. 347,584
Accrued payroll and related expenses...................... 471,278
Customer deposits......................................... 896,276
Accrued product retrofit costs............................ 135,348
Current portion of bank loans............................. 897,021
Other current liabilities................................. 732,594
------------
Total current liabilities................................... 4,955,855
Bank loans, long term....................................... 7,505
Note payable................................................ 143,200
Commitments and contingencies (Notes 10 and 11)
Stockholders' equity:
Convertible preferred stock, $0.01 par value, 1,000,000
shares authorized, 3,520 shares issued and outstanding
($3,520,000 aggregate liquidation value)............... 35
Common stock, $0.01 par value, 15,000,000 shares
authorized; 5,650,400 shares issued and outstanding.... 56,504
Additional paid-in capital................................ 42,343,287
Deferred stock compensation............................... (85,638)
Preferred stock discount.................................. (239,736)
Accumulated other comprehensive income.................... 207,216
Accumulated deficit....................................... (34,223,058)
------------
Total stockholders' equity.................................. 8,058,610
------------
$ 13,165,170
============
</TABLE>
See accompanying notes.
F-3
<PAGE> 24
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
---------------------------
1997 1998
----------- ------------
<S> <C> <C>
Net sales................................................... $ 4,933,824 $ 6,146,434
Cost of sales............................................... 2,182,842 3,413,221
----------- ------------
2,750,982 2,733,213
Operating expenses:
Selling, general and administrative....................... 3,701,264 6,216,240
Research and development.................................. 3,063,925 6,602,550
Stock compensation........................................ 155,474 131,352
In-process research and development acquired.............. 331,668 --
----------- ------------
7,252,331 12,950,142
Other income (expense):
Interest income........................................... 214,913 240,959
Interest expense.......................................... (26,495) (124,095)
Foreign currency gain (loss).............................. (147,390) 129,158
Other, net................................................ 32,028 (269,737)
----------- ------------
Loss before provision for income taxes...................... (4,428,293) (10,240,644)
Provision for income taxes.................................. 49,811 27,235
----------- ------------
Net loss.................................................... (4,478,104) (10,267,879)
Preferred stock accretion................................... -- (376,264)
----------- ------------
Net loss applicable to common stockholders.................. $(4,478,104) $(10,644,143)
=========== ============
Basic and diluted net loss per share........................ $ (1.20) $ (1.91)
=========== ============
Shares used in computing basic net loss per share........... 3,737,318 5,584,639
=========== ============
</TABLE>
See accompanying notes.
F-4
<PAGE> 25
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
CONVERTIBLE ACCUMULATED
PREFERRED STOCK COMMON STOCK ADDITIONAL DEFERRED PREFERRED OTHER
--------------- ------------------- PAID-IN STOCK STOCK COMPREHENSIVE
SHARES AMOUNT SHARES AMOUNT CAPITAL COMPENSATION DISCOUNT INCOME
------ ------ --------- ------- ----------- ------------ ---------- -------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1996... -- $-- 3,361,161 $33,611 $25,807,264 $(426,417) $ -- $ 8,657
Exercise of stock options.... -- -- 18,374 184 18,416 -- -- --
Issuance of stock options to
consultant................. -- -- -- -- 23,270 -- -- --
Issuance of warrants to
consultant................. -- -- -- -- 65,625 -- -- --
Acquisition of IMMI.......... -- -- 619,355 6,194 3,883,356 -- -- --
Issuance of common stock to
consultant................. -- -- 4,500 45 28,215 -- -- --
Sale of common stock, net of
offering expenses.......... -- -- 1,500,000 15,000 8,425,103 -- -- --
Stock compensation expense... -- -- -- -- (31,413) 186,887 -- --
Comprehensive loss:
Net loss................... -- -- -- -- -- -- -- --
Foreign currency
translation
adjustments.............. -- -- -- -- -- -- -- 17,615
Comprehensive loss........... -- -- -- -- -- -- -- --
-----------------------------------------------------------------------------------------------
Balance at December 31, 1997... -- -- 5,503,390 55,034 38,219,836 (239,530) -- 26,272
Exercise of stock options.... -- -- 142,010 1,420 14,313 -- -- --
Issuance of stock options to
consultant................. -- -- -- -- 208,386 -- -- --
Sale of common stock
warrants................... -- -- -- -- 6,930 -- -- --
Sale of convertible preferred
stock and warrants, net of
offering expenses.......... 3,520 35 5,000 50 3,300,362 -- -- --
Stock compensation expense... -- -- -- -- (22,540) 153,892 -- --
Preferred stock discount..... -- -- -- -- 616,000 -- (616,000) --
Preferred stock accretion.... -- -- -- -- -- -- 376,264
Comprehensive loss:
Net loss................... -- -- -- -- -- -- -- --
Unrealized gains of
securities............... -- -- -- -- -- -- -- 50,626
Foreign currency
translation
adjustments.............. -- -- -- -- -- -- -- 130,318
Comprehensive loss........... -- -- -- -- -- -- -- --
-----------------------------------------------------------------------------------------------
Balance at December 31, 1998... 3,520 $35 5,650,400 $56,504 $42,343,287 $ (85,638) $ (239,736) $207,216
===============================================================================================
<CAPTION>
TOTAL
ACCUMULATED STOCKHOLDERS
DEFICIT EQUITY
------------ ------------
<S> <C> <C>
Balance at December 31, 1996... $(19,100,811) $ 6,322,304
Exercise of stock options.... -- 18,600
Issuance of stock options to
consultant................. -- 23,270
Issuance of warrants to
consultant................. -- 65,625
Acquisition of IMMI.......... -- 3,889,550
Issuance of common stock to
consultant................. -- 28,260
Sale of common stock, net of
offering expenses.......... -- 8,440,103
Stock compensation expense... -- 155,474
Comprehensive loss:
Net loss................... (4,478,104) (4,478,104)
Foreign currency
translation
adjustments.............. -- 17,615
------------
Comprehensive loss........... -- (4,460,489)
------------
Balance at December 31, 1997... (23,578,915) 14,482,697
Exercise of stock options.... -- 15,733
Issuance of stock options to
consultant................. -- 208,386
Sale of common stock
warrants................... -- 6,930
Sale of convertible preferred
stock and warrants, net of
offering expenses.......... -- 3,300,447
Stock compensation expense... -- 131,352
Preferred stock discount..... -- --
Preferred stock accretion.... (376,264) --
Comprehensive loss:
Net loss................... (10,267,879) (10,267,879)
Unrealized gains of
securities............... -- 50,626
Foreign currency
translation
adjustments.............. -- 130,318
------------
Comprehensive loss........... -- (10,086,935)
------------
Balance at December 31, 1998... $(34,223,058) $ 8,058,610
</TABLE>
See accompanying notes.
F-5
<PAGE> 26
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
---------------------------
1997 1998
----------- ------------
<S> <C> <C>
Cash flows from operating activities:
Net loss.................................................... $(4,478,104) $(10,267,879)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation.............................................. 228,788 579,666
In-process research and development acquired.............. 331,678 --
Amortization of intangible assets......................... 279,680 839,040
Stock compensation........................................ 155,474 131,352
Issuance of stock options to consultant................... 23,270 208,386
Unrealized gain on short-term investments................. -- 50,626
Equity in net loss of Marbella High Care B.V. ............ -- 317,000
Changes in operating assets and liabilities:
Accounts receivable..................................... (809,338) (478,596)
Inventory............................................... (894,739) (1,110,320)
Other current assets.................................... (155,998) 9,188
Accounts payable........................................ 532,121 65,539
Value added taxes payable............................... 160,809 (91,098)
Accrued payroll and related expenses.................... 126,997 54,655
Customer deposits....................................... 13,672 757,604
Other current liabilities............................... 46,592 262,217
Note payable............................................ 778 (203)
----------- ------------
Net cash used in operating activities....................... (4,438,320) (8,672,823)
Cash flows from investing activities:
Purchase of short-term investments........................ -- (2,024,278)
Investment in Marbella High Care B.V. .................... -- (563,273)
Investment in sales-type lease............................ (453,250) --
Principal payments received on sales-type lease........... 19,967 88,425
Purchases of property and equipment....................... (376,573) (1,746,127)
Payments in connection with purchase of subsidiary, net of
cash acquired........................................... (118,880) --
Decrease (increase) in other assets....................... 4,446 (12,868)
----------- ------------
Net cash used in investing activities....................... (924,290) (4,258,121)
Cash flows from financing activities:
Proceeds from bank loans.................................. 71,422 678,447
Payments on bank loans.................................... (94,421) (69,138)
Proceeds from sale of preferred stock and warrants........ -- 3,300,447
Net proceeds from sale of common stock and warrants....... 8,440,103 6,930
Proceeds from exercise of stock options................... 18,600 15,733
----------- ------------
Net cash provided by financing activities................... 8,435,704 3,932,419
Effect of exchange rate changes on cash and cash
equivalents............................................... 17,615 130,318
----------- ------------
Net increase (decrease) in cash and cash equivalents........ 3,090,709 (8,868,207)
Cash and cash equivalents at beginning of year.............. 6,001,079 9,091,788
----------- ------------
Cash and cash equivalents at end of year.................... $ 9,091,788 $ 223,581
=========== ============
Supplemental disclosure of cash flow information:
Cash paid for interest...................................... $ 25,392 $ 118,925
</TABLE>
See accompanying notes.
F-6
<PAGE> 27
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1998
1. DESCRIPTION OF BUSINESS
Integrated Surgical Systems, Inc. (the "Company") was incorporated on
October 1, 1990 in Delaware. The Company develops, manufactures, markets and
services computer-controlled, image-directed robotic products for surgical
applications. The Company's principal product is the ROBODOC(R) Surgical
Assistant System (ROBODOC(R)), which is designed for orthopedic applications.
ROBODOC(R) is currently marketed in Europe.
On September 5, 1997, the Company acquired all of Innovative Medical
Machines International, S.A.'s ("IMMI") issued and outstanding capital stock,
stock warrants and convertible debt in a transaction accounted for as a purchase
(Note 3). IMMI develops, manufactures and markets image guided robotic devices
for surgical applications. Its principal product is the NeuroMate(R), a computer
controlled surgical robot supporting neurosurgical procedures.
On June 1, 1994, the Company acquired all shares of Gasfabriek Thijssen
Holding BV (later renamed Integrated Surgical Systems BV), a non-operating
Netherlands corporation, for approximately $4,000. The acquisition was accounted
for as a purchase. Integrated Surgical Systems BV purchases and licenses
products and technology from Integrated Surgical Systems, Inc. for distribution
in Europe and other markets.
2. SIGNIFICANT ACCOUNTING POLICIES
CONSOLIDATION
The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiaries. All significant intercompany balances and
transactions have been eliminated in consolidation.
FOREIGN CURRENCY TRANSLATION
The financial position and results of operations of IMMI and Integrated
Surgical Systems BV are measured using their respective local currencies. The
subsidiary balance sheet accounts are translated at the year-end exchange rate
and statement of operations amounts are translated at the average exchange rate
for the period. Translation adjustments are recorded as a separate component of
stockholders' equity. Foreign currency transaction gain (loss) was ($147,390)
and $129,158 during the years ended December 31, 1997 and December 31, 1998,
respectively.
REVENUE RECOGNITION
Revenues from sales without significant Company obligations beyond delivery
are recognized upon delivery of the products. Revenues pursuant to agreements
which include significant Company obligations beyond delivery are deferred until
the Company's remaining obligations are insignificant. Revenues are recognized
net of any deferrals for estimated future liabilities under contractual product
warranty provisions. Estimated future product retrofit costs for ROBODOC(R) sold
for clinical trials have been accrued in the accompanying financial statements.
Future retrofit costs are those expected to be required to update ROBODOC(R) to
the equivalent level of performance expected to be approved by the Food and Drug
Administration ("FDA").
RESEARCH AND DEVELOPMENT
Software development costs incurred subsequent to the determination of the
product's technological feasibility and prior to the product's general release
to customers are not material to the Company's financial position or results of
operations, and have been charged to research and development expense in the
F-7
<PAGE> 28
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
accompanying consolidated statements of operations. Grants received from third
parties for research and development activities are recorded as reductions of
expense over the term of the agreement as the related activities are conducted.
Research and development costs are expensed as incurred.
CONCENTRATION OF CREDIT RISK
The Company sells its products to companies in the healthcare industry and
performs periodic credit evaluations of its customers and generally does not
require collateral. The Company believes that adequate provision for
uncollectible accounts receivable has been made in the accompanying financial
statements. The Company maintains substantially all of its cash at four
financial institutions.
FINANCIAL STATEMENT ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
The Company invests its excess cash in various investment grade,
interest-bearing securities. As of December 31, 1998, cash equivalents and
short-term investments consisted of money market mutual funds, U.S. Treasury
Strips and a certificate of deposit. The Company has not experienced any losses
on such investments.
Management determines the appropriate classification of debt securities at
the time of purchase and re-evaluates such designation as of each balance sheet
date. At December 31, 1998, the Company's entire portfolio of investments is
classified as available-for-sale. These securities are stated at fair market
value, determined based on quoted market prices, with the unrealized gains and
losses reported in a separate component of stockholders' equity.
The amortized cost of debt securities classified as available-for-sale is
adjusted for amortization of premiums and accretion of discounts to maturity,
over the estimated life of the security. Such amortization is included in
interest income. Realized gains and losses were not material in any year
presented. The cost of securities sold is based on the specific identification
method.
For purposes of reporting cash flows, the Company considers highly liquid
investments with original maturities of three months or less as cash
equivalents.
FAIR VALUES OF FINANCIAL INSTRUMENTS
The carrying values of the bank loans approximate their fair values as of
December 31, 1998, based on current incremental borrowing rates for similar
types of borrowing arrangements.
Active markets for the Company's other financial instruments that are
subject to the fair value disclosure requirements of Statement of Financial
Accounting Standards No. 107, which consist of long-term lease receivables and
notes payable, do not exist and there are no quoted market prices for these
assets and liabilities. Accordingly, it is not practicable to estimate the fair
values of such financial instruments because of the limited information
available to the Company and because of the significance of the cost to obtain
independent appraisals for this purpose.
F-8
<PAGE> 29
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
INTANGIBLE ASSETS
The Company continually evaluates the value and future benefits of its
intangible assets. The Company assesses recoverability from future operations
using cash flows and income from operations of the related acquired business as
measures. Under this approach, the carrying value would be reduced if it becomes
probable that the Company's best estimate for expected future cash flows of the
related business would be less than the carrying amount of the related
intangible assets. There have been no adjustments to the carrying amounts of
intangible assets resulting from these evaluations as of December 31, 1998.
PROPERTY AND EQUIPMENT
Property and equipment are stated at cost. Depreciation is calculated using
the straight-line method over estimated useful lives of 3 to 5 years, or the
lease term, whichever is shorter.
NET INVESTMENT IN SALES-TYPE LEASES
The net investment in sales-type leases consists of the following at
December 31, 1998:
<TABLE>
<S> <C>
Total minimum lease payments receivable..................... $388,904
Less unearned interest...................................... (38,828)
--------
Net investment in sales type leases......................... 350,076
Less current portion........................................ (87,742)
--------
Long-term net investment in sales-type leases............... $262,334
========
</TABLE>
The following represents future minimum lease payments to be received by
the Company under its net investment in sales-type leases as of December 31,
1998:
<TABLE>
<S> <C>
1999...................................................... $106,667
2000...................................................... 106,667
2001...................................................... 106,667
2002...................................................... 68,903
--------
$388,904
========
</TABLE>
OPERATING LEASES
The Company leases certain of its ROBODOC systems to customers under
cancelable operating leases. The typical lease period is 5 years and certain of
the leases contain purchase options. The cost of equipment under operating
leases as of December 31, 1998 was $733,781 and the related accumulated
amortization thereon was $92,370.
INVENTORY
Inventory is recorded at the lower of cost (first-in, first-out method) or
market and consists of materials and supplies used in the manufacture and
service support of the ROBODOC(R) and NeuroMate(TM) Systems. Inventory consists
of the following at December 31, 1998:
<TABLE>
<S> <C>
Raw materials............................................... $1,057,141
Work-in process............................................. 763,624
Finished goods.............................................. 1,184,893
----------
$3,005,658
==========
</TABLE>
F-9
<PAGE> 30
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
STOCK-BASED COMPENSATION
As permitted under the provisions of Statement of Financial Accounting
Standards No. 123 "Accounting for Stock-Based Compensation" ("SFAS No. 123"),
the Company has elected to account for stock-based compensation using the
intrinsic value method prescribed by Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" ("APB No. 25"). Under the intrinsic
value method, compensation cost is the excess, if any, of the quoted market
price or fair value of the stock at the grant date or other measurement date
over the amount an employee must pay to acquire the stock.
INCOME TAXES
The liability method is used to account for income taxes. Under this
method, deferred income tax assets and liabilities are determined based on
differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that are
scheduled to be in effect when the differences are expected to reverse.
NET LOSS PER SHARE
In 1997, the Financial Accounting Standards Board ("FASB") issued Statement
No. 128, Earnings per Share. Statement 128 replaced the calculation of primary
and fully diluted earnings per share with basic and diluted earnings per share.
Unlike primary earnings per share, basic earnings per share excludes any
dilutive effects of options, warrants and convertible securities. Diluted
earnings per share is very similar to the previously reported fully diluted
earnings per share. All earnings per share amounts have been presented on the
basis set forth in Statement 128 (Note 10).
SIGNIFICANT CUSTOMERS AND FOREIGN SALES
The Company recognized approximately 86% of its revenues from seven
customers, each representing at least 10% of the Company's total revenue, during
the year ended December 31, 1997 and 64% of its revenue from five customers each
representing at least 10% of the Company's total revenue, during the year ended
December 31, 1998. Foreign sales were approximately $4,919,000 and $6,005,000
for the years ended December 31, 1997 and December 31, 1998, respectively.
NEW ACCOUNTING PRONOUNCEMENTS
As of January 1, 1998, the Company adopted Statement 130, Reporting
Comprehensive Income. Statement 130 establishes new rules for the reporting and
display of comprehensive income and its components. Statement 130 requires
unrealized gains or losses on the Company's available-for-sale securities and
the foreign currency translation adjustments, which prior to adoption were
reported separately in stockholders' equity, to be included in other
comprehensive income. Prior year financial statements have been reclassified to
conform to the requirements of Statement 130.
In June 1998, the Financial Accounting Standards Board issued Statement
133, Accounting for Derivative Instruments and Hedging Activities, which is
required to be adopted in years beginning after June 15, 1999. Management does
not anticipate that the adoption of the new Statement will have a significant
effect on earnings or the financial position of the Company.
RECLASSIFICATIONS
Certain amounts reported in prior years financial statements have been
reclassified to conform with the 1998 presentation.
F-10
<PAGE> 31
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
3. ACQUISITION OF IMMI
Effective September 5, 1997, ISS acquired all of IMMI's issued and
outstanding capital stock, stock warrants and convertible debt in a transaction
accounted for as a purchase. The purchase price included 619,355 shares of ISS
common stock with a fair market value of approximately $3.9 million and
liabilities assumed and acquisition costs of approximately $1.1 million. The
purchase agreement places certain restrictions on the future sale of the ISS
stock issued in connection with the purchase for a period of eighteen months.
The purchase price consists of the following:
<TABLE>
<S> <C>
619,355 shares of ISS common stock.......................... $3,889,549
Liabilities assumed......................................... 883,044
Acquisition costs........................................... 266,085
----------
$5,038,678
==========
</TABLE>
The Company retained independent valuation professionals to assist in the
values to be assigned to the individual assets acquired including the
intangibles and in-process research and development. A summary of the allocation
of purchase price is as follows:
<TABLE>
<S> <C>
Tangible assets acquired.................................... $ 573,302
Identified intangible assets................................ 4,133,698
In-process research and development......................... 331,678
----------
$5,038,678
==========
</TABLE>
Intangible assets consist primarily of developed technology relating to the
NeuroMate(R). Accumulated amortization on intangible assets was $1,118,720 as of
December 31, 1998. In the opinion of ISS and IMMI management, the developed
technology was completed and had alternative future uses. The estimated useful
lives are expected to range from 3 to 5 years. ISS management did not believe
that technological feasibility of the acquired in-process research and
development had been established. Further, ISS management believed the acquired
in-process research and development has no alternative future uses. Therefore,
the amount allocated to in-process research and development was required to be
immediately expensed under generally accepted accounting principles.
The following represents unaudited proforma statement of operations
information as if the acquisition of IMMI occurred on January 1, 1997.
<TABLE>
<CAPTION>
YEAR ENDED
DECEMBER 31,
1997
------------
(UNAUDITED)
<S> <C>
Revenue............................................... $ 5,554,000
===========
Net loss.............................................. $(5,394,000)
===========
Basic net loss per share.............................. $ (1.24)
===========
</TABLE>
The above proforma information is presented for illustrative purposes only
and may not be indicative of the results that would have been obtained had the
transaction actually occurred on January 1, 1997, nor is it necessarily
indicative of future combined results of operations.
F-11
<PAGE> 32
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
4. SHORT-TERM INVESTMENTS
Marketable debt securities are classified as available for sale and consist
of 1,849,000 shares of U.S. Treasury Strips. The shares have an original cost of
$1,767,773 on August 11, 1998 and a fair market value of $1,818,399 at December
31, 1998. The shares mature on May 15, 1999. The shares noted above have been
pledged as collateral for the line of credit with a bank (Note 7). The net
unrealized holding gain as of December 31, 1998 of $50,626 has been included as
a separate component of stockholders' equity.
Additionally, the Company purchased a 1-year certificate of deposit in June
1998 having an original cost of $200,000 and a fair market value of $205,879 on
December 31, 1998. The certificate of deposit is collateral under a letter of
credit to the benefit of the lessor of the Company's U.S. facility. The letter
of credit expires on June 30, 1999.
5. PROPERTY AND EQUIPMENT
Property and equipment consists of the following at December 31, 1998:
<TABLE>
<S> <C>
ROBODOC and NeuroMate System equipment...................... $ 1,039,261
Other equipment............................................. 1,677,695
Furniture and fixtures...................................... 291,798
Leasehold improvements...................................... 49,448
-----------
3,058,202
Less accumulated depreciation............................... (1,707,363)
-----------
$ 1,350,839
===========
</TABLE>
6. INVESTMENT IN MARBELLA HIGH CARE B.V.
Other assets consist primarily of the Company's investment in and advances
to Marbella High Care B.V. ("MBHC"). As of December 31, 1998, the Company owned
22% of the outstanding shares of MBHC and accounts for its investment under the
equity method. The Company's gross investment in MBHC, including loans, was
approximately $563,000 in 1998. For the year ended December 31, 1998, the
Company recorded $317,000 of expense relating to its investment and advances in
MBHC for the period, which has been included in other income (expense).
7. BANK LOANS AND NOTE PAYABLE
Bank loans consist of the following at December 31, 1998:
<TABLE>
<S> <C>
Revolving line of credit established in June 1998 with an
available amount of $1.5 million at December 31, 1998,
with interest accruing at prime plus .75% per annum
(aggregating 8.5% as of December 31, 1998) and expiring on
June 15, 1999............................................. $678,447
Revolving line of credit established in July 1996 for five
years with an available amount of $196,900 at December 31,
1998, with interest accruing at 7.15% per annum. The
amount available decreases quarterly by 5% of the original
amount beginning October 1996............................. 196,900
Bank term loan with monthly principal and interest payments
of approximately $1,762 over three years from May 1997,
with interest accruing at 5.75% per annum................. 29,179
--------
904,526
Less current portion........................................ 897,021
--------
Long-term bank loans........................................ $ 7,505
========
</TABLE>
F-12
<PAGE> 33
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The $1.5 million revolving line of credit is secured by a security interest
in the Company's marketable securities with a carrying value of $1,818,399 at
December 31, 1998. The Company is required to maintain sufficient collateral
equal to or greater than the credit limit, plus $100,000.
The bank term loan is secured by substantially all of IMMI's tangible
assets (with a net book value of approximately $1,804,000 at December 31, 1998)
and is guaranteed by the Company.
The Company received an interest free loan with a balance of $143,200 at
December 31, 1998 from a grant organization for the development of a new system.
In the case of failure of the project, the grant organization may decide to
forgive all or part of the repayments. If the Company sells either a license for
the related technology, the prototype developed, or articles manufactured
specifically for the research project, 50% of the revenue must be paid to the
grant organization in the subsequent year, up to the balance of the loan amount
outstanding. According to the contract, any such payments would be considered to
be an advance repayment of the loan. The Company has not made any sales of this
type through December 31, 1998.
8. STOCKHOLDERS' EQUITY
COMMON STOCK
As of December 31, 1998 the Company has reserved a total of 8,333,782
shares of common stock pursuant to Series A Convertible Preferred Stock,
warrants and options outstanding and reserved for future issuance.
INITIAL PUBLIC OFFERING
In November 1996, the Company sold in its initial public offering, a total
of 1,525,000 shares of common stock at $5.00 per share and 1,753,750 warrants at
$0.10 per warrant. In addition, the Company sold to its underwriter warrants to
purchase an additional 305,000 shares for total consideration of $10.00. The net
proceeds after underwriters' commissions and fees and other costs associated
with the offering were approximately $6,137,000.
Each warrant entitles the holder to purchase one share of common stock at
an exercise price of $6.00 per share, subject to adjustment in certain events,
at any time during the period commencing November 20, 1997, and thereafter for a
period of four years. The warrants are subject to redemption by the Company at
$0.10 per warrant at any time during the exercise period on not less than 30
days prior written notice to the holders of the warrants provided certain
criteria regarding the price performance of the Company's common stock are met.
EUROPEAN OFFERING
On November 20, 1997, the Company sold 1,500,000 shares of Common Stock at
approximately $7.00 per share in an offering to European investors (the
"European Offering"). In addition, the Company sold to its underwriters in the
European Offering warrants to purchase an additional 150,000 shares for nominal
consideration. The net proceeds of the European Offering were approximately
$8,440,000.
Each of the warrants issued to the European Offering underwriters entitles
the holder to purchase one share of common stock at an exercise price of $8.26
per share at any time during the period commencing November 21, 1998, and
thereafter for a period of four years.
CONVERTIBLE PREFERRED STOCK
As part of a Stock Purchase Agreement in December 1995 the Company sold a
warrant for $1,333,333 to purchase 1,386,390 shares of Series D Preferred Stock
at $0.01 per share, and in February 1996 sold a warrant for $666,667 to purchase
693,194 shares of Series D Preferred Stock at $0.01 per share. On October 29,
1997,
F-13
<PAGE> 34
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
the Company and IBM executed an amendment to the Stock Purchase Agreement
pursuant to which the Company and IBM agreed that these combined warrants to
purchase 2,079,584 shares of Series D Preferred Stock would be exercisable only
for 2,079,584 shares of Common Stock at $0.01 per share. The warrants expire on
December 31, 2005 and have not been exercised as of December 31, 1998. Also on
October 29, 1997, the Company delivered to CA IB Investmentbank AG ("CA IB") an
agreement not to issue any shares of Common Stock, or any warrants, options or
other rights to subscribe for or purchase shares of Series D Preferred Stock, or
any other securities convertible into or exercisable or exchangeable for, Series
D Preferred Stock, without the consent of CA IB. In addition, the Company's
management caused the Board of Directors to present a resolution at the annual
meeting of the Company's stockholders to amend the Company's Restated
Certificate of Incorporation to eliminate the Series D Preferred Stock
therefrom. On April 28, 1998 elimination of Series D Preferred Stock was adopted
by the Company's stockholders.
In November 1996, the Board of Directors amended, and the stockholders
subsequently approved, the Company's Articles of Incorporation to authorize
1,000,000 shares of undesignated preferred stock. Preferred stock may be issued
from time to time in one or more series. The Board of Directors is authorized to
determine the rights, preferences, privileges and restrictions granted to and
imposed upon any wholly unissued series of preferred stock and designation of
any such series without any vote or action by the Company's stockholders.
In September 1998, the Company received net proceeds of $3,300,447 from the
sale of 3,520 shares of Series A Convertible Preferred Stock ("Series A
Preferred Stock") and warrants ("Warrants") to purchase 44,000 shares of common
stock ("Common Stock").
The Series A Preferred Stock is convertible into shares of Common Stock, at
the option of the holder, commencing December 9, 1998, subject to certain
limitations, discussed below. The number of shares of Common Stock issuable upon
conversion of the Series A Preferred Stock is equal to the quotient of (x) the
product of $1,000 (the stated value of each share of Series A Preferred Stock)
and the number of shares of Series A Preferred Stock to be converted and (y) 85%
of the lowest sale price of the Common Stock on the Nasdaq SmallCap Market
during the five trading days preceding the date of conversion (the "Market
Price"), but in no event more than $4.96 (the "Conversion Price"). As of
December 31, 1998, the number of common shares issuable upon conversion was
1,731,262.
Holders of Series A Preferred Stock may convert 25% of their shares
commencing December 9, 1998, 50% of their shares commencing January 8, 1999, 75%
of their shares commencing February 7, 1999 and 100% of their shares commencing
March 9, 1999. The Company may require holders to convert all (but not less than
all) of the Series A Preferred Stock at any time after August 24, 2001, or buy
out all outstanding shares, at the then Conversion Price.
The value assigned to the beneficial conversion feature, as associated with
the Market Price as determined using the quoted market price of the Company's
common stock on the date the Series A Preferred Stock was sold, amounted to
$616,000, which represents a discount to the value of the Series A Preferred
Stock (the "Discount"). The Discount is being accreted using the straight-line
method through March 9, 1999. Approximately $376,000 of the Discount was
accreted in 1998.
Holders of Series A Preferred Stock are not entitled to dividends and have
no voting rights, unless required by law or with respect to certain matters
relating to the Series A Preferred Stock.
The Company may redeem the Series A Preferred Stock upon written notice to
the holders of the Series A Preferred Stock at any time after the earlier of
January 10, 1999 and the closing of a registered firm underwritten secondary
offering of equity securities, at a redemption price equal to the greater of
$1,500 per share and the Market Price of the Shares of Common Stock into which
such Series A Preferred Stock could have been converted on the date of the
notice of redemption.
F-14
<PAGE> 35
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Warrants are exercisable at any time during the period commencing March
5, 1999 and ending March 5, 2002, at an exercise price of $4.31, subject to
adjustment. The Conversion Price and the number of shares of Common Stock
issuable upon conversion are subject to adjustment based upon certain future
events.
ISSUANCE OF STOCK AND STOCK WARRANTS
In September 1997, the Company issued 4,500 shares of Common Stock and
warrants to purchase 25,000 shares of Common Stock (with an aggregate estimated
fair value of $93,885) to Rickel & Associates, Inc. for services performed in
connection with the acquisition of IMMI. The warrants have an exercise price of
$7.50 per share and expire in September 2002.
In September 1998, the Company issued 5,000 shares of Common Stock (with an
aggregate estimated fair value of $20,625) to Trinity Capital Advisors, Inc. for
services performed in connection with the Series A Preferred Stock offering.
STOCK OPTION PLANS
The Company has elected to follow Accounting Principles Board Opinion No.
25 "Accounting for Stock Issued to Employees" and related Interpretations in
accounting for its employee stock options because, as discussed below, the
alternative fair value accounting provided for under FASB Statement No. 123,
"Accounting for Stock-Based Compensation," requires use of option valuation
models that were not developed for use in valuing employee stock options.
The Company established a stock option plan in 1991 (the "1991 Plan") and
on December 13, 1995, it established a new stock option plan (the "1995 Plan").
The Company adopted a third plan on April 28, 1998 (the "1998 Plan"). Certain
employees of the Company surrendered their options under the 1991 Plan in return
for new and additional options granted under the 1995 Plan. During the year
ended December 31, 1998, the Company reduced the exercise prices of certain
outstanding stock options with exercise prices ranging from $4.31 to $8.63
(377,752 options) to $3.00 per share which was the fair market value of common
stock as determined by the Company's Board of Directors on the date of
repricing. Officers, employees, directors and consultants to the Company may
participate in the Plans. Options granted under the Plans may be incentive stock
options or non-statutory stock options. 2,099,070 shares of the Company's common
stock have been reserved for issuance under the Plans. Options granted generally
have a term of ten years from the date of the grant. The exercise price of
incentive stock options granted under the Plans may not be less than 100% of the
fair market value of the Company's common stock on the date of the grant. The
exercise price of non-statutory stock options granted under the Plans may not be
less than 85% of the fair market value of the Company's common stock on the date
of the grant. For a person who, at the time of the grant, owns stock
representing 10% of the voting power of all classes of Company stock, the
exercise price of the incentive stock options or the non-statutory stock options
granted under the Plans may not be less than 110% of the fair market value of
the common stock on the date of the grant.
Pro forma information regarding net income (loss) and earnings (loss) per
share is required by SFAS No. 123, which also requires that the information be
determined as if the Company has accounted for its employee stock options
granted subsequent to December 31, 1994 under the fair value method of that
Statement. The fair value for these options was estimated at the date of grant
using the Black-Scholes option pricing model with the following weighted-average
assumptions for 1997 and 1998, respectively: risk-free interest rates of 6.0%
and 5.0%; dividend yield of 0%; volatility factors of the expected market price
of the Company's common stock of 0.55 and 0.77; and an expected life of the
option of 4 years.
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Because the
F-15
<PAGE> 36
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Company's employee stock options have characteristics significantly different
from those of traded options, and because changes in the subjective input
assumptions can materially affect the fair value estimate, in management's
opinion, the existing models do not necessarily provide a reliable single
measure of the fair value of its employee stock options. For purposes of pro
forma disclosures, the estimated fair value of the options is amortized to
expense over the vesting period. The Company's pro forma information follows:
<TABLE>
<CAPTION>
1997 1998
----------- ------------
<S> <C> <C>
Pro forma net loss............................... $(4,624,429) $(10,997,076)
Pro forma basic net loss per share............... $ (1.24) $ (1.97)
</TABLE>
Because SFAS No. 123 is applicable only to options granted subsequent to
December 31, 1994, its pro forma effect will not be fully reflected until 1999.
The following summarizes activity under the Plans for the years ended
December 31, 1997 and 1998:
<TABLE>
<CAPTION>
WEIGHTED
NUMBER OF AVERAGE
SHARES EXERCISE PRICE
--------- --------------
<S> <C> <C>
Outstanding at December 31, 1996 (at $0.07 to $7.84
per share)........................................ 947,184 $0.42
Granted (at $5.00 to $8.88 per share)............. 354,334 6.60
Canceled (at $.07 to $8.25 per share)............. (79,771) 4.38
Exercised (at $.07 to $3.33 per share)............ (18,374) 1.01
---------
Outstanding at December 31, 1997 (at $0.07 to $8.88
per share)........................................ 1,203,373 1.97
Granted (at $2.84 to $6.06 per share)............. 724,252 3.23
Canceled (at $.07 to $8.88 per share)............. (456,356) 5.33
Exercised (at $.07 to $2.07 per share)............ (142,010) 0.11
---------
Outstanding at December 31, 1998 (at $0.07 to $8.88
per share)........................................ 1,329,259 $1.93
=========
</TABLE>
All options granted in 1997 and 1998 were granted with option prices equal
to the fair market value of the Company's stock on the grant date. The weighted
average exercise price of options granted in 1997 was $6.60 and the weighted
average grant date fair value of these options was $3.16.
The weighted average exercise price of options granted in 1998 with option
prices equal to the fair market value of the Company's stock on the grant date
was $3.23 and the weighted average grant date fair value of these options was
$1.47.
F-16
<PAGE> 37
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The following summarizes information related to options outstanding and
options exercisable at December 31, 1998:
<TABLE>
<CAPTION>
WEIGHTED AVERAGE
WEIGHTED REMAINING WEIGHTED
EXERCISE OPTIONS AVERAGE CONTRACTUAL LIFE OPTIONS AVERAGE
PRICE OUTSTANDING EXERCISE PRICE (IN YEARS) EXERCISABLE EXERCISE PRICE
- ------------------ ----------- -------------- ---------------- ----------- --------------
<S> <C> <C> <C> <C> <C> <C> <C>
$0.07 696,348 $0.07 7.1 598,475 $0.07
$2.07 6,760 $2.07 7.5 4,084 $2.07
$2.84 - $3.00 374,502 $3.00 9.7 28,477 $3.00
$3.13 - $3.94 50,750 $3.67 9.7 -- --
$4.00 - $4.88 40,500 $4.71 9.4 -- --
$5.00 - $6.13 106,399 $5.35 8.1 50,220 $5.29
$7.00 - $8.88 54,000 $7.98 8.8 17,024 $7.98
--------- ----- --- ------- -----
1,329,259 $1.93 8.2 698,280 $0.77
========= ===== === ======= =====
</TABLE>
Of the options outstanding at December 31, 1998, options to purchase
698,280 shares of common stock were immediately exercisable at a
weighted-average exercise price of $0.77 per share. A total of 197 shares were
still available for grant under the 1995 Plan at December 31, 1998. A total of
421,248 shares were still available for grant under the 1998 Plan at December
31, 1998.
During the year ended December 31, 1996, the Company recorded deferred
stock compensation of $783,666 relating to stock options granted during the
period with exercise prices less than the estimated fair value of the Company's
common stock, as determined by an independent valuation analysis, on the date of
grant. The deferred stock compensation is being amortized into expense over the
vesting period of the stock options which generally range from 3 to 5 years.
Deferred compensation relating to stock options which vested immediately was
expensed on the date of grant. The Company recorded a reduction of $31,413 and
$22,540 in deferred stock compensation relating to canceled options in 1997 and
1998, respectively. Compensation expense of $155,474 and $131,352 was recorded
during the years ended December 31, 1997 and 1998, respectively, relating to
these options. The remaining $85,638 will be amortized into expense in future
periods.
9. INCOME TAXES
The income tax provisions for the years ended December 31, 1997 and 1998
are comprised of currently payable state franchise taxes and currently payable
foreign income taxes.
F-17
<PAGE> 38
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Deferred taxes result from temporary differences in the recognition of
certain revenue and expense items for income tax and financial reporting
purposes. The significant components of the Company's deferred taxes as of
December 31, 1997 and 1998 are as follows:
<TABLE>
<CAPTION>
1997 1998
----------- -----------
<S> <C> <C>
Deferred tax assets:
Net operating loss carryover............................ $ 4,677,000 $ 5,842,000
Research and development................................ 223,000 285,000
Accrued product retrofit costs.......................... 21,000 54,000
Inventory............................................... 93,000 330,000
Depreciation............................................ 126,000 109,000
Stock compensation...................................... 220,000 256,000
Loss on investment...................................... -- 230,000
Deferred income......................................... -- 358,000
Other................................................... 158,000 248,000
----------- -----------
5,518,000 7,712,000
Less: Valuation allowance................................. (5,518,000) (7,712,000)
----------- -----------
Net deferred taxes........................................ $ -- $ --
=========== ===========
</TABLE>
The Company expects the carryforward amounts will not be utilized prior to
the expiration of the carryforward periods.
The principal reasons for the difference between the effective income tax
rate and the federal statutory income tax rate are as follows:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
--------------------------
1997 1998
----------- -----------
<S> <C> <C>
Federal benefit expected at statutory rates............... $(1,506,000) $(3,481,777)
Net operating loss with no current benefit................ 1,506,000 3,481,777
Other taxes............................................... -- 14,000
Foreign income taxes...................................... 49,811 13,235
----------- -----------
$ 49,811 $ 27,235
=========== ===========
</TABLE>
As a result of stock sales a change of ownership (as defined in Section 382
of the Internal Revenue Code of 1986, as amended) has occurred. As a result of
this change, the Company's federal and state net operating loss carryforwards
generated through December 21, 1995 (approximately $14,300,000 and $2,600,000,
respectively) will be subject to a total annual limitation in the amount of
approximately $400,000.
The Company has at December 31, 1998 a net operating loss carryover of
approximately $16,200,000 for federal income tax purposes which expires between
2005 and 2013, a net operating loss carryforward of approximately $5,700,000 for
state income tax purposes which expires through 2003, and a net operating loss
carryforward of approximately $1,500,000 for foreign income tax purposes. The
Company has at December 31, 1998 research and development credit carryovers of
approximately $294,000 and $448,000 for federal and state income tax purposes,
respectively.
The Company paid $914 and $800 for income and franchise taxes during the
years ended December 31, 1997 and 1998, respectively.
F-18
<PAGE> 39
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
10. NET LOSS PER SHARE INFORMATION
As of December 31, 1998, outstanding options to purchase 1,329,259 shares
of common stock (with exercise prices ranging from $0.07 to $8.88), outstanding
warrants to purchase 4,551,816 shares of common stock (with exercise prices from
$0.07 to $8.26) and 1,731,262 shares of common stock issuable upon conversion of
Series A Preferred Stock could potentially dilute basic earnings per share in
the future and have not been included in the computation of diluted net loss per
share because to do so would have been antidilutive for the periods presented.
11. COMMITMENTS
The Company leases its U.S. facility under a non-cancelable operating
lease. The lease is for a term of seven years and expires on June 2, 2005. The
lease provides for rent of $29,229 per month during the first year of the lease
(plus real estate taxes and assessments, utilities and maintenance), subject to
adjustment in subsequent years for cumulative increases in the cost of living
index, not to exceed 4% per year.
The Company leases its European facility under a non-cancelable operating
lease. The lease is for a term of eight years and expires on 2006. The lease
provides for rent of $7,197 per month.
Future payments under non-cancelable facility operating leases are
approximately as follows:
<TABLE>
<S> <C>
1999................................................... $ 422,000
2000................................................... 440,000
2001................................................... 450,000
2002................................................... 457,000
2003................................................... 465,000
Thereafter............................................. 424,000
----------
$2,658,000
==========
</TABLE>
Aggregate rental expense under these leases amounted to $135,000 and
$309,000 during the years ended December 31, 1997 and 1998, respectively.
Future minimum payments under non-cancelable equipment operating leases are
approximately as follows:
<TABLE>
<S> <C>
1999..................................................... $48,000
2000..................................................... 33,000
2001..................................................... 4,000
2002..................................................... --
-------
$85,000
=======
</TABLE>
Rental expense for these non-cancelable equipment operating leases during
the years ended December 31, 1997 and 1998 was approximately $17,000 and
$41,000, respectively.
12. CONTINGENCIES
The Company has from time to time been notified of various claims
incidental to its business that are not the subject of pending litigation. While
the results of claims cannot be predicted with certainty, the Company believes
that the final outcome of all such matters will not have a materially adverse
effect on its consolidated financial position, results of operations or cash
flows.
F-19
<PAGE> 40
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
13. NIST GRANT
During 1994, the Company received notification it was awarded a $1,960,000
National Institute of Science and Technology ("NIST") grant from the U.S.
Department of Commerce ("USDC"). The grant is shared by the Company and two
strategic partners to fund approximately 49% of a $4 million joint development
project to adapt the ROBODOC System for use in hip revision surgery. The
development project and related NIST Grant began in 1995. The Company received
approximately $317,000 and $514,000 in proceeds under this grant during the
years ended December 31, 1997, and 1998, respectively.
14. ANVAR GRANT
During 1996, IMMI received notification it was awarded a $222,492 grant
from the French agency Agence Nationale de Valorisation de la Recherche
("ANVAR") which is a French national agency established to aid research and
development projects. The grant is to fund the clinical tests to be performed at
two university hospitals on the NeuroMate system over a period of fifteen months
commencing March 1997. IMMI received $173,595 in proceeds under this grant
during the year ended December 31, 1997. The grant income is being recognized
ratably over the project period.
15. EMPLOYEE STOCK PURCHASE PLAN
Shareholders approved and the Board of Directors adopted the Company's
Employee Stock Purchase Plan (the "Purchase Plan") at the annual Shareholders
meeting held April 28, 1998. The Purchase Plan provides all eligible employees
an opportunity to acquire a proprietary interest in the Company on a payroll
deduction or other compensation basis at a 15% discount. The Purchase Plan is
intended to qualify as an employee stock purchase plan under Section 423 of the
Code. The Purchase Plan covers an aggregate of 300,000 shares of the Company's
Common Stock. As of December 31, 1998, no offerings have been made to employees.
F-20
<PAGE> 41
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
<TABLE>
<CAPTION>
MARCH 31, 1999
(UNAUDITED)
--------------
<S> <C>
ASSETS
Current Assets:
Cash and cash equivalents................................. $ 856,231
Short-term investments.................................... 2,041,361
Accounts receivable....................................... 1,699,846
Inventory................................................. 3,712,700
Other current assets...................................... 447,647
------------
Total current assets........................................ 8,757,785
Property and equipment, net................................. 1,243,197
Leased equipment, net....................................... 733,261
Long-term net investment in sales type leases............... 628,607
Intangible assets, net...................................... 2,805,218
Other assets................................................ 272,423
------------
Total assets...................................... $ 14,440,491
============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.......................................... $ 3,071,510
Value-added taxes payable................................. 522,336
Accrued payroll and related expenses...................... 530,331
Customer deposits......................................... 1,338,284
Accrued product retrofit costs............................ 135,348
Current portion of bank loans............................. 1,608,043
Other current liabilities................................. 689,233
------------
Total current liabilities......................... 7,895,085
Bank loans, long-term....................................... 1,740
Note payable................................................ 131,840
Commitments and contingencies
Stockholders' equity:
Convertible preferred stock, $0.01 par value 1,000,000
shares authorized; 4,180 shares issued and
outstanding............................................ 42
($4,180,000 aggregate liquidation value)
Common stock, $0.01 par value, 15,000,000 shares
authorized; 5,822,116 shares issued and outstanding.... 58,271
Additional paid-in capital................................ 43,479,375
Deferred stock compensation............................... (70,353)
Preferred stock discount.................................. (171,569)
Accumulated other comprehensive loss...................... (110,229)
Accumulated deficit....................................... (36,773,711)
------------
Total stockholder's equity........................ 6,411,826
------------
$ 14,440,491
============
</TABLE>
See notes to consolidated financial statements.
F-21
<PAGE> 42
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
--------------------------
1999 1998
----------- -----------
<S> <C> <C>
Net Sales................................................... $ 2,286,723 $ 1,383,360
Cost of Sales............................................... 1,105,379 622,773
----------- -----------
1,181,344 760,587
Operating expenses:
Selling, general and administrative....................... 1,576,615 1,377,641
Research and development.................................. 1,629,706 1,490,284
Stock compensation........................................ 15,285 18,000
----------- -----------
3,221,606 2,885,925
Other income (expense):
Interest income........................................... 37,128 100,108
Other..................................................... (288,187) (10,320)
----------- -----------
Loss before provision for income taxes...................... (2,291,321) (2,035,550)
Provision for income taxes.................................. 14,694 9,051
----------- -----------
Net loss.................................................... (2,306,015) (2,044,601)
Preferred stock accretion................................... (244,638) --
----------- -----------
Net loss applicable to common stockholders.................. $(2,550,653) $(2,044,601)
=========== ===========
Basic net loss per common share............................. $ (0.45) $ (0.37)
Shares used in computing basic net loss per-share........... 5,675,744 5,526,642
</TABLE>
See notes to consolidated financial statements
F-22
<PAGE> 43
INTEGRATED SURGICAL SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED MARCH 31,
----------------------------
1999 1998
------------ ------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss.................................................... $(2,306,015) $(2,044,601)
Adjustment to reconcile net loss to net cash used in
operating activities:
Depreciation.............................................. 231,347 75,461
Amortization of intangible assets......................... 209,760 209,760
Unrealized gain on securities............................. 14,683 --
Stock compensation........................................ 15,285 18,000
Issuance of stock options to consultants.................. 30,905 11,010
Changes in operating assets and liabilities...............
Accounts Receivable.................................... 205,292 (71,163)
Inventory.............................................. (707,042) (697,719)
Other current assets................................... 16,774 (149,093)
Accounts payable....................................... 1,595,756 332,644
Value added taxes payable.............................. 174,752 84,297
Accrued payroll and related expenses................... 59,053 (23,753)
Customer deposits...................................... 442,008 339,896
Payable to subcontractors.............................. -- (38,656)
Other current liabilities.............................. (43,361) 49,086
Note Payable........................................... (11,360) (4,058)
----------- -----------
Net cash used in operating activities....................... (72,163) (1,908,889)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in marketable securities......................... (17,083) --
Net investments in sales type leases........................ (366,273) 27,092
Purchases of property and equipment......................... (215,555) (202,047)
(Increase) decrease in other assets......................... 109 (51,934)
----------- -----------
Net cash used in investing activities....................... (598,802) (226,889)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds (payments) on bank loans........................... 705,257 (29,008)
Payment of expenses on Series A Preferred Stock offering.... (17,399) --
Proceeds from issuance of preferred stock................... 946,500 --
Proceeds from sale of warrants.............................. -- 6,930
Proceeds from exercise of stock options..................... 1,385 7,101
----------- -----------
Net cash provided by (used in) financing activities......... 1,635,743 (14,977)
Effect of exchange rate changes on cash and cash
equivalents............................................... (332,128) 56,914
----------- -----------
Net increase (decrease) in cash and cash equivalents........ 632,650 (2,093,841)
Cash and cash equivalents at beginning of period............ 223,581 9,091,788
----------- -----------
Cash and cash equivalents at end of period.................. $ 856,231 $ 6,997,947
=========== ===========
</TABLE>
See notes to consolidated financial statements.
F-23
<PAGE> 44
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
MARCH 31, 1999
NOTE A -- BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB. Accordingly,
they do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the opinion
of management, all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation have been included. Operating
results for the three-month period ended March 31, 1999 are not necessarily
indicative of the results that may be expected for the year ended December 31,
1999. For further information, refer to the consolidated financial statements
and footnotes thereto for the year ended December 31, 1998 included elsewhere
herein.
NOTE B -- INVENTORIES
The components of inventory consist of the following:
<TABLE>
<CAPTION>
MARCH 31, 1999
--------------
<S> <C>
Raw Materials............................................... $1,515,500
Work in process............................................. 717,286
Finished goods.............................................. 1,479,914
----------
$3,712,700
==========
</TABLE>
NOTE C -- CONVERTIBLE PREFERRED STOCK
In March 1999, the Company received net proceeds of $946,500 from the sale
of 1,000 shares of Series B Convertible Preferred Stock ("Series B Preferred
Stock") and warrants ("Warrants") to purchase 12,500 shares of common stock
("Common Stock"), par value $.01 per share.
The Series B Preferred Stock is convertible (the "Beneficial Conversion
Feature") into shares of Common Stock, at the option of the holder, commencing
June 24, 1999, subject to certain limitations, discussed below. The number of
shares of Common Stock issuable upon conversion of the Series B Preferred Stock
is equal to the quotient of (x) the product of $1,000 (the stated value of each
share of Series B Preferred Stock) and the number of shares of Series B
Preferred Stock to be converted and (y) 85% of the lowest sale price of the
Common Stock on the Nasdaq SmallCap Market during the five trading days
preceding the date of conversion (the "Market Price"), but in no event more than
$3.37 (the "Conversion Price").
Holders of Series B Preferred Stock may convert 25% of their shares
commencing June 24, 1999, 50% of their shares commencing July 24, 1999, 75% of
their shares Commencing August 23, 1999 and 100% of their shares commencing
September 22, 1999. The Company may require holders to convert all (but not less
than all) of the Series B Preferred Stock at any time after March 26, 2002, or
buy out all outstanding shares, at the then Conversion Price.
The value assigned to the Beneficial Conversion Feature, as determined
using the quoted market price of the Company's common stock on the date the
Series B Preferred Stock was sold, amounted to $176,000, which represents a
discount to the value of the Series B Preferred Stock (the "Discount".) The
Discount is being accreted using the straight-line method through September 22,
1999. Approximately $5,000 of the Discount was accreted during the three month
period ended March 31, 1999.
Holders of Series B Preferred Stock are not entitled to dividends and have
no voting rights, unless required by law or with respect to certain matters
relating to the Series B Preferred Stock.
F-24
<PAGE> 45
INTEGRATED SURGICAL SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (CONTINUED)
The Company may redeem the Series B Preferred Stock upon written notice to
the holders of the Series B Preferred Stock at any time after the earlier of
September 26, 1999 and the closing of a registered firm underwritten secondary
offering of equity securities, at a redemption price equal to the greater of
$1,500 per share and the Market Price of the Shares of Common Stock into which
such Series B Preferred Stock could have been converted on the date of the
notice of redemption.
The Warrants are exercisable at any time during the period commencing
September 26, 1999 and ending September 25, 2003, at an exercise price of $2.56,
subject to adjustment. The Conversion Price and the number of shares of Common
Stock issuable upon conversion are subject to adjustment based upon certain
future events.
NOTE D -- NET LOSS PER SHARE
In 1997, the Financial Accounting Standards Board ("FASB") issued Statement
No. 128, Earnings Per Share. Statement 128 replaced the calculation of primary
and fully diluted earnings per share with basic and diluted earnings per share.
Unlike primary earnings per share, basic earnings per share excludes any
dilutive effects of options, warrants and convertible securities. Diluted
earnings per share is very similar to the previously reported fully diluted
earnings per share. All net loss per share amounts have been presented on the
basis set forth in Statement 128.
As of March 31, 1999, outstanding options to purchase 1,353,164 shares of
Common Stock (with exercise prices ranging from $0.07 to $8.63) and outstanding
warrants to purchase 4,564,316 shares of Common Stock (with exercise prices
ranging from $0.01 to $8.26) could potentially dilute basic earnings per share
in the future and have not been included in the computation of diluted net loss
per share because to do so would have been antidilutive for the periods
presented.
F-25
<PAGE> 46
APPENDIX I
INTEGRATED SURGICAL SYSTEMS, INC.
STOCK AND WARRANT PURCHASE AGREEMENT
THIS STOCK AND WARRANT PURCHASE AGREEMENT (the "Agreement") is entered into
as of July , 1999, by and among INTEGRATED SURGICAL SYSTEMS, INC., a Delaware
corporation (the "COMPANY") and each of those persons and entities, severally
and not jointly, whose names are set forth on the Schedule of Purchasers
attached hereto as Exhibit A (which persons and entities are hereinafter
collectively referred to as "PURCHASERS" and each individually as a
"PURCHASER").
RECITALS
WHEREAS, the Company has authorized the sale and issuance of an aggregate
of Two Million Nine Hundred Twenty Two Thousand Three Hundred Ninety Six
(2,922,396) shares of its Common Stock (the "SHARES"); and
WHEREAS, the Company has authorized the sale and issuance of warrants
(each, a "WARRANT" and collectively, the "WARRANTS") to purchase up to a number
of shares of its Common Stock such that the number of shares issuable upon
exercise of the Warrants, together with the Shares, equals forty percent (40%)
of the fully diluted shares of the Company (taking all convertible securities as
converted into Common Stock, and all warrants exercisable for the purchase of
Common Stock as exercised and such Common Stock purchased, as of the Closing
Date); and
WHEREAS, Purchasers desire to purchase the Shares and the Warrants on the
terms and conditions set forth herein; and
WHEREAS, the Company desires to issue and sell the Shares and the Warrants
to Purchasers on the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises hereinafter set forth, the parties hereto agree as follows:
1. Agreement to Sell and Purchase
1.1 Authorization of Shares and Warrants. On or prior to the Closing (as
defined in Section 2 below), the Company shall have authorized (a) the sale and
issuance to Purchasers of the Shares; (b) the sale and issuance to the
Purchasers of the Warrants, which shall be in substantially the form attached as
Exhibit B; and (c) the issuance of the shares of Common Stock to be issued to
the Purchasers upon exercise of the Warrants.
1.2 Sale and Purchase. Subject to the terms and conditions hereof, at
the Closing, the Company hereby agrees to issue and sell to each Purchaser,
severally and not jointly, and each Purchaser agrees to purchase from the
Company, severally and not jointly, the number of Shares and Warrants, at
the Aggregate Purchase Price, set forth opposite such Purchaser's name on
Exhibit A. Prior to issuance of the Warrants, if any, each Purchaser hereby
agrees to pay to the Company the Aggregate Purchase Price as set forth
opposite such Purchaser's name on Exhibit A.
2. Closing; Delivery and Payment
2.1 Closing. The closing of the sale and purchase of the Shares and the
Warrants under this Agreement (the "CLOSING") shall take place at 10:00 a.m. on
, 1999, at the offices of Cooley Godward LLP, 3000 El Camino Real,
Palo Alto, CA 94306, or at such other time or place as the Company and
Purchasers may mutually agree (the date on which the Closing actually occurs is
hereinafter referred to as the "CLOSING DATE").
2.2 Purchasers' Deliveries. The parties acknowledge and agree that the
Purchasers have paid, and the Company has received, an advance payment on the
Aggregate Purchase Price (as shown Exhibit A) in the
<PAGE> 47
total amount of Four Hundred Thousand United States Dollars (US$400,000). The
Purchasers therefore will pay to the Company, by delivery to the Company of
check(s) or wire transfer funds at the Closing, an aggregate amount equal to
Three Million Six Hundred Thousand United States Dollars (US$3,600,000) (the
"Remaining Purchase Price") in full satisfaction of their payment obligations
hereunder.
2.3 Company's Deliveries. At the Closing, the Company will deliver to
each Purchaser a certificate representing the number of Shares set forth
opposite such Purchaser's name on Exhibit A, and a Warrant representing the
right to purchase the number of shares of the Company's Common Stock set forth
opposite such Purchaser's name on Exhibit A.
3. Representations, Warranties and Covenants of the Company
Except as may be set forth on a Schedule of Exceptions delivered by the
Company to the Purchasers at the Closing specifically identifying the relevant
Section hereof, the Company hereby represents and warrants to each Purchaser as
follows as of the date hereof and as of the Closing Date, as to itself and each
of its subsidiaries:
3.1 Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware. Each of the subsidiaries of the Company is a
corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction of its incorporation. The Company and each of its
subsidiaries has all requisite corporate power and authority to own and
operate their properties and assets, and, on the part of the Company, to
execute and deliver this Agreement and other instruments and documents as
may be associated with this Agreement, including the Registration and
Stockholder Rights Agreement in the form attached as Exhibit C
(collectively, the "RELATED AGREEMENTS"), to issue and sell the Shares and
the Warrants, and to carry out the provisions of this Agreement and the
Related Agreements and the Certificate of Incorporation of the Company, as
amended through the date of these representations and warranties, together
with all Certificates of Designation filed in connection therewith,
collectively attached hereto as Exhibit D (collectively, the "RESTATED
CHARTER") and to carry on its business as presently conducted and as
presently proposed to be conducted. The Company and each of its
subsidiaries is duly qualified and is authorized to do business and is in
good standing as a foreign corporation in all jurisdictions in which the
nature of its activities and of its properties (both owned and leased)
makes such qualification necessary, except for those jurisdictions in which
failure to do so would not have a material adverse effect on the Company or
its business.
3.2 Subsidiaries. The Company does not own or control any equity
security or other interest of any other corporation, limited partnership or
other business entity. The Company is not a participant in any joint
venture, partnership or similar arrangement.
3.3 Capitalization; Voting Rights. The authorized issued and
outstanding capital stock of the Company immediately prior to the Closing,
and the par value thereof, will be as set forth on Part 3.3 of the Schedule
of Exceptions, which shall also set forth the shares of the Company's
capital stock which are reserved for future issuance to employees pursuant
to the Company's 1998 Stock Option Plan. All issued and outstanding shares
of the Company's Common Stock and Preferred Stock (a) have been duly
authorized and validly issued, (b) are fully paid and nonassessable, and
(c) were issued in compliance with all applicable state and federal laws
concerning the issuance of securities. The rights, preferences, privileges
and restrictions of all shares of the Company's capital stock are as stated
in the Restated Charter. Other than the 391,182 shares reserved for
issuance under the Company's 1998 Stock Option Plan, and except as may be
granted pursuant to the Related Agreements, there are no outstanding
options, warrants, rights (including conversion or preemptive rights and
rights of first refusal), proxy or shareholder agreements, or agreements of
any kind for the purchase or acquisition from the Company of any of its
securities, except as set forth and described on Part 3.3 of the Schedule
of Exceptions. Of such reserved shares of Common Stock, (i) no shares have
been issued pursuant to restricted stock purchase agreements, (ii) options
to purchase 1,325,170 shares have been granted and are currently
outstanding, and (iii) 391,182 shares of Common Stock remain available for
issuance to officers, directors, employees and consultants pursuant to such
Stock Option Plan. When issued in compliance with the provisions of
2
<PAGE> 48
this Agreement and the Restated Charter, the Shares will be validly issued,
fully paid and nonassessable, and will be free of any liens or
encumbrances; provided, however, that the Shares may be subject to
restrictions on transfer under state and/or federal securities laws as set
forth herein or as otherwise required by such laws at the time a transfer
is proposed. Except as set forth on the Schedule of Exceptions, no stock
plan, stock purchase, stock option or other agreement or understanding
between the Company and any holder of any equity securities or rights to
purchase equity securities provides for acceleration or other changes in
the vesting provisions or other terms of such agreement or understanding as
the result of any merger, consolidated sale of stock or assets, change in
control or any other transaction(s) by the Company.
3.4 Authorization; Binding Obligations. All corporate action on the
part of the Company, its directors and its shareholders necessary for the
authorization, execution, delivery and performance of this Agreement and
the Related Agreements by the Company and the performance of the Company's
obligations hereunder and thereunder, including the authorization, sale,
issuance and delivery of the Shares and Warrants and the reservation of the
equity securities issuable upon exercise of the Warrants has been taken or
will be taken prior to the Closing or, in respect of the Warrants and the
reservation of the equity securities issuable upon exercise of the
Warrants, prior to the issuance of the Warrants. This Agreement, the
Warrants and the Related Agreements, when executed and delivered by the
Company, will be valid and binding obligations of the Company enforceable
in accordance with their terms, subject to laws of general application
relating to bankruptcy, insolvency, the relief of debtors and, with respect
to rights to indemnity, subject to federal and state securities laws. The
Shares and the Warrants, when issued in compliance with the provisions of
this Agreement, will not violate any preemptive rights or rights of first
refusal, will be issued in compliance with all applicable federal and State
securities laws, and will be free of any liens or encumbrances, other than
any liens or encumbrances created by or imposed upon the holders through no
action of the Company; provided, however, that the Shares and the Warrants
may be subject to restrictions on transfer under State and/or federal
securities laws as set forth herein or as otherwise required by such laws
at the time the transfer is proposed.
3.5 Financial Statements. The Company has made available to each
Purchaser (a) its audited balance sheet as at December 31, 1998 and audited
statement of income and cash flows for the twelve months ending December
31, 1998 and (b) its unaudited balance sheet as, and its unaudited
consolidated statement of operations and cash flows for the five month
period ending on May 31, 1999 (the "Statement Date")(collectively, the
"Financial Statements"), in each case reflecting the operations and
financial condition of the Company and each of its subsidiaries, copies of
which are attached as Exhibit E. The Financial Statements, together with
the notes thereto, are complete and correct in all material respects, have
been prepared in accordance with generally accepted accounting principles
applied on a consistent basis throughout the periods indicated, except as
disclosed therein, and present fairly the financial condition and position
of the Company as of December 31, 1998 and the Statement Date; provided,
however, that the unaudited financial statements are subject to normal
recurring year-end audit adjustments (which are not expected to be
material), and do not contain all footnotes required under generally
accepted accounting principles.
3.6 Liabilities. The Company has no material liabilities and, to the
best of its knowledge, has no material contingent liabilities, not
disclosed in the Financial Statements, except current liabilities incurred
in the ordinary course of business subsequent to the Statement Date which
have not been, either in any individual case or in the aggregate,
materially adverse.
3.7 Agreements; Action
(a) There are no oral or written agreements, proposed transactions or
understanding to which the Company considers itself bound, between the
Company and any of its officers, directors, affiliates or any affiliate
thereof.
(b) There are no agreements, instruments, contracts, proposed
transactions, judgments, orders, writs or decrees to which the Company is a
party or to its knowledge by which it is bound which may involve (i)
obligations (contingent or otherwise) of, or payments to, the Company in
excess of $10,000
3
<PAGE> 49
(other than obligations of, or payments to, the Company arising from
purchase or sale agreements entered into in the ordinary course of
business), or (ii) the transfer or license of any patent, copyright, trade
secret or other proprietary right to or from the Company (other than
licenses arising from the purchase of "off the shelf" or other standard
products), or (iii) provisions restricting the development, manufacture or
distribution of the Company's products or services, or (iv) indemnification
by the Company with respect to infringements of proprietary rights (other
than indemnification obligations arising from purchase or sale or license
agreements entered into in the ordinary course of business).
(c) The Company has not (i) declared or paid any dividends, or
authorized or made any distribution upon or with respect to any class or
series of its capital stock, other than as disclosed in its periodic
filings under the Securities Exchange Act of 1934; (ii) incurred any
indebtedness for money borrowed or any other liabilities (other than with
respect to dividend obligations, distributions, indebtedness and other
obligations incurred in the ordinary course of business or as disclosed in
the Financial Statements) individually in excess of $10,000 or, in the case
of indebtedness and/or liabilities individually less than $10,000, in
excess of $25,000 in the aggregate, (iii) made any loans or advances to any
person, other than ordinary advances for travel expenses, or (iv) sold,
exchanged or otherwise disposed of any of its assets or rights, other than
the sale of its inventory in the ordinary course of business.
(d) For the purposes of subsections (b) and (c) above, all
indebtedness, liabilities, agreements, understandings, instruments,
contracts and proposed transactions involving the same person or entity
(including persons or entities the Company has reason to believe are
affiliated therewith) shall be aggregated for the purpose of meeting the
individual minimum dollar amounts of such subsections.
(e) The Company has not engaged in the past three (3) months in any
discussion (i) with any representative of any corporation or corporations
regarding the consolidation or merger of the Company with or into any such
corporation or corporations, (ii) with any corporation, partnership,
association or other business entity or any individual regarding the sale,
conveyance or disposition of all or substantially all of the assets of the
Company, or a transaction or series of related transactions in which more
than fifty percent (50%) of the voting power of the Company is disposed of,
or (iii) regarding any other form of acquisition, liquidation, dissolution
or winding up of the Company.
3.8 Obligations to Related Parties. There are no obligations of the
Company to officers, directors, shareholders, or employees of the Company
other than (a) for payment of salary for services rendered, (b)
reimbursement for reasonable expenses incurred on behalf of the Company and
(c) for other standard employee benefits made generally available to all
employees (including stock option agreements outstanding under any stock
option plan approved by the Board of Directors of the Company). None of the
officers, directors or shareholders of the Company, or any members of their
immediate families, are indebted to the Company or have any direct or
indirect ownership interest in any firm or corporation with which the
Company is affiliated or with which the Company has a business
relationship, or any firm or corporation which competes with the Company,
except that officers, directors and/or shareholders of the Company may own
stock in publicly traded companies which may compete with the Company. No
officer, director or shareholder, or any member of their immediate
families, is, directly or indirectly, interested in any material contract
with the Company (other than such contracts as relate to any such person's
ownership of capital stock or other securities of the Company). Except as
may be disclosed in the Financial Statements, the Company is not a
guarantor or indemnitor of any indebtedness of any other person, firm or
corporation.
3.9 Changes. Since the Statement Date, there has not been to the
Company's knowledge:
(a) Any change in the assets, liabilities, financial condition or
operations of the Company from that reflected in the Financial
Statements, other than changes in the ordinary course of business, none
of which individually or in the aggregate has had or is expected to have
a material adverse effect on such assets, liabilities, financial
condition, operations or prospects of the Company;
4
<PAGE> 50
(b) Any resignation or termination of any officer or key employee
of the Company; and the Company, to the best of its knowledge, does not
know of the impending resignation or termination of employment of any
such officer or key employee;
(c) Any material change, except in the ordinary course of business,
in the contingent obligations of the Company by way of guaranty,
endorsement, indemnity, warranty or otherwise;
(d) Any damage, destruction or loss, whether or not covered by
insurance, materially and adversely affecting the properties, business
or prospects or financial condition of the Company;
(e) Any waiver by the Company of a valuable right or of a material
debt owed to it;
(f) Any direct or indirect loans made by the Company to any
shareholder, employee, officer or director of the Company, other than
advances made in the ordinary course of business;
(g) Any material change in any compensation arrangement or
agreement with any employee, officer, director or shareholder;
(h) Any declaration or payment of any dividend or other
distribution of the assets of the Company;
(i) Any labor organization activity;
(j) Any debt, obligation or liability incurred, assumed or
guaranteed by the Company, except those for immaterial amounts and for
current liabilities incurred in the ordinary course of business;
(k) Any sale, assignment or transfer of any patents, trademarks,
copyrights, trade secrets or other intangible assets;
(l) Any change in any material agreement to which the Company is a
party or by which it is bound which materially and adversely affects the
business, assets, liabilities, financial condition, operations or
prospects of the Company; or
(m) Any other event or condition of any character that, either
individually or cumulatively, has materially and adversely affected the
business, assets, liabilities, financial condition, operations or
prospects of the Company.
(n) Any arrangement or commitment by the Company to do any of the
acts described in subsection (a) through (m) above.
3.10 Title to Properties and Assets; Liens, Etc. The Company has
good and marketable title to its properties and assets, including the
properties and assets reflected in the most recent balance sheet included
in the Financial Statements, and good title to its leasehold estates, in
each case subject to no mortgage, pledge, lien, lease, encumbrance or
charge, other than (a) those resulting from taxes which have not yet become
delinquent, (b) minor liens and encumbrances which do not materially
detract from the value of the property subject thereto or materially impair
the operations of the Company, and (c) those that have otherwise arisen in
the ordinary course of business. All facilities, machinery, equipment,
fixtures, vehicles and other properties owned, leased or used by the
Company are in good operating condition and repair and are reasonably fit
and usable for the purposes for which they are being used. The Company is
in compliance with all material terms of each lease to which it is a party
or is otherwise bound.
3.11 Patents and Trademarks. The Company owns or possesses
sufficient legal rights to all patents, trademarks, service marks, trade
names, copyrights, trade secrets, licenses, information and other
proprietary rights and processes necessary for its business as now
conducted and as presently proposed to be conducted, without any known
infringement of the rights of others. There are no outstanding options,
licenses or agreements of any kind relating to the foregoing, nor is the
Company bound by or a party to any options, licenses or agreements of any
kind with respect to the patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information and other proprietary
rights and processes of any other person or entity other than such licenses
or agreements arising from the purchase of "off the
5
<PAGE> 51
shelf" or standard products. The Company has not received any
communications alleging that the Company has violated or, by conducting its
business as presently proposed, would violate any of the patents,
trademarks, service marks, trade names, copyrights or trade secrets or
other proprietary rights of any other person or entity. The Company is not
aware that any of its employees is obligated under any contract (including
licenses, covenants or commitments of any nature) or other agreement, or
subject to any judgment, decree or order of any court or administrative
agency, that would interfere with their duties to the Company or that would
conflict with the Company's business as presently proposed to be conducted.
Neither the execution nor delivery of this Agreement or the Related
Agreements, nor the carrying on of the Company's business by the employees
of the Company, nor the conduct of the Company's business as presently
proposed, will, to the Company's knowledge, conflict with or result in a
breach of the terms, conditions or provisions of, or constitute a default
under, any contract, covenant or instrument under which any employee is now
obligated. The Company does not believe it is or will be necessary to
utilize any inventions, trade secrets or proprietary information of any of
its employees made prior to their employment by the Company, except for
inventions, trade secrets or proprietary information that have been
assigned to the Company and which are disclosed in the Schedule of
Exceptions hereto.
3.12 Compliance with Other Instruments.
(a) The Company is not in material violation or default of any term of
its Restated Charter or Bylaws, or of any provision of any mortgage,
indenture, agreement, instrument or contract to which it is party or by
which it is bound or of any judgment, decree, order, writ. The execution,
delivery, and performance of and compliance with this Agreement, and the
Related Agreements, the issuance and sale of the Shares and Warrants
pursuant hereto, and the issuance and sale of the Common Stock issuable
upon exercise of the Warrants, will not, with or without the passage of
time or giving of notice, result in any such material violation or default,
or be in conflict with any such term or provision, or result in the
creation of any mortgage, pledge, lien, encumbrance or charge upon any of
the properties or assets of the Company or the suspension, revocation,
impairment, forfeiture or nonrenewal of any permit, license, authorization
or approval applicable to the Company, its business or operations or any of
its assets or properties.
(b) The Company has avoided every condition, and has not performed any
act, the occurrence of which would result in the Company's loss of any
right granted under any license, distribution agreement or other agreement
required to be disclosed on the Schedule of Exceptions.
3.13 Litigation. There is no action, suit, or proceeding pending, or
to the Company's knowledge currently threatened, or to the Company's
knowledge any investigation currently pending or threatened, against or
involving the Company that questions the validity of this Agreement or the
Related Agreements or the right of the Company to enter into any of such
agreements, or to consummate the transactions contemplated hereby or
thereby, or which might result, either individually or in the aggregate, in
any material adverse change in the assets, condition, affairs or prospects
of the Company, financially or otherwise, or any change in the current
equity ownership of the Company, nor is the Company aware that there is any
basis for any of the foregoing. The foregoing includes, without limitation,
actions pending or threatened (or any basis therefor known to the Company)
involving the prior employment of any of the Company's employees, their use
in connection with the Company's business of any information or techniques
allegedly proprietary to any of their former employers, or their
obligations under any agreements with prior employers. The Company is not a
party or subject to the provisions of any order, writ, injunction, judgment
or decree of any court or government agency or instrumentality. There is no
action, suit, proceeding or investigation by the Company currently pending
or which the Company intends to initiate.
3.14 Tax Returns and Payments. The Company has timely filed all tax
returns (federal, state and local) required to be filed by it. All taxes
shown to be due and payable on such returns, any assessments imposed, and
to the Company's knowledge all other taxes due and payable by the Company
on or before the Closing, have been paid or will be paid prior to the time
they become delinquent. The Company has not been advised (a) that any of
its returns, federal, state or other, have been or are being audited as of
6
<PAGE> 52
the date hereof, or (b) of any deficiency in assessment or proposed
judgment to its federal, state or other taxes. The Company has no knowledge
of any liability of any tax to be imposed upon its properties or assets as
of the date of this Agreement that is not adequately provided for in the
Financial Statements.
3.15 Employees. The Company has no collective bargaining agreements
with any of its employees. There is no labor union organizing activity
pending or, to the Company's knowledge, threatened with respect to the
Company. Except as disclosed in the Schedule of Exceptions, no employee has
any agreement or contract, written or verbal, regarding his/her employment.
The Company is not a party to or bound by any currently effective
employment contract, deferred compensation arrangement, bonus plan,
incentive plan, profit sharing plan, retirement agreement or other employee
compensation plan or agreement. To the Company's knowledge, no employee of
the Company, nor any consultant with whom the Company has contracted, is in
violation of any term of any employment contract, proprietary information
agreement or any other agreement relating to the right of any such
individual to be employed by, or to contract with, the Company because of
the nature of the business to be conducted by the Company; and to the
Company's knowledge the continued employment by the Company of its present
employees, and the performance of the Company's contracts with its
independent contractors, will not result in any such violation. The Company
has not received any notice alleging that any such violation has occurred.
No employee of the Company has been granted the right to continued
employment by the Company or to any material compensation following
termination of employment with the Company. The Company is not aware that
any officer or key employee, or that any group of key employees, intends to
terminate his, her or their employment with the Company, nor does the
Company have a present intention to terminate the employment of any
officer, key employee or group of key employees.
3.16 Proprietary Information and Inventions Agreements. Each former
and current employee, officer and consultant of the Company has executed a
Proprietary Information and Inventions Agreement in the form(s) as
delivered to the Purchasers. No current employee, officer or consultant of
the Company has excluded works or inventions made prior to his or her
employment with the Company from his or her assignment of inventions
pursuant to such employee, officer or consultant's Proprietary Information
and Inventions Agreement.
3.17 Obligations of Management. Each officer of the Company is
currently devoting one hundred percent (100%) of his/her business time to
the conduct of the business of the Company. The Company is not aware that
any officer or key employee of the Company is planning to work less than
full time at the Company in the future. No officer or key employee is
currently working or, to the Company's knowledge, plans to work for a
competitive enterprise, whether or not such officer or key employee is or
will be compensated by such enterprise.
3.18 Registration Rights and Voting Rights.
(a) Except as set forth in the Registration and Stockholder Rights
Agreement or in Part 3.18 of the Schedule of Exceptions, the Company is
presently not under any obligation, and has not granted any rights, to
register (as defined in Section 1.1 of the Registration and Stockholder
Rights Agreement) any of the Company's presently outstanding securities or
any of its securities that may hereafter be issued.
(b) Except as may be set forth in Part 3.18 of the Schedule of
Exceptions, to the Company's knowledge, no shareholder of the Company has
entered into any agreement with respect to the voting of equity securities
of the Company.
3.19 Compliance with Laws; Permits. The Company is not in violation
of any applicable statute, rule, regulation, order or restriction of any
domestic or foreign government or any instrumentality or agency thereof in
respect of the conduct of its business or the ownership of its properties
which violation would materially and adversely affect the business, assets,
liabilities, financial condition, operations or prospects of the Company.
No governmental orders, permissions, consents, approvals or authorizations
are required to be obtained and no registrations or declarations are
required to be filed in connection with the execution and delivery of this
Agreement and the issuance of the Shares or the Warrants, except such as
has been duly and validly obtained or filed, or with respect to any filings
that must be made after the
7
<PAGE> 53
Closing, as will be filed in a timely manner. The Company has all
franchises, permits, licenses and any similar authority necessary for the
conduct of its business as now being conducted by it, the lack of which
could materially and adversely affect the business, properties, prospects
or financial condition of the Company and believes it can obtain, without
undue burden or expense, any similar authority for the conduct of its
business as planned to be conducted.
3.20 Environmental and Safety Laws. To its knowledge, the Company is
not in violation of any applicable statute, law or regulation relating to
the environment or occupational health and safety, and to its knowledge, no
material expenditures are or will be required in order to comply with any
such existing statute, law or regulation. No Hazardous Materials (as
defined below) are used or have been used, stored, or disposed of by the
Company or, to the Company's knowledge after reasonable investigation, by
any other person or entity on any property owned, leased or used by the
Company. For the purposes of the preceding sentence, "Hazardous Materials"
shall mean (a) materials which are listed or otherwise defined as
"hazardous" or "toxic" under any applicable local, state, federal and/or
foreign laws and regulations that govern the existence and/or remedy of
contamination on property, the protection of the environment from
contamination, the control of hazardous wastes, or other activities
involving hazardous substances, including building materials, or (b) any
petroleum products or nuclear materials.
3.21 Offering Valid. Assuming the accuracy of the representations
and warranties of the Purchasers contained in Section 4.2 hereof, the
offer, sale and issuance of the Shares and the Warrants will be exempt from
the registration requirements of the Securities Act of 1933, as amended
(the "SECURITIES ACT"), and will have been registered or qualified (or are
exempt from registration and qualification) under the registration, permit
or qualification requirements of all applicable state securities laws.
Neither the Company nor any agent on its behalf has solicited or will
solicit any offers to sell or has offered to sell or will offer to sell all
or any part of the Shares to any person or persons so as to bring the sale
of such Shares by the Company within the registration provisions of the
Securities Act or any state securities laws.
3.22 Full Disclosure. The Company has made available to the
Purchasers all information requested by the Purchasers in connection with
their decision to purchase the Shares and the Warrants. Neither this
Agreement, the Exhibits hereto, nor the Related Agreements contain any
untrue statement of a material fact or, omit to state a material fact
necessary in order to make the statements contained herein or therein not
misleading. There are no facts which (individually or in the aggregate)
materially adversely affect the business, assets, liabilities, financial
condition, prospects or operations of the Company that have not been set
forth in the Agreement, the Exhibits hereto, the Related Agreements, the
periodic filings made by the Company under the Securities Exchange Act of
1934, or in other documents delivered to Purchasers or their attorneys or
agents in connection herewith.
3.23 Minute Books. The minute books of the Company made available to
the Purchasers contain a materially complete summary of all meetings of
directors and shareholders since the time of incorporation.
3.24 Real Property Holding Corporation. The Company is not a real
property holding corporation within the meaning of Code Section 897(c)(2)
and any regulations promulgated thereunder.
3.25 Insurance. The Company has fire and casualty insurance policies
with coverage customary for companies similarly situated to the Company.
4. Representations and Warranties of the Purchasers
Each Purchaser hereby represents and warrants to the Company as follows,
with respect to such Purchaser and not with respect to any other Purchaser (such
representations and warranties do not lessen or obviate the representations and
warranties of the Company set forth in this Agreement) as of the date hereof and
the Closing Date:
4.1 Requisite Power and Authority. Purchaser has all necessary power
and authority under all applicable provisions of law to execute and deliver
this Agreement and the Related Agreements and to carry out their
provisions. All action on Purchaser's part required for the lawful
execution and delivery of
8
<PAGE> 54
this Agreement and the Related Agreements has been or will be effectively
taken prior to the Closing. Upon their execution and delivery, this
Agreement and the Related Agreements will be valid and binding obligations
of Purchaser, enforceable in accordance with their terms, subject to laws
of general application relating to bankruptcy, insolvency, the relief of
debtors and, with respect to rights to indemnity, subject to federal and
state securities laws.
4.2 Investment Representations. Purchaser understands that neither
the Shares nor the Warrants have been registered under the Securities Act.
Purchaser also understands that the Shares and the Warrants are being
offered and sold pursuant to an exemption from registration contained in
the Securities Act based in part upon each Purchaser's representations
contained in the Agreement. Purchaser hereby represents and warrants as
follows:
(a) Purchaser Bears Economic Risk. Purchaser has substantial
experience in evaluating and investing in private placement transactions
of securities in companies similar to the Company so that it is capable
of evaluating the merits and risks of its investment in the Company and
has the capacity to protect its own interests. Purchaser must bear the
economic risk of this investment indefinitely unless the Shares are
registered pursuant to the Securities Act, or an exemption from
registration is available. Purchaser understands that the Company has no
present intention of registering the Shares. Purchaser also understands
that there is no assurance that any exemption from registration under
the Securities Act will be available and that, even if available, such
exemption may not allow Purchaser to transfer all or any portion of the
Shares Shares under the circumstances, in the amounts or at the times
Purchaser might propose.
(b) Acquisition for Own Account. Purchaser is acquiring the Shares
for Purchaser's own account for investment only, and not with a view
towards their distribution.
(c) Purchaser Can Protect Its Interest. Purchaser represents that
by reason of its, or of its management's, business or financial
experience, Purchaser has the capacity to protect its own interests in
connection with the transactions contemplated in this Agreement, and the
Related Agreements. Further, Purchaser is aware of no publication of any
advertisement in connection with the transactions contemplated in the
Agreement.
(d) Accredited Investor. Purchaser represents that it is an
accredited investor within the meaning of Regulation D under the
Securities Act.
(e) Company Information. Purchaser has received and read the
Financial Statements and has had an opportunity to discuss the Company's
business, management and financial affairs with directors, officers and
management of the Company and has had the opportunity to review the
Company's operations and facilities. Purchaser has also had the
opportunity to ask questions of and receive answers from, the Company
and its management regarding the terms and conditions of this
investment.
(f) Rule 144. Purchaser acknowledges and agrees that the Shares
must be held indefinitely unless they are subsequently registered under
the Securities Act, an exemption from such registration is available, or
the resale of such Shares is permitted under Rule144 of the Securities
Act subject to the satisfaction of each of the conditions set forth
therein.
(g) Residence. If Purchaser is an individual, then Purchaser
resides in the location identified in the address of the Purchaser set
forth on Exhibit A; if Purchaser is a partnership, corporation, limited
liability company or other entity, then the office or offices of such
Purchaser in which its investment decision was made is located at the
address or addresses of such Purchaser set forth on Exhibit A.
9
<PAGE> 55
5. Conditions to Closing.
5.1 Conditions to Purchasers' Obligations at the Closing. Purchasers'
obligations to purchase the Shares and the Warrants at the Closing are subject
to the satisfaction, at or prior to the Closing Date, of the following
conditions:
(a) Representations and Warranties True; Performance of
Obligations. The representations and warranties made by the Company in
Section 3 hereof shall be true and correct as of the Closing Date with the
same force and effect as if they had been made as of the Closing Date,
except as may have been agreed to in writing by the Purchasers prior to the
Closing Date, and the Company shall have performed all obligations and
conditions herein required to be performed or observed by it on or prior to
the Closing.
(b) Legal Investment. On the Closing Date, the sale and issuance of
the Shares and the proposed issuance of Common Stock issuable upon exercise
of the Warrants shall be legally permitted by all laws and regulations to
which Purchasers and the Company are subject.
(c) Consents, Permits, and Waivers. The Company shall have obtained
any and all consents, permits and waivers necessary or appropriate for
consummation of the transactions contemplated by the Agreement and the
Related Agreements (except for such as may be properly obtained subsequent
to the Closing).
(d) No Proceedings. Since the date of this Agreement, there shall not
have been commenced or threatened against the Purchasers, or against any
person affiliated with the Purchasers, any proceeding (a) involving any
challenge to, or seeking damages or other relief in connection with, any of
the transactions contemplated by this Agreement and the Related Agreements,
or (b) that may have the effect of preventing, delaying, making illegal or
otherwise interfering with any such transactions.
(e) Filing of Restated Charter. The Restated Charter shall have been
filed with the Secretary of State of the State of Delaware and shall
continue to be in full force and effect as of the Closing Date.
(f) Corporate Documents. The Company shall have delivered to
Purchasers or their counsel copies of all corporate documents of the
Company as Purchasers shall reasonably request.
(g) Reservation of Shares to be Issued Upon Exercise of Warrants. The
shares of the Company's Common Stock issuable upon exercise of the Warrants
shall have been duly authorized and reserved for issuance upon such
exercise.
(h) Adverse Change. There shall have been no adverse change in the
business, condition, assets, liabilities, operations, financial
performance, net income or prospects (or in any aspect or portion thereof)
of the Company and its subsidiaries since the date of this Agreement.
(i) Compliance Certificate. The Company shall have delivered to
Purchasers a Compliance Certificate, executed by the President of the
Company, dated the Closing Date, to the effect that the conditions
specified in subsections (a), (c), (e), (g) and (h) of this Section 5.1
have been satisfied.
(j) Registration and Stockholder Rights Agreement. A Registration and
Stockholder Rights Agreement substantially in the form attached hereto as
Exhibit C shall have been executed and delivered by the parties hereto.
(k) Distribution Agreement. The Company shall have entered into that
certain Distribution Agreement between the Company and SPARK 1st Vision
Verwaltungs GmbH.
(l) Board of Directors. Upon the Closing, the authorized size of the
Board of Directors of the Company shall be five members and the Board shall
consist of Falah Al-Khadi, Bernd Herrmann, and Urs Wettstein, John N.
Kapoor and Dr. Ramesh C. Trivedi.
(m) Legal Opinion. The Purchasers shall have received from legal
counsel to the Company an opinion addressed to them, dated as of the
Closing Date, in substantially the form attached hereto as Exhibit F.
10
<PAGE> 56
(n) Proceedings and Documents. All corporate and other proceedings in
connection with the transactions contemplated at the Closing hereby and all
documents and instruments incident to such transactions shall be reasonably
satisfactory in substance and form to the Purchasers and their special
counsel, and the Purchasers and their special counsel shall have received
all such counterpart originals or certified or other copies of such
documents as they may reasonably request.
5.2 Conditions to Obligations of the Company. The Company's obligation to
issue and sell the Shares and the Warrants at the Closing is subject to the
satisfaction, on or prior to the Closing Date, of the following conditions:
(a) Representations and Warranties True. The representations and
warranties in Section 4 made by those Purchasers acquiring Shares and the
Warrants shall be true and correct at the date of the Closing, with the
same force and effect as if they had been made on and as of said date.
(b) Performance of Obligations. Such Purchasers shall have performed
and complied with all agreements and conditions herein required to be
performed or complied with by such Purchasers on or before the Closing.
(c) Filing of Restated Charter. The Restated Charter shall have been
filed with the Secretary of State of the State of Delaware and shall
continue to be in full force and effect as of the Closing Date.
(d) Registration and Stockholder Rights Agreement. A Registration and
Stockholder Rights Agreement substantially in the form attached hereto as
Exhibit C shall have been executed and delivered by the parties hereto.
(e) Distribution Agreement. The Company shall have entered into that
certain Distribution Agreement between the Company and SPARK 1st Vision
Verwaltungs GmbH.
(f) Consents, Permits, and Waivers. The Company shall have obtained
any and all consents, permits and waivers necessary or appropriate for
consummation of the transactions contemplated by the Agreement and the
Related Agreements (except for such as may be properly obtained subsequent
to the Closing).
6. Miscellaneous.
6.1 Governing Law. This Agreement shall be governed in all respects by
the laws of the State of California as such laws are applied to agreements
between California residents entered into and performed entirely in California.
6.2 Survival. The representations, warranties, covenants and agreements
made herein shall survive any investigation made by any Purchaser and the
closing of the transactions contemplated hereby for a period of two (2) years
following the Closing. All statements as to factual matters contained in any
certificate or other instrument delivered by or on behalf of the Company
pursuant hereto in connection with the transactions contemplated hereby shall be
deemed to be representations and warranties by the Company hereunder solely as
of the date of such certificate or instrument.
6.3 Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors and administrators of the
parties hereto and shall inure to the benefit of and be enforceable by each
person who shall be a holder of the Shares or the Warrants from time to time.
6.4 Entire Agreement. This Agreement, the Exhibits and Schedules hereto,
the Related Agreements and the other documents delivered pursuant hereto
constitute the full and entire understanding and agreement between the parties
with regard to the subjects hereof and no party shall be liable or bound to any
other in any manner by any representations, warranties, covenants and agreements
except as specifically set forth herein and therein.
11
<PAGE> 57
6.5 Severability. In case any provision of the Agreement shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.
6.6 Amendment and Waiver.
(a) This Agreement may be amended or modified only upon the written
consent of the Company and holders of at least sixty-six and two-thirds
percent (66 2/3%) of the Shares (including any shares of the Company's
Common Stock acquired by any Purchaser upon exercise of a Warrant).
(b) The obligations of the Company and the rights of the holders of
the Shares and the Warrants under the Agreement may be waived only with the
written consent of the holders of at least sixty-six and two-thirds percent
(66 2/3%) of the Shares (including any shares of the Company's Common Stock
acquired by any Purchaser upon exercise of a Warrant).
6.7 Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power or remedy accruing to any party, upon any breach,
default or noncompliance by another party under this Agreement, the Related
Agreements or the Restated Charter, shall impair any such right, power or
remedy, nor shall it be construed to be a waiver of any such breach, default or
noncompliance, or any acquiescence therein, or of or in any similar breach,
default or noncompliance thereafter occurring. It is further agreed that any
waiver, permit, consent or approval of any kind or character on any Purchaser's
part of any breach, default or noncompliance under this Agreement, the Related
Agreements or under the Restated Charter or any waiver on such party's part of
any provisions or conditions of the Agreement, or the Related Agreements, or the
Restated Charter must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this
Agreement, or the Related Agreements, the Restated Charter, by law, or otherwise
afforded to any party, shall be cumulative and not alternative.
6.8 Notices. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the
party to be notified, (b) when sent by confirmed facsimile if sent during normal
business hours of the recipient, if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (d) two (2) days after deposit with an
internationally recognized overnight courier, specifying no less than delivery
within 48 hours, with written verification of receipt. All communications shall
be sent to the Company at the address as set forth on the signature page hereof
and to Purchaser at the address set forth on Exhibit A attached hereto or at
such other address as the Company or Purchaser may designate by ten (10) days
advance written notice to the other parties hereto.
6.9 Expenses. Each party shall pay all costs and expenses that it incurs
with respect to the negotiation, execution, delivery and performance of the
Agreement.
6.10 Attorneys' Fees. In the event that any suit or action is instituted
to enforce any provision in this Agreement, the prevailing party in such dispute
shall be entitled to recover from the losing party all fees, costs and expenses
of enforcing any right of such prevailing party under or with respect to this
Agreement, including without limitation, such reasonable fees and expenses of
attorneys and accountants, which shall include, without limitation, all fees,
costs and expenses of appeals.
6.11 Titles and Subtitles. The titles of the sections and subsections of
the Agreement are for convenience of reference only and are not to be considered
in construing this Agreement.
6.12 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
6.13 Broker's Fees. Each party hereto represents and warrants that no
agent, broker, investment banker, person or firm acting on behalf of or under
the authority of such party hereto is or will be entitled to any broker's or
finder's fee or any other commission directly or indirectly in connection with
the transactions contemplated herein. Each party hereto further agrees to
indemnify each other party for any claims, losses or expenses incurred by such
other party as a result of the representation in this Section 6.13 being untrue.
12
<PAGE> 58
6.14 Exculpation Among Purchasers. Each Purchaser acknowledges that it is
not relying upon any person, firm, or corporation, other than the Company and
its officers and directors, in making its investment or decision to invest in
the Company. Each Purchaser agrees that no Purchaser nor the respective
controlling persons, officers, directors, partners, agents, or employees of any
Purchaser shall be liable to any other Purchaser for any action heretofore or
hereafter taken or omitted to be taken by any of them in connection with the
Shares and the Warrants.
6.15 Confidentiality. Each party hereto agrees that, except with the
prior written consent of the other party, it shall at all times keep
confidential and not divulge, furnish or make accessible to anyone any
confidential information, knowledge or data concerning or relating to the
business or financial affairs of the other parties to which such party has been
or shall become privy by reason of this Agreement or the Related Agreements,
discussions or negotiations relating to this Agreement or the Related
Agreements, the performance of its obligations hereunder or the ownership of the
Shares purchased hereunder. The provisions of this Section 6.15 shall be in
addition to, and not in substitution for, the provisions of any separate
nondisclosure agreement executed by the parties hereto.
6.16 Pronouns. All pronouns contained herein, and any variations thereof,
shall be deemed to refer to the masculine, feminine or neutral, singular or
plural, as to the identity of the parties hereto may require.
6.17 California Corporate Securities Law. THE SALE OF THE SECURITIES
WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR
PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH
QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE
COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED
UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION
BEING AVAILABLE.
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
13
<PAGE> 59
IN WITNESS WHEREOF, the parties hereto have executed this STOCK AND WARRANT
PURCHASE AGREEMENT as of the date set forth in the first paragraph hereof.
<TABLE>
<CAPTION>
COMPANY: PURCHASERS:
<S> <C>
INTEGRATED SURGICAL SYSTEMS, INC. ILTAG INTERNATIONAL LICENSING HOLDING S.A.L.
By: ---------------------------------------------- By:
-------------------------------------------------
Its:
Its:
By:
-------------------------------------------------
Its:
-------------------------------------------------
Bernd Herrmann
-------------------------------------------------
Urs Wettstein
</TABLE>
14
<PAGE> 60
<TABLE>
<S> <C>
LIST OF EXHIBITS
SCHEDULE OF PURCHASERS Exhibit A
FORM OF WARRANT Exhibit B
REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT Exhibit C
RESTATED CERTIFICATE Exhibit D
FINANCIAL STATEMENTS Exhibit E
FORM OF LEGAL OPINION Exhibit G
</TABLE>
15
<PAGE> 61
EXHIBIT A
SCHEDULE OF PURCHASERS
<TABLE>
<CAPTION>
AMOUNT PAID REMAINING AGGREGATE
NAME AND ADDRESS SHARES WARRANTS PRIOR TO CLOSING PURCHASE PRICE PURCHASE PRICE
- ---------------- --------- --------- ---------------- -------------- --------------
<S> <C> <C> <C> <C> <C>
Iltag International Licensing
Holding S.A.L. ............. 1,461,198 [50%] $200,000 $1,800,000 $2,000,000
[ADDRESS]
Bernd Herrmann................ 730,599 [25%] 100,000 $ 900,000 $1,000,000
[ADDRESS]
Urs Wettstein................. 730,599 [25%] 100,000 $ 900,000 $1,000,000
Gartenstrasse 33,8002
Zurich, Switzerland
--------- --------- -------- ---------- ----------
Total......................... 2,922,396 [100%] $400,000 $3,600,000 $4,000,000
========= ========= ======== ========== ==========
</TABLE>
i
<PAGE> 62
EXHIBIT B
NO. PW-
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY
STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE
ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.
WARRANT TO PURCHASE SHARES
OF COMMON STOCK OF
INTEGRATED SURGICAL SYSTEMS, INC.
[EXPIRES , 2002]
This certifies that or its assigns (the "HOLDER"), for value
received, is entitled to purchase from Integrated Surgical Systems, Inc., a
Delaware corporation (the "COMPANY"), having a place of business at 1850
Research Park Drive, Davis, CA 95616-4884, a maximum of fully paid and
nonassessable shares (the "Exercise Shares") of the Company's Common Stock for
cash at a price per share equal to [75% of the Aggregate Purchase Price shown on
Exhibit A to the Stock and Warrant Purchase Agreement] divided by the maximum
number of Exercise Shares as set forth herein (the "STOCK PURCHASE PRICE") at
any time or from time to time, up to 5:00 p.m. on a date which is three (3)
years from the date of this Warrant (the "EXPIRATION DATE"), upon surrender to
the Company at its principal office (or at such other location as the Company
may advise the Holder in writing) of this Warrant properly endorsed with the
Form of Subscription attached hereto duly filled in and signed and, if
applicable, upon payment in cash or by check of the aggregate Stock Purchase
Price for the number of shares for which this Warrant is being exercised
determined in accordance with the provisions hereof. The Stock Purchase Price
and the number of shares purchasable hereunder are subject to adjustment as
provided in Section 3 of this Warrant.
This Warrant is subject to the following terms and conditions:
1. Exercise; Issuance of Certificates; Payment for Shares. This Warrant
is exercisable at the option of the Holder, at any time or from time to time up
to the Expiration Date, subject to the provisions of Section , for all or any
part of the shares of Common Stock (but not for a fraction of a share) which may
be purchased hereunder. The Company agrees that the shares of Common Stock
purchased under this Warrant shall be and are deemed to be issued to the Holder
hereof as the record owner of such shares as of the close of business on the
date on which this Warrant shall have been surrendered, properly endorsed, the
completed, executed Form of Subscription delivered and payment made for such
shares. Certificates for the shares of Common Stock so purchased, together with
any other securities or property to which the Holder hereof is entitled upon
such exercise, shall be delivered to the Holder hereof by the Company at the
Company's expense within a reasonable time after the rights represented by this
Warrant have been so exercised. In case of a purchase of less than all the
shares which may be purchased under this Warrant, the Company shall cancel this
Warrant and execute and deliver a new Warrant or Warrants of like tenor for the
balance of the shares purchasable under the Warrant surrendered upon such
purchase to the Holder hereof within a reasonable time. Each stock certificate
so delivered shall be in such denominations of Common Stock as may be requested
by the Holder hereof and shall be registered in the name of such Holder.
2. Shares to be Fully Paid; Reservation of Shares. The Company covenants
and agrees that all shares of Common Stock which may be issued upon the exercise
of the rights represented by this Warrant will, upon issuance, be duly
authorized, validly issued, fully paid and nonassessable and free from all
preemptive rights of any shareholder and free of all taxes, liens and charges
with respect to the issue thereof. The Company further covenants and agrees
that, during the period within which the rights represented by this Warrant may
be exercised, the Company will at all times have authorized and reserved, for
the purpose of issue or transfer upon exercise of the subscription rights
evidenced by this Warrant, a sufficient number of shares of authorized but
unissued Common Stock, or other securities and property, when and as required to
provide for the exercise
<PAGE> 63
of the rights represented by this Warrant. The Company will take all such action
as may be necessary to assure that such shares of Common Stock may be issued as
provided herein without violation of any applicable law or regulation, or of any
requirements of any domestic securities exchange upon which the Common Stock may
be listed; provided, however, that the Company shall not be required to effect a
registration under Federal or State securities laws with respect to such
exercise. The Company will not take any action which would result in any
adjustment of the Stock Purchase Price (as set forth in Section 3 hereof) (i) if
the total number of shares of Common Stock issuable after such action upon
exercise of all outstanding warrants, together with all shares of Common Stock
then outstanding and all shares of Common Stock then issuable upon exercise of
all options and upon the conversion of all convertible securities then
outstanding, would exceed the total number of shares of Common Stock then
authorized by the Company's Restated Certificate of Incorporation, or (ii) if
the total number of shares of Common Stock issuable after such action upon the
conversion of all such shares of Common Stock, together with all shares of
Common Stock then issuable upon exercise of all options and upon the conversion
of all such shares of Common Stock, together with all shares of Common Stock
then outstanding and all shares of Common Stock then issuable upon exercise of
all options and upon the conversion of all convertible securities then
outstanding would exceed the total number of shares of Common Stock then
authorized by the Company's Restated Certificate of Incorporation.
3. Adjustment of Stock Purchase Price and Number of Shares. The Stock
Purchase Price and the number of shares purchasable upon the exercise of this
Warrant shall be subject to adjustment from time to time upon the occurrence of
certain events described in this Section 3. Upon each adjustment of the Stock
Purchase Price, the Holder of this Warrant shall thereafter be entitled to
purchase, at the Stock Purchase Price resulting from such adjustment, the number
of shares obtained by multiplying the Stock Purchase Price in effect immediately
prior to such adjustment by the number of shares purchasable pursuant hereto
immediately prior to such adjustment, and dividing the product thereof by the
Stock Purchase Price resulting from such adjustment.
Subdivision or Combination of Stock. In case the Company shall at any
time subdivide its outstanding shares of Common Stock into a greater number
of shares, the Stock Purchase Price in effect immediately prior to such
subdivision shall be proportionately reduced, and conversely, in case the
outstanding shares of Common Stock of the Company shall be combined into a
smaller number of shares, the Stock Purchase Price in effect immediately
prior to such combination shall be proportionately increased.
Dividends in Common Stock, Other Stock, Property,
Reclassification. If at any time or from time to time the Holders of
Common Stock (or any shares of stock or other securities at the time
receivable upon the exercise of this Warrant) shall have received or become
entitled to receive, without payment therefor,
Common Stock or any shares of stock or other securities which are at
any time directly or indirectly convertible into or exchangeable for Common
Stock, or any rights or options to subscribe for, purchase or otherwise
acquire any of the foregoing by way of dividend or other distribution,
any cash paid or payable otherwise than as a cash dividend, or
Common Stock or additional stock or other securities or property
(including cash) by way of spinoff, split-up, reclassification,
combination of shares or similar corporate rearrangement, (other than
shares of Common Stock issued as a stock split or adjustments in respect
of which shall be covered by the terms of Section 3.1 above), then and
in each such case, the Holder hereof shall, upon the exercise of this
Warrant, be entitled to receive, in addition to the number of shares of
Common Stock receivable thereupon, and without payment of any additional
consideration therefor, the amount of stock and other securities and
property (including cash in the cases referred to in clause (b) above
and this clause (c)) which such Holder would hold on the date of such
exercise had it been the holder of record of such Common Stock as of the
date on which holders of Common Stock received or became entitled to
receive such shares or all other additional stock and other securities
and property.
2
<PAGE> 64
Reorganization, Reclassification, Consolidation, Merger or Sale. If
any recapitalization, reclassification or reorganization of the capital
stock of the Company, or any consolidation or merger of the Company with
another corporation, or the sale of all or substantially all of its assets
or other transaction shall be effected in such a way that holders of Common
Stock shall be entitled to receive stock, securities, or other assets or
property (an "ORGANIC CHANGE"), then, as a condition of such Organic
Change, lawful and adequate provisions shall be made by the Company whereby
the Holder hereof shall thereafter have the right to purchase and receive
(in lieu of the shares of the Common Stock of the Company immediately
theretofore purchasable and receivable upon the exercise of the rights
represented hereby) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange for a
number of outstanding shares of such Common Stock equal to the number of
shares of such stock immediately theretofore purchasable and receivable
upon the exercise of the rights represented hereby; provided, however, that
in the event the value of the stock, securities or other assets or property
(determined in good faith by the Board of Directors of the Company)
issuable or payable with respect to one share of the Common Stock of the
Company immediately theretofore purchasable and receivable upon the
exercise of the rights represented hereby is in excess of the Stock
Purchase Price hereof effective at the time of a merger and securities
received in such reorganization, if any, are publicly traded, then this
Warrant shall expire unless exercised prior to such Organic Change. In the
event of any Organic Change, appropriate provision shall be made by the
Company with respect to the rights and interests of the Holder of this
Warrant to the end that the provisions hereof (including, without
limitation, provisions for adjustments of the Stock Purchase Price and of
the number of shares purchasable and receivable upon the exercise of this
Warrant) shall thereafter be applicable, in relation to any shares of
stock, securities or assets thereafter deliverable upon the exercise
hereof. The Company will not effect any such consolidation, merger or sale
unless, prior to the consummation thereof, the successor corporation (if
other than the Company) resulting from such consolidation or the
corporation purchasing such assets shall assume by written instrument
reasonably satisfactory in form and substance to the Holders of a majority
of the warrants to purchase Common Stock then outstanding, executed and
mailed or delivered to the registered Holder hereof at the last address of
such Holder appearing on the books of the Company, the obligation to
deliver to such Holder such shares of stock, securities or assets as, in
accordance with the foregoing provisions, such Holder may be entitled to
purchase.
Certain Events. If any change in the outstanding Common Stock of the
Company or any other event occurs as to which the other provisions of this
Section 3 are not strictly applicable or if strictly applicable would not
fairly protect the purchase rights of the Holder of the Warrant in
accordance with such provisions, then the Board of Directors of the Company
shall make an adjustment in the number and class of shares available under
the Warrant, the Stock Purchase Price or the application of such
provisions, so as to protect such purchase rights as aforesaid. The
adjustment shall be such as will give the Holder of the Warrant upon
exercise for the same aggregate Stock Purchase Price the total number,
class and kind of shares as it would have owned had the Warrant been
exercised prior to the event and had it continued to hold such shares until
after the event requiring adjustment.
Notices of Change. Immediately upon any adjustment in the number or
class of shares subject to this Warrant and of the Stock Purchase Price,
the Company shall give written notice thereof to the Holder, setting forth
in reasonable detail and certifying the calculation of such adjustment.
The Company shall give written notice to the Holder at least 10
business days prior to the date on which the Company closes its books or
takes a record for determining rights to receive any dividends or
distributions.
The Company shall also give written notice to the Holder at least
30 business days prior to the date on which an Organic Change shall take
place.
4. Registration Rights. The Holders shall have such registration and
other rights as set forth in that certain Registration and Stockholder Rights
Agreement of even date herewith.
5. Issue Tax. The issuance of certificates for shares of Common Stock
upon the exercise of the Warrant shall be made without charge to the Holder of
the Warrant for any issue tax (other than any
3
<PAGE> 65
applicable income taxes) in respect thereof; provided, however, that the Company
shall not be required to pay any tax which may be payable in respect of any
transfer involved in the issuance and delivery of any certificate in a name
other than that of the then Holder of the Warrant being exercised.
6. Closing of Books. The Company will at no time close its transfer books
against the transfer of any warrant or of any shares of Common Stock issued or
issuable upon the exercise of any warrant in any manner which interferes with
the timely exercise of this Warrant.
7. No Voting or Dividend Rights; Limitation of Liability. Nothing
contained in this Warrant shall be construed as conferring upon the Holder
hereof the right to vote or to consent or to receive notice as a shareholder of
the Company or any other matters or any rights whatsoever as a shareholder of
the Company. No dividends or interest shall be payable or accrued in respect of
this Warrant or the interest represented hereby or the shares purchasable
hereunder until, and only to the extent that, this Warrant shall have been
exercised. No provisions hereof, in the absence of affirmative action by the
holder to purchase shares of Common Stock, and no mere enumeration herein of the
rights or privileges of the holder hereof, shall give rise to any liability of
such Holder for the Stock Purchase Price or as a shareholder of the Company,
whether such liability is asserted by the Company or by its creditors.
8. Warrants Transferable. Subject to compliance with applicable federal
and state securities laws, this Warrant and all rights hereunder are
transferable, in whole or in part, without charge to the holder hereof (except
for transfer taxes), upon surrender of this Warrant properly endorsed. Each
taker and holder of this Warrant, by taking or holding the same, consents and
agrees that this Warrant, when endorsed in blank, shall be deemed negotiable,
and that the holder hereof, when this Warrant shall have been so endorsed, may
be treated by the Company, at the Company's option, and all other persons
dealing with this Warrant as the absolute owner hereof for any purpose and as
the person entitled to exercise the rights represented by this Warrant, or to
the transfer hereof on the books of the Company any notice to the contrary
notwithstanding; but until such transfer on such books, the Company may treat
the registered owner hereof as the owner for all purposes.
9. Rights and Obligations Survive Exercise of Warrant. The rights and
obligations of the Company, of the holder of this Warrant and of the holder of
shares of Common Stock issued upon exercise of this Warrant, shall survive the
exercise of this Warrant.
10. Modification and Waiver. This Warrant and any provision hereof may be
changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of the same is sought.
11. Notices. Any notice, request or other document required or permitted
to be given or delivered to the holder hereof or the Company shall be delivered
or shall be sent by certified mail, postage prepaid, to each such holder at its
address as shown on the books of the Company or to the Company at the address
indicated therefor in the first paragraph of this Warrant or such other address
as either may from time to time provide to the other.
12. Binding Effect on Successors. This Warrant shall be binding upon any
corporation succeeding the Company by merger, consolidation or acquisition of
all or substantially all of the Company's assets. All of the obligations of the
Company relating to the Common Stock issuable upon the exercise of this Warrant
shall survive the exercise and termination of this Warrant. All of the covenants
and agreements of the Company shall inure to the benefit of the successors and
assigns of the holder hereof.
13. Descriptive Headings and Governing Law. The description headings of
the several sections and paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant. This Warrant shall be
construed and enforced in accordance with, and the rights of the parties shall
be governed by, the laws of the State of California.
14. Lost Warrants. The Company represents and warrants to the Holder
hereof that upon receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction, or mutilation of this Warrant and, in the case of
any such loss, theft or destruction, upon receipt of an indemnity reasonably
satisfactory to
4
<PAGE> 66
the Company, or in the case of any such mutilation upon surrender and
cancellation of such Warrant, the Company, at its expense, will make and deliver
a new Warrant, of like tenor, in lieu of the lost, stolen, destroyed or
mutilated Warrant.
15. Fractional Shares. No fractional shares shall be issued upon exercise
of this Warrant. The Company shall, in lieu of issuing any fractional share, pay
the holder entitled to such fraction a sum in cash equal to such fraction
multiplied by the then effective Stock Purchase Price.
[THIS SPACE INTENTIONALLY LEFT BLANK]
5
<PAGE> 67
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by
its officers.
DATED: , 1999 INTEGRATED SURGICAL SYSTEMS, INC.
a Delaware corporation
By:
--------------------------------------
Title:
--------------------------------------
ATTEST:
- ---------------------------------------------------------
Secretary
6
<PAGE> 68
EXHIBIT A
SUBSCRIPTION FORM
Date: ____________, 19__
Integrated Surgical Systems, Inc.
[address]
Attn: President
Ladies and Gentlemen:
The undersigned hereby elects to exercise the warrant issued to it by
(the "Company") and dated , Warrant No.
PW- (the "Warrant") and to purchase thereunder
shares of the Common Stock of the Company (the "Shares") at a purchase price of
Dollars ($ ) per Share or an aggregate purchase price of
Dollars ($ ) (the "Purchase Price").
Pursuant to the terms of the Warrant the undersigned has delivered the
Purchase Price herewith in full in cash or by certified check or wire transfer.
Very truly yours,
--------------------------------------
By:
--------------------------------------
Title:
--------------------------------------
<PAGE> 69
INTEGRATED SURGICAL SYSTEMS, INC.
REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT
THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (THE "AGREEMENT") is
entered into as of the day of , 199 , by and among INTEGRATED
SURGICAL SYSTEMS, INC. a Delaware corporation (the "COMPANY") and the purchasers
of the Company's Common Stock ("COMMON STOCK") set forth on Exhibit A of that
certain Stock and Warrant Purchase Agreement of even date herewith (the
"PURCHASE AGREEMENT") and Exhibit A hereto. The purchasers of the Common Stock
shall be referred to hereinafter as the "PURCHASERS" and each individually as a
"PURCHASER." Capitalized terms not otherwise defined herein shall have the
meanings ascribed to them in the Purchase Agreement.
RECITALS
WHEREAS, the Company proposes to sell and issue the Shares pursuant to the
Purchase Agreement, consisting of up to Two Million Nine Hundred Twenty Two
Thousand Three Hundred Ninety Six (2,922,396) shares of its Common Stock AND
WARRANTS (THE "WARRANTS") FOR THE PURCHASE OF UP TO AN ADDITIONAL NUMBER OF
SHARES OF ITS COMMON STOCK SUCH THAT THE NUMBER OF SHARES ISSUABLE UPON EXERCISE
OF THE WARRANTS, TOGETHER WITH THE SHARES, EQUALS FORTY PERCENT (40%) OF THE
FULLY DILUTED SHARES OF THE COMPANY (TAKING ALL CONVERTIBLE SECURITIES AS
CONVERTED INTO COMMON STOCK, AND ALL WARRANTS EXERCISABLE FOR THE PURCHASE OF
COMMON STOCK AS EXERCISED AND SUCH COMMON STOCK PURCHASED, AS OF THE CLOSING
DATE); and
WHEREAS, as a condition of entering into the Purchase Agreement, the
Purchasers have requested that the Company extend to them registration rights,
information rights and other rights as set forth below.
NOW, THEREFORE, in consideration of the mutual promises, representations,
warranties, covenants and conditions set forth in this Agreement and in the
Purchase Agreement, the parties mutually agree as follows:
SECTION 1. GENERAL
1.1 Definitions. As used in this Agreement the following terms shall have
the following respective meanings:
"EXCHANGE ACT" means the Securities Exchange Act of 1934, as amended.
"FORM S-3" means such form under the Securities Act as in effect on
the date hereof or any successor registration form under the Securities Act
subsequently adopted by the SEC which permits inclusion or incorporation of
substantial information by reference to other documents filed by the
Company with the SEC.
"HOLDER" means any person owning of record Registrable Securities that
have not been sold to the public or any assignee of record of such
Registrable Securities in accordance with Section 2.10 hereof.
"REGISTER," "REGISTERED," and "REGISTRATION" refer to a registration
effected by preparing and filing a registration statement in compliance
with the Securities Act, and the declaration or ordering of effectiveness
of such registration statement or document.
"REGISTRABLE SECURITIES" means (a) the Shares; (b) any Common Stock of
the Company issued upon the exercise of the Warrants; and (c) any Common
Stock of the Company issued as (or issuable upon the conversion or exercise
of any warrant, right or other security which is issued as) a dividend or
other distribution with respect to, or in exchange for or in replacement
of, such above-described securities. Notwithstanding the foregoing,
Registrable Securities shall not include any securities sold by a person to
the public either pursuant to a registration statement or Rule 144 or sold
in a private transaction in which the transferor's rights under Section 2
of this Agreement are not assigned.
2
<PAGE> 70
"REGISTRABLE SECURITIES THEN OUTSTANDING" shall be the number of
shares determined by calculating the total number of shares of the
Company's Common Stock that are Registrable Securities and either (a) are
then issued and outstanding or (b) are issuable pursuant to then
exercisable or convertible securities, including the Warrants.
"REGISTRATION EXPENSES" shall mean all expenses incurred by the
Company in complying with Sections 2.2, 2.3 and 2.4 hereof, including,
without limitation, all registration and filing fees, printing expenses,
fees and disbursements of counsel for the Company, reasonable fees and
disbursements not to exceed twenty-five thousand dollars ($25,000) of a
single special counsel for the Holders, blue sky fees and expenses and the
expense of any special audits incident to or required by any such
registration (but excluding the compensation of regular employees of the
Company which shall be paid in any event by the Company).
"SEC" or "COMMISSION" means the Securities and Exchange Commission.
"SECURITIES ACT" shall mean the Securities Act of 1933, as amended.
"SELLING EXPENSES" shall mean all underwriting discounts and selling
commissions applicable to the sale.
"SHARES" shall mean the Company's Common Stock issued pursuant to the
Purchase Agreement and held by the Purchasers listed on Exhibit A hereto
and their permitted assigns.
SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER
2.1 Restrictions on Transfer.
(a) Each Holder agrees not to make any disposition of all or any portion of
the Shares or Registrable Securities unless and until:
(i) There is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is
made in accordance with such registration statement; or
(ii) (A) The transferee has agreed in writing to be bound by the terms
of this Agreement, (B) such Holder shall have notified the Company of the
proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and
(C) if reasonably requested by the Company, such Holder shall have
furnished the Company with an opinion of counsel, reasonably satisfactory
to the Company, that such disposition will not require registration of such
shares under the Securities Act. It is agreed that the Company will not
require opinions of counsel for transactions made pursuant to Rule 144
except in unusual circumstances.
(iii) Notwithstanding the provisions of paragraphs (i) and (ii) above,
no such registration statement or opinion of counsel shall be necessary for
a transfer by a Holder which is (A) a partnership to its partners or former
partners in accordance with partnership interests, (B) a corporation to its
shareholders in accordance with their interest in the corporation, (C) a
limited liability company to its members or former members in accordance
with their interest in the limited liability company, or (D) to the
Holder's family member or trust for the benefit of an individual Holder;
provided that in each case the transferee will be subject to the terms of
this Agreement to the same extent as if he were an original Holder
hereunder.
(b) Each certificate representing Shares or Registrable Securities shall
(unless otherwise permitted by the provisions of the Agreement) be stamped or
otherwise imprinted with a legend substantially similar to the following (in
addition to any legend required under applicable state securities laws):
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION
IS NOT REQUIRED.
3
<PAGE> 71
(c) The Company shall be obligated to reissue promptly unlegended
certificates at the request of any holder thereof if the holder shall have
obtained an opinion of counsel (which counsel may be counsel to the Company)
reasonably acceptable to the Company to the effect that the securities proposed
to be disposed of may lawfully be so disposed of without registration,
qualification or legend.
(d) Any legend endorsed on an instrument pursuant to applicable state
securities laws and the stop-transfer instructions with respect to such
securities shall be removed upon receipt by the Company of an order of the
appropriate blue sky authority authorizing such removal.
2.2 Demand Registration.
(a) Subject to the conditions of this Section 2.2, if the Company shall
receive a written request from the Holders of a majority of the Registrable
Securities then outstanding (the "INITIATING HOLDERS") that the Company file a
registration statement under the Securities Act covering the registration of at
least twenty-five percent (25%) of the Registrable Securities then outstanding
(or a lesser percent if the anticipated aggregate offering price, net of
underwriting discounts and commissions, would exceed $2,000,000 (a "QUALIFIED
PUBLIC OFFERING")), then the Company shall, within thirty (30) days of the
receipt thereof, give written notice of such request to all Holders, and subject
to the limitations of this Section 2.2, use its best efforts to effect, as soon
as practicable, the registration under the Securities Act of all Registrable
Securities that the Holders request to be registered.
(b) If the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so
advise the Company as a part of their request made pursuant to this Section 2.2
or any request pursuant to Section 2.4 and the Company shall include such
information in the written notice referred to in Section 2.2(a) or Section
2.4(a), as applicable. In such event, the right of any Holder to include its
Registrable Securities in such registration shall be conditioned upon such
Holder's participation in such underwriting and the inclusion of such Holder's
Registrable Securities in the underwriting to the extent provided herein. All
Holders proposing to distribute their securities through such underwriting shall
enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting by a majority in interest of the
Initiating Holders (which underwriter or underwriters shall be reasonably
acceptable to the Company). Notwithstanding any other provision of this Section
2.2 or Section 2.4, if the underwriter advises the Company that marketing
factors require a limitation of the number of securities to be underwritten
(including Registrable Securities) then the Company shall so advise all Holders
of Registrable Securities which would otherwise be underwritten pursuant hereto,
and the number of shares that may be included in the underwriting shall be
allocated to the Holders of such Registrable Securities on a pro rata basis
based on the number of Registrable Securities held by all such Holders
(including the Initiating Holders); provided, however, that the number of shares
of Registrable Securities to be included in such underwriting and registration
shall not be reduced unless all other securities of the Company are first
entirely excluded from the underwriting and registration. Any Registrable
Securities excluded or withdrawn from such underwriting shall be withdrawn from
the registration.
The Company shall not be required to effect a registration pursuant to this
Section 2.2:
(i) after the Company has effected two (2) registrations pursuant to
this Section 2.2, and such registrations have been declared or ordered
effective;
(ii) during the period starting with the date of filing of, and ending
on the date one hundred eighty (180) days following the effective date of
the registration statement pertaining to a public offering; provided that
the Company makes reasonable good faith efforts to cause such registration
statement to become effective;
(iii) if within thirty (30) days of receipt of a written request from
Initiating Holders pursuant to Section 2.2(a), the Company gives notice to
the Holders of the Company's intention to make a public offering within
ninety (90) days;
(iv) if the Company shall furnish to Holders requesting a registration
statement pursuant to this Section 2.2, a certificate signed by the
Chairman of the Board stating that in the good faith judgment of
4
<PAGE> 72
the Board of Directors of the Company, it would be seriously detrimental to
the Company and its shareholders for such registration statement to be
effected at such time, in which event the Company shall have the right to
defer such filing for a period of not more than one hundred twenty (120)
days after receipt of the request of the Initiating Holders; provided that
such right to delay a request shall be exercised by the Company not more
than once in any twelve (12) month period; or
(v) if the Initiating Holders propose to dispose of shares of
Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 2.4 below.
2.3 Piggyback Registrations. The Company shall notify all Holders of
Registrable Securities in writing at least fifteen (15) days prior to the filing
of any registration statement under the Securities Act for purposes of a public
offering of securities of the Company (including, but not limited to,
registration statements relating to secondary offerings of securities of the
Company, but excluding registration statements relating to employee benefit
plans or with respect to corporate reorganizations or other transactions under
Rule 145 of the Securities Act) and will afford each such Holder an opportunity
to include in such registration statement all or part of such Registrable
Securities held by such Holder. Each Holder desiring to include in any such
registration statement all or any part of the Registrable Securities held by it
shall, within fifteen (15) days after the above-described notice from the
Company, so notify the Company in writing. Such notice shall state the intended
method of disposition of the Registrable Securities by such Holder. If a Holder
decides not to include all of its Registrable Securities in any registration
statement thereafter filed by the Company, such Holder shall nevertheless
continue to have the right to include any Registrable Securities in any
subsequent registration statement or registration statements as may be filed by
the Company with respect to offerings of its securities, all upon the terms and
conditions set forth herein.
(a) Underwriting. If the registration statement under which the
Company gives notice under this Section 2.3 is for an underwritten
offering, the Company shall so advise the Holders of Registrable
Securities. In such event, the right of any such Holder to be included in a
registration pursuant to this Section 2.3 shall be conditioned upon such
Holder's participation in such underwriting and the inclusion of such
Holder's Registrable Securities in the underwriting to the extent provided
herein. All Holders proposing to distribute their Registrable Securities
through such underwriting shall enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for such
underwriting by the Company. Notwithstanding any other provision of the
Agreement, if the underwriter determines in good faith that marketing
factors require a limitation of the number of shares to be underwritten,
the number of shares that may be included in the underwriting shall be
allocated, first, to the Company; second, to the Holders on a pro rata
basis based on the total number of Registrable Securities held by the
Holders; and third, to any shareholder of the Company (other than a Holder)
on a pro rata basis. No such reduction shall (i) reduce the securities
being offered by the Company for its own account to be included in the
registration and underwriting, or (ii) reduce the amount of securities of
the selling Holders included in the registration below twenty-five percent
(25%) of the total amount of securities included in such registration. In
no event will shares of any other selling shareholder be included in such
registration which would reduce the number of shares which may be included
by Holders without the written consent of Holders of not less than
sixty-six and two-thirds percent (66 2/3%) of the Registrable Securities
proposed to be sold in the offering. If any Holder disapproves of the terms
of any such underwriting, such Holder may elect to withdraw therefrom by
written notice to the Company and the underwriter, delivered at least ten
(10) business days prior to the effective date of the registration
statement. Any Registrable Securities excluded or withdrawn from such
underwriting shall be excluded and withdrawn from the registration. For any
Holder which is a partnership or corporation, the partners, retired
partners and shareholders of such Holder, or the estates and family members
of any such partners and retired partners and any trusts for the benefit of
any of the foregoing person shall be deemed to be a single "HOLDER", and
any pro rata reduction with respect to such "Holder" shall be based upon
the aggregate amount of shares carrying registration rights owned by all
entities and individuals included in such "Holder," as defined in this
sentence.
(b) Right to Terminate Registration. The Company shall have the right
to terminate or withdraw any registration initiated by it under this
Section 2.3 prior to the effectiveness of such registration whether
5
<PAGE> 73
or not any Holder has elected to include securities in such registration.
The Registration Expenses of such withdrawn registration shall be borne by
the Company in accordance with Section 2.5 hereof.
2.4 Form S-3 Registration. In case the Company shall receive from any
Holder or Holders of Registrable Securities a written request or requests that
the Company effect a registration on Form S-3 (or any successor to Form S-3) or
any similar short-form registration statement and any related qualification or
compliance with respect to all or a part of the Registrable Securities owned by
such Holder or Holders, the Company will:
(a) promptly give written notice of the proposed registration, and any
related qualification or compliance, to all other Holders of Registrable
Securities; and
(b) as soon as practicable, effect such registration and all such
qualifications and compliances as may be so requested and as would permit
or facilitate the sale and distribution of all or such portion of such
Holder's or Holders' Registrable Securities as are specified in such
request, together with all or such portion of the Registrable Securities of
any other Holder or Holders joining in such request as are specified in a
written request given within fifteen (15) days after receipt of such
written notice from the Company; provided, however, that the Company shall
not be obligated to effect any such registration, qualification or
compliance pursuant to this Section 2.4:
(i) if Form S-3 (or any successor or similar form) is not available
for such offering by the Holders, or
(ii) if the Holders, together with the holders of any other
securities of the Company entitled to inclusion in such registration,
propose to sell Registrable Securities and such other securities (if
any) at an aggregate price to the public of less than one million
dollars ($1,000,000), or
(iii) if within thirty (30) days of receipt of a written request
from any Holder or Holders pursuant to this Section 2.4, the Company
gives notice to such Holder or Holders of the Company's intention to
make a public offering within ninety (90) days;
(iv) if the Company shall furnish to the Holders a certificate
signed by the Chairman of the Board of Directors of the Company stating
that in the good faith judgment of the Board of Directors of the
Company, it would be seriously detrimental to the Company and its
shareholders for such Form S-3 registration to be effected at such time,
in which event the Company shall have the right to defer the filing of
the Form S-3 registration statement for a period of not more than ninety
(90) days after receipt of the request of the Holder or Holders under
this Section 2.4; provided, that such right to delay a request shall be
exercised by the Company not more than once in any twelve (12) month
period, or
(v) if the Company has, within the twelve (12) month period
preceding the date of such request, already effected two (2)
registrations on Form S-3 for the Holders pursuant to this Section 2.4,
or
(vi) in any particular jurisdiction in which the Company would be
required to qualify to do business or to execute a general consent to
service of process in effecting such registration, qualification or
compliance.
(c) Subject to the foregoing, the Company shall file a Form S-3
registration statement covering the Registrable Securities and other
securities so requested to be registered as soon as practicable after
receipt of the request or requests of the Holders. Registrations effected
pursuant to this Section 2.4 shall not be counted as demands for
registration or registrations effected pursuant to Sections 2.2 or 2.3,
respectively. All such Registration Expenses incurred in connection with
registrations requested pursuant to this Section 2.4 after the first two
(2) registrations shall be paid by the selling Holders pro rata in
proportion to the number of shares sold by each.
2.5 Expenses of Registration. Except as specifically provided herein, all
Registration Expenses incurred in connection with any registration,
qualification or compliance pursuant to Section 2.2 or any
6
<PAGE> 74
registration under Section 2.3 or Section 2.4 herein shall be borne by the
Company. All Selling Expenses incurred in connection with any registrations
hereunder, shall be borne by the holders of the securities so registered pro
rata on the basis of the number of shares so registered. The Company shall not,
however, be required to pay for expenses of any registration proceeding begun
pursuant to Section 2.2 or 2.4, the request of which has been subsequently
withdrawn by the Initiating Holders unless (a) the withdrawal is based upon
material adverse information concerning the Company of which the Initiating
Holders were not aware at the time of such request or (b) the Holders of a
majority of Registrable Securities agree to forfeit their right to one requested
registration pursuant to Section 2.2 or Section 2.4, as applicable, in which
event such right shall be forfeited by all Holders). If the Holders are required
to pay the Registration Expenses, such expenses shall be borne by the holders of
securities (including Registrable Securities) requesting such registration in
proportion to the number of shares for which registration was requested. If the
Company is required to pay the Registration Expenses of a withdrawn offering
pursuant to clause (a) above, then the Holders shall not forfeit their rights
pursuant to Section 2.2 or Section 2.4 to a demand registration.
2.6 Obligations of the Company. Whenever required to effect the
registration of any Registrable Securities, the Company shall, as expeditiously
as reasonably possible:
(a) Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use all reasonable efforts to
cause such registration statement to become effective, and, upon the
request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for up to
thirty (30) days or, if earlier, until the Holder or Holders have completed
the distribution related thereto. The Company shall not be required to
file, cause to become effective or maintain the effectiveness of any
registration statement that contemplates a distribution of securities on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act.
(b) Prepare and file with the SEC such amendments and supplements to
such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of
the Securities Act with respect to the disposition of all securities
covered by such registration statement for the period set forth in
paragraph (a) above.
(c) Furnish to the Holders such number of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of
the Securities Act, and such other documents as they may reasonably request
in order to facilitate the disposition of Registrable Securities owned by
them.
(d) Use its reasonable best efforts to register and qualify the
securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by the Holders; provided that the Company shall not be required
in connection therewith or as a condition thereto to qualify to do business
or to file a general consent to service of process in any such states or
jurisdictions.
(e) In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering. Each
Holder participating in such underwriting shall also enter into and perform
its obligations under such an agreement.
(f) Notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any
event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in the light of the
circumstances then existing.
(g) Use its best efforts to furnish, on the date that such Registrable
Securities are delivered to the underwriters for sale, if such securities
are being sold through underwriters, (i) an opinion, dated as of such date,
of the counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters
in an underwritten public offering, addressed to the underwriters, if any,
and (ii) a letter dated as of such date, from the independent certified
public
7
<PAGE> 75
accountants of the Company, in form and substance as is customarily given
by independent certified public accountants to underwriters in an
underwritten public offering addressed to the underwriters.
2.7 Termination of Registration Rights. All registration rights granted
under this Section 2 shall terminate and be of no further force and effect as to
any Holder and Registrable Securities held by such Holder when (i) all such
Registrable Securities shall have been effectively registered under the Act and
sold by the Holder in accordance with such registration; (b) such Holder
(together with its affiliates, partners and former partners) holds less than 1%
of the Company's outstanding Common Stock (treating all share of convertible
Preferred Stock on an as converted basis)] or (c) all Registrable Securities
held by and issuable to such Holder (and its affiliates, partners, former
partners, members and former members) may be sold under Rule 144 during any
ninety (90) day period.
2.8 Delay of Registration; Furnishing Information.
(a) No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any such registration as the result of any
controversy that might arise with respect to the interpretation or
implementation of this Section 2.
(b) It shall be a condition precedent to the obligations of the Company to
take any action pursuant to Section 2.2, 2.3 or 2.4 that the selling Holders
shall furnish to the Company such information regarding themselves, the
Registrable Securities held by them and the intended method of disposition of
such securities as shall be required to effect the registration of their
Registrable Securities.
(c) The Company shall have no obligation with respect to any registration
requested pursuant to Section 2.2 or Section 2.4 if, due to the operation of
subsection 2.2(b), the number of shares or the anticipated aggregate offering
price of the Registrable Securities to be included in the registration does not
equal or exceed the number of shares or the anticipated aggregate offering price
required to originally trigger the Company's obligation to initiate such
registration as specified in Section 2.2 or Section 2.4, whichever is
applicable.
2.9 Indemnification. In the event any Registrable Securities are included
in a registration statement under Sections 2.2, 2.3 or 2.4:
(a) To the extent permitted by law, the Company will indemnify and
hold harmless each Holder, the partners, officers and directors of each
Holder, any underwriter (as defined in the Securities Act) for such Holder
and each person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any losses,
claims, damages, or liabilities (joint or several) to which they may become
subject under the Securities Act, the Exchange Act or other federal or
state law, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon any of the
following statements, omissions or violations (collectively a "VIOLATION")
by the Company: (i) any untrue statement or alleged untrue statement of a
material fact contained in such registration statement, including any
preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary
to make the statements therein not misleading, or (iii) any violation or
alleged violation by the Company of the Securities Act, the Exchange Act,
any state securities law or any rule or regulation promulgated under the
Securities Act, the Exchange Act or any state securities law in connection
with the offering covered by such registration statement; and the Company
will pay as incurred to each such Holder, partner, officer, director,
underwriter or controlling person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability or action; provided however, that
the indemnity agreement contained in this Section 2.9(a) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of the Company,
which consent shall not be unreasonably withheld, nor shall the Company be
liable in any such case for any such loss, claim, damage, liability or
action to the extent that it arises out of or is based upon a Violation
which occurs in reliance upon and in conformity with written information
furnished expressly
8
<PAGE> 76
for use in connection with such registration by such Holder, partner,
officer, director, underwriter or controlling person of such Holder.
(b) To the extent permitted by law, each Holder will, if Registrable
Securities held by such Holder are included in the securities as to which
such registration qualifications or compliance is being effected, indemnify
and hold harmless the Company, each of its directors, its officers and each
person, if any, who controls the Company within the meaning of the
Securities Act, any underwriter and any other Holder selling securities
under such registration statement or any of such other Holder's partners,
directors or officers or any person who controls such Holder, against any
losses, claims, damages or liabilities (joint or several) to which the
Company or any such director, officer, controlling person, underwriter or
other such Holder, or partner, director, officer or controlling person of
such other Holder may become subject under the Securities Act, the Exchange
Act or other federal or state law, insofar as such losses, claims, damages
or liabilities (or actions in respect thereto) arise out of or are based
upon any Violation, in each case to the extent (and only to the extent)
that such Violation occurs in reliance upon and in conformity with written
information furnished by such Holder under an instrument duly executed by
such Holder and stated to be specifically for use in connection with such
registration; and each such Holder will pay as incurred any legal or other
expenses reasonably incurred by the Company or any such director, officer,
controlling person, underwriter or other Holder, or partner, officer,
director or controlling person of such other Holder in connection with
investigating or defending any such loss, claim, damage, liability or
action if it is judicially determined that there was such a Violation;
provided, however, that the indemnity agreement contained in this Section
2.9(b) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without
the consent of the Holder, which consent shall not be unreasonably
withheld; provided further, that in no event shall any indemnity under this
Section 2.9 exceed the net proceeds from the offering received by such
Holder.
(c) Promptly after receipt by an indemnified party under this Section
2.9 of notice of the commencement of any action (including any governmental
action), such indemnified party will, if a claim in respect thereof is to
be made against any indemnifying party under this Section 2.9, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the
extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with
counsel mutually satisfactory to the parties; provided, however, that an
indemnified party shall have the right to retain its own counsel, with the
fees and expenses to be paid by the indemnifying party, if representation
of such indemnified party by the counsel retained by the indemnifying party
would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if materially prejudicial to its ability to defend such action,
shall relieve such indemnifying party of any liability to the indemnified
party under this Section 2.9, but the omission so to deliver written notice
to the indemnifying party will not relieve it of any liability that it may
have to any indemnified party otherwise than under this Section 2.9.
(d) If the indemnification provided for in this Section 2.9 is held by
a court of competent jurisdiction to be unavailable to an indemnified party
with respect to any losses, claims, damages or liabilities referred to
herein, the indemnifying party, in lieu of indemnifying such indemnified
party thereunder, shall to the extent permitted by applicable law
contribute to the amount paid or payable by such indemnified party as a
result of such loss, claim, damage or liability in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the
one hand and of the indemnified party on the other in connection with the
Violation(s) that resulted in such loss, claim, damage or liability, as
well as any other relevant equitable considerations. The relative fault of
the indemnifying party and of the indemnified party shall be determined by
a court of law by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission to state a
material fact relates to information supplied by the indemnifying party or
by the indemnified party and the parties' relative intent, knowledge,
access to information and opportunity to correct or prevent such
9
<PAGE> 77
statement or omission; provided, that in no event shall any contribution by
a Holder hereunder exceed the [NET] proceeds from the offering received by
such Holder.
(e) The obligations of the Company and Holders under this Section 2.9
shall survive completion of any offering of Registrable Securities in a
registration statement and the termination of this agreement. No
Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any
judgment or enter into any settlement which does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim
or litigation.
2.10 Assignment of Registration Rights. The rights to cause the Company
to register Registrable Securities pursuant to this Section 2 may be assigned by
a Holder to a transferee or assignee of Registrable Securities which (a) is a
subsidiary, parent, general partner, limited partner, retired partner, member or
retired member of a Holder, (b) is a Holder's family member or trust for the
benefit of an individual Holder, or (c) acquires at least fifty thousand
(200,000) shares of Registrable Securities (as adjusted for stock splits and
combinations); provided, however, (i) the transferor shall, within ten (10) days
after such transfer, furnish to the Company written notice of the name and
address of such transferee or assignee and the securities with respect to which
such registration rights are being assigned and (ii) such transferee shall agree
to be subject to all restrictions set forth in this Agreement.
2.11 Amendment of Registration Rights. Any provision of this Section 2
may be amended and the observance thereof may be waived (either generally or in
a particular instance and either retroactively or prospectively), only with the
written consent of the Company and the Holders of at least sixty-six and two-
thirds percent (66 2/3%) of the Registrable Securities then outstanding. Any
amendment or waiver effected in accordance with this Section 2.11 shall be
binding upon each Holder and the Company. By acceptance of any benefits under
this Section 2, Holders of Registrable Securities hereby agree to be bound by
the provisions hereunder.
2.12 Limitation on Subsequent Registration Rights. After the date of this
Agreement, the Company shall not, without the prior written consent of the
Holders of sixty-six and two-thirds percent (66 2/3%) of the Registrable
Securities then outstanding, enter into any agreement with any holder or
prospective holder of any securities of the Company that would grant such holder
registration rights pari passu or senior to those granted to the Holders
hereunder.
2.13 Rule 144 Reporting. With a view to making available to the Holders
the benefits of certain rules and regulations of the SEC which may permit the
sale of the Registrable Securities to the public without registration, the
Company agrees to use its best efforts to:
(a) Make and keep public information available, as those terms are
understood and defined in SEC Rule 144 or any similar or analogous rule
promulgated under the Securities Act, at all times after the effective date of
the first registration filed by the Company for an offering of its securities to
the general public;
(b) File with the SEC, in a timely manner, all reports and other documents
required of the Company under the Exchange Act; and
(c) So long as a Holder owns any Registrable Securities, furnish to such
Holder forthwith upon request: a written statement by the Company as to its
compliance with the reporting requirements of said Rule 144 of the Securities
Act, and of the Exchange Act (at any time after it has become subject to such
reporting requirements); a copy of the most recent annual or quarterly report of
the Company; and such other reports and documents as a Holder may reasonably
request in availing itself of any rule or regulation of the SEC allowing it to
sell any such securities without registration.
SECTION 3. COVENANTS OF THE COMPANY
3.1 Basic Financial Information and Reporting.
(a) The Company will maintain true books and records of account in which
full and correct entries will be made of all its business transactions pursuant
to a system of accounting established and administered in
10
<PAGE> 78
accordance with generally accepted accounting principles consistently applied,
and will set aside on its books all such proper accruals and reserves as shall
be required under generally accepted accounting principles consistently applied.
(b) Unless otherwise made publicly available, as soon as practicable after
the end of each fiscal year of the Company, and in any event within one hundred
twenty (120) days thereafter, to the extent requested by a Purchaser the Company
will furnish each Purchaser a balance sheet of the Company, as at the end of
such fiscal year, and a statement of income and a statement of cash flows of the
Company, for such year, all prepared in accordance with generally accepted
accounting principles consistently applied and setting forth in each case in
comparative form the figures for the previous fiscal year, all in reasonable
detail. Such financial statements shall be accompanied by a report and opinion
thereon by independent public accountants of national standing selected by the
Company's Board of Directors.
(c) Unless otherwise made publicly available, the Company will furnish each
Purchaser, as soon as practicable after the end of the first, second and third
quarterly accounting periods in each fiscal year of the Company, and in any
event within forty-five (45) days thereafter, to the extent requested by such
Purchaser a balance sheet of the Company as of the end of each such quarterly
period, and a statement of income and a statement of cash flows of the Company
for such period and for the current fiscal year to date, prepared in accordance
with generally accepted accounting principles, with the exception that no notes
need be attached to such statements and year-end audit adjustments may not have
been made.
3.2 Inspection Rights. Each Holder of at least Five Hundred Thousand
(500,000) shares of Common Stock ("MAJOR STOCKHOLDER") shall have the right to
visit and inspect any of the properties of the Company or any of its
subsidiaries, and to discuss the affairs, finances and accounts of the Company
or any of its subsidiaries with its officers, and to review such information as
is reasonably requested all at such reasonable times and as often as may be
reasonably requested; provided, however, that the Company shall not be obligated
under this Section 3.2 with respect to a competitor of the Company or with
respect to information which the Board of Directors determines in good faith is
confidential and should not, therefore, be disclosed.
3.3 Confidentiality of Records. Each Purchaser agrees to use, and to use
its best efforts to insure that its authorized representatives use, the same
degree of care as such Purchaser uses to protect its own confidential
information to keep confidential any information furnished to it which the
Company identifies as being confidential or proprietary (so long as such
information is not in the public domain), except that such Purchaser may
disclose such proprietary or confidential information to any partner, subsidiary
or parent of such Purchaser for the purpose of evaluating its investment in the
Company as long as such partner, subsidiary or parent is advised of the
confidentiality provisions of this Section 3.3.
3.4 Reservation of Common Stock. The Company will at all times reserve
and keep available, solely for issuance and delivery upon the exercise of the
Warrants, all Common Stock issuable from time to time upon such exercise.
3.5 Visitation Rights. The Company shall allow one representative
designated by each Purchaser the right to attend all meetings of the Company's
Board of Directors in a nonvoting capacity, and in connection therewith, the
Company shall give such representative copies of all notices, minutes, consents
and other materials, financial or otherwise, which the Company provides to its
Board of Directors; provided, however, that the Company reserves the right to
exclude such representative from access to any material or meeting or portion
thereof if the Company believes upon advice of counsel that such exclusion is
reasonably necessary to preserve the attorney-client privilege, to protect
highly confidential proprietary information or for other similar reasons.
3.6 Termination of Covenants. All covenants of the Company contained in
Section 3 of this Agreement shall expire and terminate as to each Purchaser upon
(a) the sale, lease or other disposition of all or substantially all of the
assets of the Company or (b) an acquisition of the Company by another
corporation or entity by consolidation, merger or other reorganization in which
the holders of the Company's outstanding voting stock immediately prior to such
transaction own, immediately after such transaction, securities representing
less than fifty percent (50%) of the voting power of the corporation or other
entity surviving such
11
<PAGE> 79
transaction, provided that this Section 3.8(b) shall not apply to a merger
effected exclusively for the purpose of changing the domicile of the Company (a
"CHANGE IN CONTROL").
SECTION 4. MISCELLANEOUS
4.1 Governing Law. This Agreement shall be governed by and construed
under the laws of the State of California as applied to agreements among
California residents entered into and to be performed entirely within
California.
4.2 Survival. The representations, warranties, covenants, and agreements
made herein shall survive any investigation made by any Holder and the closing
of the transactions contemplated hereby. All statements as to factual matters
contained in any certificate or other instrument delivered by or on behalf of
the Company pursuant hereto in connection with the transactions contemplated
hereby shall be deemed to be representations and warranties by the Company
hereunder solely as of the date of such certificate or instrument.
4.3 Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors, and administrators of the
parties hereto and shall inure to the benefit of and be enforceable by each
person who shall be a holder of Registrable Securities from time to time;
provided, however, that prior to the receipt by the Company of adequate written
notice of the transfer of any Registrable Securities specifying the full name
and address of the transferee, the Company may deem and treat the person listed
as the holder of such shares in its records as the absolute owner and holder of
such shares for all purposes, including the payment of dividends or any
redemption price.
4.4 Entire Agreement. This Agreement, the Exhibits and Schedules hereto,
the Purchase Agreement and the other documents delivered pursuant thereto
constitute the full and entire understanding and agreement between the parties
with regard to the subjects hereof and no party shall be liable or bound to any
other in any manner by any representations, warranties, covenants and agreements
except as specifically set forth herein and therein.
4.5 Severability. In the event one or more of the provisions of this
Agreement should, for any reason, be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality, or unenforceability
shall not affect any other provisions of this Agreement, and this Agreement
shall be construed as if such invalid, illegal or unenforceable provision had
never been contained herein.
4.6 Amendment and Waiver.
(a) Except as otherwise expressly provided, this Agreement may be amended
or modified only upon the written consent of the Company and the holders of at
least two-thirds (66 2/3%) of the Registrable Securities.
(b) Except as otherwise expressly provided, the obligations of the Company
and the rights of the Holders under this Agreement may be waived only with the
written consent of the holders of at least sixty-six and two-thirds percent
(66 2/3%) of the Registrable Securities.
(c) Notwithstanding the foregoing, this Agreement may be amended with only
the written consent of the Company to include additional purchasers of Shares as
"PURCHASERS," "HOLDERS" and parties hereto.
4.7 Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power, or remedy accruing to any Holder, upon any breach,
default or noncompliance of the Company under this Agreement shall impair any
such right, power, or remedy, nor shall it be construed to be a waiver of any
such breach, default or noncompliance, or any acquiescence therein, or of any
similar breach, default or noncompliance thereafter occurring. It is further
agreed that any waiver, permit, consent, or approval of any kind or character on
any Holder's part of any breach, default or noncompliance under the Agreement or
any waiver on such Holder's part of any provisions or conditions of this
Agreement must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this
Agreement, by law, or otherwise afforded to Holders, shall be cumulative and not
alternative.
4.8 Notices. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the
party to be notified, (b) when sent by confirmed telex or
12
<PAGE> 80
facsimile if sent during normal business hours of the recipient; if not, then on
the next business day, (c) five (5) days after having been sent by registered or
certified mail, return receipt requested, postage prepaid, or (d) two (2) days
after deposit with an internationally recognized overnight courier, specifying
no less than delivery within 48 hours, with written verification of receipt. All
communications shall be sent to the party to be notified at the address as set
forth on the signature pages hereof or Exhibit A hereto or at such other address
as such party may designate by ten (10) days advance written notice to the other
parties hereto.
4.9 Attorneys' Fees. In the event that any suit or action is instituted
to enforce any provision in this Agreement, the prevailing party in such dispute
shall be entitled to recover from the losing party all fees, costs and expenses
of enforcing any right of such prevailing party under or with respect to this
Agreement, including without limitation, such reasonable fees and expenses of
attorneys and accountants, which shall include, without limitation, all fees,
costs and expenses of appeals.
4.10 Titles and Subtitles. The titles of the sections and subsections of
this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement.
4.11 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.
[THIS SPACE INTENTIONALLY LEFT BLANK]
13
<PAGE> 81
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date set forth in the first paragraph hereof.
<TABLE>
<S> <C>
COMPANY: PURCHASERS:
</TABLE>
<TABLE>
<S> <C>
INTEGRATED SURGICAL SYSTEMS, INC. ILTAG INTERNATIONAL LICENSING HOLDINGS S.A.L.
By: By:
- ------------------------------------------------- -------------------------------------------------
Its: Its:
-----------------------------------------------------
Bernd Hermann
-----------------------------------------------------
Urs Wettstein
</TABLE>
PURCHASER RIGHTS AGREEMENT
SIGNATURE PAGE
<PAGE> 82
INTEGRATED SURGICAL SYSTEMS, INC.
1550 RESEARCH PARK DRIVE
DAVIS, CALIFORNIA 95616-4884
PROXY
The undersigned, a holder of Common Stock of INTEGRATED SURGICAL SYSTEMS,
INC., a Delaware corporation (the "Company"), hereby appoints DR. RAMESH C.
TRIVEDI and MARK W. WINN, and each of them, the proxy of the undersigned, with
full power of substitution, to attend represent and vote for the undersigned,
all of the shares of the Company which the undersigned would be entitled to
vote, at the Special Meeting of Stockholders of the Company to be held on August
18, 1999 and any adjournments thereof, as follows:
1. The approval of the issue and sale to ILTAG International Licensing Holding
S.A.L., Bernd Herrmann and URS Wettstein of an aggregate of 2,922,240 shares
of common stock and warrants to purchase an additional number of shares of
common stock, at an exercise price of $1.02656 per share, that if exercised
would give them 40% of the fully diluted Common Stock, for a total purchase
price of $4 million.
<TABLE>
<S> <C> <C>
[ ] FOR [ ] AGAINST [ ] ABSTAIN
</TABLE>
2. The transaction of such business as may properly come before the Special
Meeting and any adjournments thereof.
The undersigned hereby revokes any other proxy to vote at such Special
Meeting, and hereby ratifies and confirms all that said attorneys and proxies,
and each of them, may lawfully do by virtue hereof. With respect to matters not
known at the time of the solicitations hereby, said proxies are authorized to
vote in accordance with their best judgment.
(continued, and to be signed, on other side)
<PAGE> 83
(continued from other side)
THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN ACCORDANCE WITH THE
INSTRUCTIONS ON THE OTHER SIDE HEREOF. IF NO DIRECTION IS MADE, THIS PROXY WILL
BE VOTED FOR THE ADOPTION OF PROPOSAL 1.
THE UNDERSIGNED ACKNOWLEDGES RECEIPT OF A COPY OF THE NOTICE OF SPECIAL
MEETING DATED JULY , 1999 RELATING TO THE SPECIAL MEETING.
<TABLE>
<S> <C>
Date: , 1999
----------------------------------- ------------------------------------------------------------
------------------------------------------------------------
------------------------------------------------------------
SIGNATURE(S) OF STOCKHOLDER(S)
The signature(s) hereon should correspond exactly with the
name(s) of the Stockholder(s) appearing on the Stock
Certificate. If stock is jointly held, all joint owners
should sign. When signing as attorney, executor,
administrator, trustee or guardian, please give full title
as such. If signer is a corporation, please sign the full
corporate name, and give title of signing officer.
</TABLE>
THIS PROXY IS SOLICITED BY THE BOARD OF
DIRECTORS OF INTEGRATED SURGICAL
SYSTEMS, INC. PLEASE MARK, SIGN, DATE
AND RETURN THE PROXY PROMPTLY USING THE
ENCLOSED ENVELOPE.
